The role of gp130 receptor signalling in inflammation and metabolism by Neill, B
0 
The Role of gp130 Receptor Signalling 
in Inflammation and Metabolism 
A Thesis Presented in Total Fulfilment for the Degree of Doctor of Philosophy 
By 
Bronwyn Anne Neill 
Bachelor of Applied Science (Biotechnology/Biomedical Science) 
(Honours) 
School of Medical Sciences 
College of Science, Engineering and Technology 
RMIT University 
June 2009 
i 
Publications 
Data contained within this dissertation has been published in the following 
research article: 
Holmes AG, Mesa JL, Neill BA, Chung J, Carey AL, Steinberg GR, Kemp BE, 
Southgate RJ, Lancaster GI, Bruce CR, Watt MJ and Febbraio MA. 2008. 
Prolonged interleukin-6 administration enhances glucose tolerance and increases 
skeletal muscle PPARα and UCP2 expression in rats. J Endocrinol. 198:367-374 
ii 
Declaration 
I, the candidate, Bronwyn Anne Neill, certify that: 
 All data included within this thesis is that obtained by the candidate alone
 Except where due acknowledgement has been made, the work is that of the
candidate alone whilst enrolled as a student at The Royal Melbourne
Institute of Technology.
 The work has not been submitted previously, in whole or in part, to qualify
for any other academic award
 The content of this dissertation is the result of work which has been
completed since the official commencement date of the approved research
program
      Signature of Candidate 
22nd March 2010 
iii 
 
Acknowledgements 
 
I would personally like to extend my sincerest thanks and gratitude to the 
following, for whom, with their support over the past 4 years, made 
successful completion of this thesis possible: 
 My primary supervisor, Professor Mark Febbraio for his endless guidance 
and advice and for fostering my growth and potential as a career researcher  
   
 Dr Vance Matthews for his outstanding mentorship intellectually and within 
the laboratory.   
 
 Ms Nadine Watson for cutting and assisting with the staining of the 
histological sections and staining within Chapter 6.  
 
 Mr Steve Risis for his assistance with animal dissection in Chapters 5 and 6 
  
 Dr Anna Greer Holmes for the Intermittent and Chronically IL-6 infused 
tissues analysed in Chapter 3. 
 
 Professor Stefan Rose-John, Biochemisches Institut, Christian-Albrechts-
Universität Zu Kiel, Germany, for the kind gift of recombinant human IL-6, 
Hyper IL-6 and sgp130Fc used throughout the studies of this dissertation. 
 
 To past and present members of the Cellular and Molecular Metabolism 
Laboratory; Tamara Allen, Clinton Bruce, Andrew Carey, Anna Greer 
Holmes, Stanley Chan, Jason Chung, Michelle Hage, Darren Henstridge, 
Greg Kowalski, Graeme Lancaster, Hai Li, Brigitte Lindegaard, Vance 
Matthews, Hayley Nicholls, Chia Peng, Oja Prelovsek, Steve Risis, Beata 
Skiba, Robert Southgate, Sarah Turpin, Nadine Watson, Matthew Watt, 
Martin Whitham, Derek Yuen and Lee Zaffino. I am grateful that you all 
iv 
 
contributed to a memorable journey that was, for the most part a colourful 
and exuberant experience. 
 
 All my dear friends at the Baker IDI and RMIT University who made for an 
enjoyable chapter within my professional career, especially; Nicole Pelaez, 
Richard Bayles, Brooke Harcourt, Sebastian Lunke, Andrew Murphy, Nicole 
Dellios, Kristy Shield, Josie Smith and Dani Sevior. 
 
 Associate Professor Terry Piva for his administrative support and council 
over the duration of my candidature. 
 
 NHMRC and RMIT University for providing research funding and financial 
support through out my candidature 
 
 Cameron Rodda, Leora Isaacs, Meghan Coulter, Hayley Nicholls, Beata 
Skiba and Lee Zaffino Your friendship, patience and support over the past 
few years will always be appreciated. 
 
 My gorgeous partner Dean Cartwright, for always being there, for giving me 
a push if needed, the grounding when required and taking some of the load 
when necessary. For demonstrating faith and confidence in my abilities and 
allowing me to confide in him when desired the most. Ultimately, for always 
being patient and supportive, I could not have completed my dream without 
your love, support and companionship.  
 
 To my beautiful family, I dedicate this thesis to you. Mum, Dad, Dean, 
Rosalee and Cameron, John, Sara and Rhys, Felicity and Krystina, I will 
never be able to thank you enough. I would not have been able to achieve 
all that I have without your network of endless love and interminable 
support, not only over the past four years, but throughout my life journey. 
 
v 
 
 Finally, to my dear parents Roger and Sheryl Neill, who instilled in me gain 
of knowledge and skills is to constantly grow in life. For always encouraging 
my curiosity, for their perpetual support of my education and all that I aspire 
to. Thank you for reminding me of my aspirations when required, for your 
faith and support in all that I pursue. Most of all for your everlasting 
guidance and love.  
vi 
 
Table of Contents 
 
Publications .................................................................... i 
Declaration ...................................................................... ii 
Acknowledgements ........................................................ iii 
Table of Contents ........................................................... vi 
List of Figures ................................................................. ix 
List of Tables .................................................................. xiv 
List of Abbreviations ...................................................... xv 
Abstract ........................................................................... xvii 
 
CHAPTER ONE 
Introduction and Review of the Literature....................... 1 
1.1 Introduction.......................................................................................... 2 
1.2 Interleukin-6......................................................................................... 3 
1.3 IL-6 Receptor and its Interaction with gp130 ....................................... 5 
1.4 Interleukin-6 Signalling ........................................................................ 6 
1.5 Interleukin-6 in Health and Disease ................................................... 11 
1.6 Soluble gp130: the natural antagonist of IL-6 Signalling ................... 17 
1.7 The Designer Cytokine Hyper IL-6 .................................................... 20 
 
CHAPTER TWO 
Aims of the Study ............................................................ 23 
2.1  Aims of the study .............................................................................. 24 
 
vii 
 
CHAPTER THREE 
IL-6 does not mediate transcription and translation of the 
co-transcription factor PGC-1α in vitro or in vivo ......... 25 
3.1  Introduction....................................................................................... 26 
3.2 Materials and Methods ...................................................................... 32 
3.3 Results .............................................................................................. 37 
3.4 Discussion ......................................................................................... 44 
 
CHAPTER FOUR 
Hyper IL-6 augments metabolic cell signalling and 
physiological parameters in myotubes and liver cells in 
vitro .................................................................................. 53 
4.1 Introduction........................................................................................ 54 
4.2 Materials and Methods ...................................................................... 57 
4.3 Results .............................................................................................. 59 
4.4 Discussion ......................................................................................... 80 
 
CHAPTER FIVE 
Acute Hyper IL-6 administration has tissue specific 
effects on metabolic signalling pathways in vivo ......... 87 
5.1 Introduction........................................................................................ 88 
5.2 Materials and Methods ...................................................................... 90 
5.3 Results .............................................................................................. 92 
5.4 Discussion ......................................................................................... 109 
viii 
 
CHAPTER SIX 
Prolonged Hyper IL-6 treatment perturbs insulin 
sensitivity and induces liver injury in mice on a high fat 
diet ................................................................................... 122 
6.1 Introduction...................................................................................... 123 
6.2 Materials and Methods .................................................................... 125 
6.3 Results ............................................................................................ 130 
6.4 Discussion ....................................................................................... 146 
 
CHAPTER SEVEN 
Summary and Conclusions ............................................ 153 
7.1 Introduction...................................................................................... 154 
 
REFERENCES ................................................................. 158 
ix 
 
List of Figures 
 
Figure No. Figure Title ...................................................................... page  
 
Figure 1.1 Structure of Interleukin-6 ...................................................... 4 
Figure 1.2 The structural organisation of IL-6, IL-6R and gp130 ........... 7 
Figure 1.3 Mechanisms of IL-6 Signal transduction: a simplified 
schematic ............................................................................. 10 
Figure 1.4 IL-6 dependent “tissue cross-talk” during exercise .............. 13 
Figure 1.5 The role of IL-6 in transition from innate immunity to an 
acquired immune response ................................................. 15 
Figure 1.6 Kinetic profile of acute phase protein production induced by  
IL-6 ...................................................................................... 17 
Figure 1.7 Inhibitory mechanism of sgp130 .......................................... 18 
Figure 1.8 Schematic of the structure of sgp130Fc .............................. 19 
Figure 1.9 The fusion protein Hyper IL-6 .............................................. 22 
 
 
 
Figure 3.1 PGC-1α transcriptional targets and physiological functions in 
various tissues .................................................................... 27 
Figure 3.2 gp130 Ligands mediate fat oxidation in skeletal muscle via an 
AMPK dependent manner ................................................... 31 
Figure 3.3 Schematic of signalling pathways that are postulated to be 
involved in the regulation of PGC-1α expression and 
mitochondrial activity by IL-6 ............................................... 32 
Figure 3.4 PGC-1α protein expression in tissues harvested from 
Intermittent and Chronic IL-6 infused rats ........................... 40 
Figure 3.5 PGC-1α and downstream target gene expression in Hyper IL-6 
treated L6 myotubes............................................................ 42 
x 
 
Figure 3.6 PGC-1α and downstream target gene expression in Hyper IL-6 
treated CRL1439 hepatocytes ............................................. 43 
Figure 3.7 Hyper IL-6 has little effect on phosphorylation of AMPK but 
induces that of Akt and p38 MAPK in L6 myotubes............. 44 
 
 
 
Figure 4.1 Hyper IL-6 has a greater bioactivity than that of other IL-6 
species within L6 myotubes ................................................ 60 
Figure 4.2 Hyper IL-6 increases phospho Aktser473 but has no significant 
effect on phospho AMPKthr172 .............................................. 61 
Figure 4.3 Hyper IL-6 phosphorylates STAT-3 in a dose dependent 
manner ................................................................................ 64 
Figure 4.4 Membrane bound IL-6Rα signalling has greater bioactivity in 
CRL1439s than in L6 myotubes .......................................... 65 
Figure 4.5 Hyper IL-6 co-treatment results in potentiation of Insulin 
stimulated glucose uptake in L6 myotubes .......................... 68 
Figure 4.6 Hyper IL-6 activates STAT-3 and induces SOCS-3 protein in 
L6 myotubes under conditions used in the glucose uptake 
assay ................................................................................... 69 
Figure 4.7 Insulin stimulated activation of Akt remains unchanged with 
Hyper IL-6 co-treatment where as phosphorylation of p38 
MAPK is potentiated under these conditions ....................... 70 
Figure 4.8 Hyper IL-6 has no effect on phospho AMPKthr172 protein 
abundance under conditions used in the glucose uptake assay 
  ............................................................................................ 71 
Figure 4.9 IL-6/sIL-6R signalling attenuates palmitate oxidation in L6 
myotubes ............................................................................. 74 
Figure 4.10 Co-treatment with sgp130Fc augments Hyper IL-6, Insulin 
stimulated glucose uptake ................................................... 75 
Figure 4.11  sgp130Fc has no effect on basal phosphorylation of STAT-3 in  
  L6 myotubes ......................................................................... 76 
xi 
 
 
Figure 4.12  sgp130Fc has no effect on basal phosphorylation of p38  
                                 MAPK  or Akt in L6 myotubes ............................................. 77 
Figure 4.13  sgp130Fc inhibits Hyper IL-6 in a cell type dependent manner 
  ............................................................................................... 79 
 
 
 
Figure 5.1 Hyper IL-6 increases STAT-3 activation and has a propensity 
to increase basal and potentiate insulin stimulated phospho 
Aktser473 in liver .................................................................... 93 
Figure 5.2 IL-6 trans-signalling events occur in WAT in vivo ................ 95 
Figure 5.3 IL-6 trans-signalling occurs in soleus muscle in vivo ........... 96 
Figure 5.4 Hyper IL-6 trans-signalling is bioactive in EDL in vivo but 
displays moderated increases upon co- administration with 
sgp130Fc ............................................................................ 97 
Figure 5.5 In liver, Hyper IL-6 trans-signalling has a propensity of 
regulating proteins that mediate fat oxidation regardless of the 
presence of sgp130Fc ......................................................... 100 
Figure 5.6 Hyper IL-6 has a tendency to increase β- Oxidation signalling 
proteins and significantly increases protein expression of 
PGC-1α in WAT .................................................................. 101 
Figure 5.7 Hyper IL-6 has a tendency to increase phospho ACCser79 but in 
contrast decreases phospho AMPKthr172 in soleus in vivo ... 103 
Figure 5.8 Hyper IL-6 mediates fat oxidation signalling in a fibre type 
specific manner as demonstrated by the contrast in signalling 
between EDL and that of soleus ......................................... 104 
Figure 5.9 In liver, acute Hyper IL-6 treatment does not stimulate robust 
activation of IKK or JNK, proteins implicated in the induction of 
inflammation ........................................................................ 105 
Figure 5.10 Markers of inflammatory signalling are induced in WAT of mice 
administered Hyper IL-6 ...................................................... 106 
xii 
 
Figure 5.11 Inflammatory signalling was not induced in skeletal muscle 
upon administration of Hyper IL-6 ....................................... 107 
Figure 5.12  SOCS-3 protein expression has a tendency to be induced with 
acute sIL-6/sIL-6R complex mediated signalling events...... 108 
 
 
 
Figure 6.1 Schematic of the experimental design................................. 125 
Figure 6.5 Prolonged Hyper IL-6 treatment has no effect on food intake or 
lean body mass but decreases fat mass relative to whole body 
weight .................................................................................. 132 
Figure 6.3 Hyper IL-6, regardless of the presence of sgp130Fc, has no 
effect on glucose tolerance ................................................. 133 
Figure 6.4 Continued Hyper IL-6 treatment decreases insulin sensitivity 
with time as determined by ITT ........................................... 134 
Figure 6.5 Hyper IL-6 treatment has little or no effect on metabolic 
parameters as determined by CLAMS ................................ 135 
Figure 6.6 Hyper IL-6 administration had little effect on acute phase 
protein production but a tendency to induce chronic liver injury 
  ............................................................................................ 137 
Figure 6.7 Livers from Saline treated C57Bl6 mice on a HFD have 
disrupted morphology and macro-steatosis whereas Hyper IL-
6 treated livers have infiltration of progenitor cells indicating 
regeneration ........................................................................ 139 
Figure 6.8 High basal expression of phospho Aktser473 is evident in liver of 
mice regardless of compound administered, an affect that is 
not conserved in all tissue types ......................................... 142 
Figure 6.9 Prolonged hyper IL-6 treatment has little effect on phospho 
Aktthr308 protein abundance in liver, Soleus or WAT ............ 143 
Figure 6.10 Hyper IL-6 has no effect on the activation of AMPK but in the 
presence of sgp130Fc reduces phosphorylation of ACC in liver 
  ............................................................................................ 144 
xiii 
 
Figure 6.11 Prolonged Hyper IL-6 treatment does not significantly alter 
protein abundance of pro TNF or SOCS-3 in tissues of interest 
in mice on a HFD................................................................. 145 
  
xiv 
 
List of Tables 
 
Table No. Table Title  ..................................................................... Page 
 
Table 3.1 Accession number and forward and reverse primer sequences 
used for genes of interest in real-time PCR analyses.......... 36 
Table 3.2 mRNA expression of PGC-1α and downstream targets 
remains similar in TA from rats administered IL-6 irrespective 
of mode of delivery .............................................................. 39 
xv 
 
List of Abbreviations 
 
α-MEM    alpha minimum essential medium 
ACC     Acetyl CoA Carboxylase 
ACT     α1-antichymotrypsin 
ADAM    A disintegrin and metalloprotease 
Akt     v-akt murine thymoma viral oncogene homolog 
     (Also known as Protein Kinase B) 
ALT     Alanine Aminotransferase   
AMPK    AMP activated mitogen protein kinase 
ANOVA    Analysis of variance of analysis 
AS160    Akt substrate of 160 kDa 
AST     Aspartate Aminotransferase 
BSF-2     Human B Cell stimulatory factor 
CBM     Cytokine Binding Module 
CNTF     Cilliary Neurotropic Factor  
COX IV    Cyclooxygenase IV 
CRP     C-Reactive Protein 
EDL     Extensor Digitorum Longus 
FBS     Foetal Bovine Serum     
G-6-Pase    Glucose-6-phosphatase 
GLUT4    Glucose Transporter 4 
gp130     Glycoprotein 130 
h     hour 
HFD     High Fat Diet 
IFN-β2    Interferon β2 
IgG     Immunoglobulin G 
IKK     IKappaB Kinase 
IL-6     Interleukin-6 
IL-6Rα    Interleukin-6 receptor α 
IRS     Insulin Receptor Substrate 
JAK     Janus Kinase 
xvi 
 
JNK     c-jun-N- terminal kinase 
KO     Knock out 
MEF-2    Myocyte Enhancer Factor-2 
min     minute 
MKK6     Mitogen Activated Protein Kinase Kinase 6 
mRNA    messenger RNA 
mtDNA    mitochondrial DNA 
mtFAM    mitochondrial Transcription Factor A 
mTOR    mammalian Target of Rapamycin 
NRF     Nuclear Receptor Factor 
OXPHOS    Oxidative Phosphorylation 
p38 MAPK    p38 Mitogen Activated Protein Kinase  
PEPCK    phosphoenolpyruvate carboxy kinase 1 
PGC-1α    Peroxisome Proliferators Activator Receptor γ 
     Co-activator-1α 
PI3-K     Phosphatidylinositol 3 Kinase 
PRMT-1    Arginine Methylation Transferase-1 
RER     Respiratory Exchange Rate 
rh-IL-6    recombinant human Interleukin-6 
SEM     standard error of mean 
sgp130    Soluble gp130 
sIL-6R    soluble Interleukin-6 receptor 
SIRT-1    Sirtuin-1 
SOCS-3    Suppressor of Cytokine Signalling 3 
SRC-2  Steroid Receptor Coactivator-2 
STAT-3 Signal Transducers and Activators of 
Transcription-3 
TNF     Tumour Necrosis Factor 
UCP     Uncoupling Protein 
WAT     White Adipose Tissue 
WT     Wild type 
VO2     Capacity for volume of Oxygen 
xvii 
 
Abstract 
 
Upon exercise Interleukin-6 (IL-6) is released by contracting skeletal muscle. This 
increased release of this cytokine increases fat and glucose oxidative metabolism 
within muscle and adipose and suppress hepatic glucose output.  IL-6 is an 
unsuitable anti-obesity therapeutic agent as it is implicated in the pathogenesis of 
many inflammatory conditions. Classic IL-6 signal transduction occurs through a 
trans-membrane complex consisting of an IL-6 receptor α homo-dimer and gp130 
receptor-β (gp130Rβ). Alternatively, signalling may occur through a complex of IL-
6 and its soluble receptor (sIL-6R) which in turn targets membrane bound 
gp130Rβ.  This phenomenon known as “IL-6 trans-signalling” has implications, as 
cells devoid of the membrane bound IL-6 receptor remain responsive to the 
cytokine due to the ubiquitous expression of gp130. Futhermore, it is known that 
the pro inflammatory effects of IL-6 are mostly mediated via IL-6 trans-signalling. 
Interestingly, in transgenic mice over expressing a soluble form of gp130 (sgp130), 
the naturally occurring competitive inhibitor of sIL-6R signalling, inflammation is 
prevented. Thereby, co-treatment with IL-6 and sgp130 may have therapeutic 
advantages for obesity related diseases, providing signalling exclusively through 
the membrane bound IL-6Rα/gp130β.  
 
The primary focus of this dissertation was to examine the effect of IL-6/sIL-6R 
signalling in the presence and absence of sgp130 on inflammation and metabolism 
within skeletal muscle, adipose and liver in vitro and in vivo. Hyper IL-6, a designer 
cytokine consisting of rh-IL-6 and sIL-6R connected via a polypeptide linker, was 
utilised to mimic IL-6 trans-signalling. In vitro, phosphorylation of STAT3 (Tyr705), 
and Akt (Ser473) were elevated in both L6 myotubes and CRL1439 hepatocytes 
incubated with Hyper IL-6 when compared with control. Importantly, signalling was 
reduced upon co-treatment with sgp130Fc in CRL1439 whilst it was entirely 
preserved in myotubes. Moreover, Hyper IL-6 potentiated Insulin stimulated 
glucose uptake in the absence and presence of sgp130Fc.   
 
xviii 
 
Consistent with the fore mentioned data, IL-6 trans-signalling events occured in 
liver, muscle and epidydimal White Adipose Tissue (WAT) in vivo, in a tissue type 
dependent manner. Moreover, it was demonstrated sgp130Fc inhibited Hyper IL-6 
induced signalling, however the degree to which inhibition occurred was tissue type 
dependent.  
 
Finally, contrary to the transient release seen during exercise, states of disease are 
often associated with chronically elevated IL-6 within the circulation leading to 
aberrant pathway activation and inflammation within many tissues. As this paradox 
exists, prolonged Hyper IL-6 administration on inflammation and whole body 
energy metabolism was examined in vivo. Although sgp130Fc was able to prevent 
severe injury and chronic inflammation in the liver as a consequence of prolonged 
Hyper IL-6 treatment, it was unable to improve insulin resistance induced by this 
cytokine. This could reflect the enhanced bioactivity of the designer cytokine.          
 
Collectively, these data support the proposition that in muscle, Hyper IL-6 induced 
trans-signalling is neutralised by sgp130Fc whilst the beneficial effects on 
metabolism associated with membrane bound signalling remains intact in vitro. In 
vivo, acute administration of this designer cytokine is able to regulate signalling 
pathways associated with metabolism and inflammation, an effect that sgp130Fc 
co-administration inhibited in a tissue type dependent manner. Due to the potency 
of Hyper IL-6, even when co-administered sgp130FC, it remains a poor candidate 
as a therapeutic tool in the war against obesity. This, however, does not discount 
the potential of a gp130 receptor/ligand like drug design as an anti-obesity agent.     
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CHAPTER ONE 
 
Introduction and Literature  
Review  
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1.1 Introduction 
The prevalence of diabetes has severely increased world wide over recent years. 
In Australia alone, where the incidence of the disease is particularly high, it is 
estimated that 1 million people are afflicted by diabetes and that, by the year 2025, 
it is predicted 333 million people world wide will be suffering from this debilitating 
disease. This disease has great social and economical ramifications, in 2004 the 
cost of diabetes to the Australian community exceeded $900 million 
(http://www.health.gov.au/internet/main/publishing.nsf/content/pq-diabetes-stats, 
last updated: May 2008). Hallmarks of this debilitating disease are obesity and 
associated inflammation of metabolic tissues. As this is so, the need for a 
therapeutic and/or prophylactic agent is in high demand. One such potential 
therapeutic anti obesity agent may be a gp130 receptor/ligand like drug design, 
and such ligands have already entered clinical trials (Ettinger et al., 2003).    
 
Upon Interleukin-6 binding to its receptor, a transmembrane complex is formed 
with a homo-dimer of the gp130 receptor. This causes the subsequent activation of 
JAK/STAT, PI3-Kinase and MAPK pathways to occur (Febbraio, 2007). This is of 
utmost importance as previous research has demonstrated that these pathways 
are important regulators of metabolism within skeletal muscle. As skeletal muscle 
is the major tissue involved in limiting the rate of insulin-stimulated glucose 
disposal (Yki-Järvinen et al., 1987) it is therefore, logical that this tissue may be a 
player in the development of insulin resistance. In vitro, co-treating L6 myotubes 
with IL-6 potentiates insulin induced glucose uptake and increases fatty acid 
oxidation (Carey et al., 2006). Furthermore, in vivo studies have implicated IL-6 in 
the oxidation of glucose and lipid (Carey et al., 2006 and Van Hall et al., 2003). 
However, deregulated production of this cytokine and the soluble form of its 
receptor is associated with many pro-inflammatory conditions, making the cytokine 
alone a poor candidate as a therapeutic agent. Interestingly, in transgenic mice 
over expressing a soluble form of gp130 (sgp130), the naturally occurring 
antagonist of sIL-6R signalling, inflammation is prevented (Rabe et al., 2008). 
Moreover, signalling mediated via the membrane bound receptor remains intact. 
As this is the case, co-treatment with IL-6 and sgp130 may have therapeutic 
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advantages for obesity related diseases, providing signalling exclusively through 
the membrane bound IL-6Rα/gp130β whilst maintaining the beneficial effects often 
associated with IL-6 signalling.  
 
1.2 Interleukin-6 
Interleukin-6, a pleiotropic cytokine, was first identified well over 25 years ago. In 
1980, IL-6 was isolated in fibroblasts and cloned (Weissenbach et al., 1980). Initial 
indications from this study, were that IL-6 possessed anti viral activity similar to 
Interferon-β-1, an effect that would later be disproved (Content et al., 1982; 
Poupart, et al., 1987). As a result of their studies, Weissenbach and colleagues 
called the molecule Interferon-β-2. Over the proceeding decade, the biological 
function of IFN-β-2 remained controversial, a reflection of which was the numerous 
pseudonyms assigned to the protein. These included; B Cell Differentiation Factor 
(Okada et al., 1983), 26 kDa protein (Haegeman et al., 1986), Hybridoma Growth 
Factor (Van Damme et al., 1987a and 1987b) and Hepatocyte Stimulating Factor 
(Ritchie and Fuller, 1983), to name a few. This cytokine was also described as 
human B-Cell stimulatory factor (BSF-2) as it was capable of inducing maturation 
of B cells into immunoglobulin secreting cells (Hirano et al., 1986). BSF-2 was 
purified and the NH2-terminal amino acid sequence encoding a novel interleukin 
that was “functionally and structurally unlike any other known protein” was 
determined. Most interestingly, it was  noted that patients with Cardiac Myxoma 
cells produced high levels of BSF-2 and were prone to “auto immune disease like 
symptoms” (Hirano et al., 1986). As a consequence, these authors proposed that 
deregulated production of this cytokine contributes to autoimmune pathogenesis, 
the first evidence of a “pro-inflammatory” role for this cytokine. In 1987, Poupart 
confirmed that IFN-β-2 had no anti-viral activity and in support of the fore 
mentioned study, was highly efficacious at modulating growth and differentiation of 
B cells. Poupart proposed to adopt the name of “Interleukin 6”, thereby eliminating 
the confusion caused by the varying nomenclature.  
  
In humans, IL-6 is a pro-inflammatory glycoprotein of 184 amino acids with a 
molecular weight of 21-30 kDa (May et al., 1989). The variation in mass of IL-6 is 
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dependent on N-glycosylation and post translational modification of this protein 
(May et al., 1989; Santhanam et al., 1989). A member of the IL-6 family of 
cytokines that includes; Cardiotrophin 1, Cardiotrophin like cytokine, Ciliary 
Neurotropic Factor (CNTF), Interleukin-11, Leukemia Inhibitory Factor and 
Oncostatin M, it consists of 4 α-helices; A, B, C and D, linked by a short chain and 
2 long chain loops folded in a „up-up-down-down‟ topology (Figure 1.1) (Somers, 
Stahl and Seehra, 1997). Although IL-6 family members recognise and bind their 
own specific receptor complex they are unified by the required recruitment of 
glycoprotein-130 (gp130) receptor complex for cellular signal transduction to occur 
(Heinrich et al., 2003).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  Structure of Interleukin-6. IL-6 consists of four long helices, depicted 
here as A (red), B (blue), C (yellow) and D (green), joined by two long chains and a 
short chain. The binding sites of IL-6R and gp130 are circled (Heinrich et al., 
2003).   
 
 
In humans, mice and rats, the IL-6 gene contains 4 introns and 5 exons (Yasukawa 
et al., 1987) and is located at chromosome 7p21-p14 in human (Lahn et al., 1997) 
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and at chromosome 5 in the mouse genome (Mock et al., 1989). A high degree of 
homology for the nucleotide and amino acid sequences exists across IL-6 species. 
Human and murine IL-6 share 60 % nucleotide and 42 % amino acid homology 
and similarly rat IL-6 shares 68 % and 58 %, respectively, sequence homology with 
that of human IL-6 (Tanabe et al., 1988, Northemann et al., 1989).  Northemann 
(ibid) also noted that rat and murine IL-6 also share a high degree of nucleotide (92 
%) and amino acid (93 %) sequence homology. Although high sequence homology 
exists between IL-6 species, the same can not be said for their respective 
receptors. As a consequence there is limited cross reactivity, however the murine 
IL-6 receptor is still capable of binding human IL-6.   
 
1.3 IL-6 receptor and its interaction with gp130  
The membrane bound IL-6 receptor (IL-6R) is an 80 kDa, type I membrane protein 
that consists of an extracellular N-terminus, a trans-membrane domain and a 
cytoplasmic domain (Figure 1.2). This cytokine receptor consists of 468 amino 
acids; including a 19 amino acid signal peptide sequence and a cytoplasmic 
domain of approximately 80 amino acids (Yamasaki et al., 1988). Like most 
cytokine receptors, it has a conserved structural feature of a cytokine binding 
module. The cytokine binding module (CBM) consists of an N terminal of 4 
cysteine residues, two fibronectin type-III-like domains (D2 and D3) and a WSXWS 
motif in the C terminal (Bazan, 1990). Proximal to the CBM, an Ig-like domain (D1) 
of approximately 90 amino acids is located at the N-terminal (Yamasaki et al., 
1988).   
 
It is well established that IL-6 may also bind the agonistically soluble form of the IL-
6 receptor, known as soluble IL-6 receptor (sIL-6R). The IL-6/sIL-6R targets the 
ubiquitously expressed gp130 receptor, so cells normally devoid of membrane 
bound IL-6R remain IL-6 responsive. This phenomenon is commonly known as “IL-
6 trans-signalling”. Initially, characterisation of the sIL-6R led to the conclusion it 
was biologically relevant. HepG2 cells, which are naturally devoid of the membrane 
bound receptor, were co-treated with IL-6 and the sIL-6R receptor (Stoyan et al., 
1993). As a consequence the acute phase protein α1-antichymotrypsin (ACT) was 
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produced. Many studies subsequently demonstrated that the sIL-6R was capable 
of inducing other acute phase proteins, such as haptoglobin (Weiergräber et al., 
1995) and serum amyloid A (Rabe et al., 2008). Soluble IL-6R has since been 
implicated in inflammatory conditions often associated with high concentrations of 
IL-6 within the circulation.  
 
Initial studies demonstrated that upon challenge with bacterial toxins and chemical 
assault, rapid shedding of membrane bound IL-6R from human macrophages 
occurred (Walev et al., 1996). Importantly, sIL-6R collected from the supernatant of 
bacterially challenged monocytes was biologically active. In HepG2 cells, it was 
able to bind to its ligand and induce haptoglobin mRNA, an IL-6 dependent 
response. Soluble IL-6R is generated by ectodomain shedding of the receptor by 
metalloproteases. These proteins proteolytically cleave the receptor close to the 
membrane anchors, thus releasing the extracellular domains of the receptor into 
the extracellular space. Metalloproteases responsible for ectodomain shedding 
may be either endogenous, for example ADAM 10 and ADAM17 (Matthews et al., 
2003) or exogenous such as microbial proteases (Vollmer et al., 1996). Secondly, 
sIL-6R may be generated through alternatively spliced mRNA (Lust et al., 1992). 
Although the soluble form of the receptor lacks the trans-membrane and 
cytoplasmic fragments typical of the membrane bound species, the ability to bind to 
its ligand remains unaffected as the extracellular CBM remains intact (Lust et al., 
1992).  
 
1.4 Interleukin 6 signalling  
IL-6 binds to the cytokine binding module of IL-6R, forming a ligand/receptor 
complex. In turn, the IL-6/IL-6R complex binds to the cytokine binding module of 
gp130, ultimately leading to the homodimerisation of gp130 and internalisation of 
the complex (Graeve et al., 1996). gp130, a 130 kDa glycoprotein, was first 
isolated from mixed lymphocyte cultures (Andersson et al., 1978). gp130, a 
ubiquitously expressed glycoprotein, is the central player in IL-6 family cytokine 
signalling. The extracellular domain of gp130 consists of 597 amino acids divided 
into 5 fibronectin III-like domains and an Ig-like N-terminal domain. Domains 1, 2 
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and 3 are β-sheet sandwich domains important in cytokine engagement with the 
CBM (domains 2 and 3) of gp130 (Figure 1.2, Chow et al., 2001 and Heinrich et al., 
2003). IL-6 and its receptor interact through the site I epitope on the B and D 
helical faces of the cytokine (Figure 1.1). This complex then interacts with the 
cytokine binding module of gp130 at Site II, forming an intermediate trimolecular 
complex. For signal transduction to occur the trimolecular complex must become 
activated. Binding of the Ig-like domain must occur at Site III of IL-6, thus forming 
an activated ternary complex. This ternary complex transitions to form a signalling 
competent, high affinity hexameric complex consisting of two IL-6, two IL-6R and 
two gp130 molecules (Boulanger et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2  The structural organisation of IL-6, IL-6Rα and gp130. Depicted here 
as Ig-like: Ig like domain, FNIII: Fibronectin-Like domain, CBM: Cytokine Binding 
Module, TM: transmembrane, Y: tyrosine phosphorylation site (adapted from 
Heinrich et al., 2003) 
 
 
It is well established, upon homodimerisation of gp130 the intermediatory step of 
recruitment and activation of gp130 associated Janus Kinases (JAK-1 and JAK-2) 
occurs (Stahl et al., 1994; Wang and Fuller, 1994). This is sequentially important in 
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mediating downstream signal transduction. Upon complex formation, JAK is 
activated and phosphorylates the last 4 carboxyl terminal tyrosine containing motifs 
within the cytoplasmic tail of gp130 (Stahl et al., 1995). Tyrosine phosphorylation 
leads to the formation of Src Homology 2 phosphotyrosine binding domains for 
protein-protein interaction with Signal Transducers and Activators of Transcription 
(STAT-1 and STAT-3). STAT proteins, which contain SH2 binding domains, dock 
with the autophosphorylated tyrosine residues subsequently leading to 
phosphorylation of STAT-3 and homo- or hetero- dimer formation to occur 
(Lütticken et al., 1994). The STAT dimer then translocates to the nucleus where it 
initiates gene transcription. Post translocation, STAT-3 has the ability to recognise 
the IL-6 responsive TT(N)4AA motif within the 5‟ flanking region of the promoter of 
transcriptional targets (Hattori et al., 1990; Zhang et al., 1996). IL-6 induced 
transcriptional targets include those encoding proteins commonly associated with 
the acute phase response, such as C-Reactive Protein (CRP) (Zhang et al., 1996), 
α1-antichymotrypsin (ACT) (Kordula et al., 1998), rat α2-macroglobulin (Hattori et 
al., 1990) and importantly, Suppressor of Cytokine Signalling-3 (SOCS-3) 
(Auernhammer, Bousquet and Melmed, 1999).   STAT-3 dependent activation of 
SOCS-3 mRNA is induced rapidly upon IL-6 stimulation and is considered to be of 
great importance in the negative feedback inhibition of IL-6 signalling. 
 
SOCS-3 regulates IL-6 signalling through a negative autoregulatory loop by binding 
gp130 at Tyr757, thereby preventing associated JAK activity (Krebs and Hilton, 
2001). This limits the autophosphorylation of gp130 and prevents STAT interaction 
with the cytoplasmic domain of the receptor. Alternatively, SOCS-3 may also target 
the receptor complex for proteosomal degradation by ubiquitination (Krebs and 
Hilton, 2001).  The increase in SOCS-3 has further implications with regards to 
metabolic signalling as this protein is a known inhibitor of insulin signalling within 
the liver. SOCS-3 has the ability to bind to the Insulin Receptor at Tyr960, a key 
recognition site for IRS-1 and -2, thereby preventing phosphorylation of these 
proteins and subsequently suppressing insulin induced activation of PI3-Kinase 
and Akt (Ueki, Kondo and Kahn, 2004 and Torisu et al., 2007).    
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Alternatively, IL-6 induced gp130 activity may also lead to the activation of either or 
both of PI3-Kinase (Weigel et al., 2008) and Ras-MAPK pathway (Leu et al., 2003 
and Heinrich et al., 2003).  These fore mentioned signalling pathways are 
important mediators of many intracellular processes including protein synthesis, 
cell proliferation and differentiation, insulin signalling and glucose and fatty acid 
metabolism.  
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Figure 1.3  Mechanisms of IL-6 signal transduction – a simplified schematic. (a) 
Classic cognate membrane bound IL-6R signalling occurs through the 
transmembrane complex of IL-6 receptor α homodimer and gp130. gp130 receptor 
activation by the IL-6/IL-6R complex causes the intracellular tyrosine 
phosphorylation of its cytoplasmic tail by its associated JAKs. This leads to the 
docking of STAT 1 and 3 to the phospho-tyrosine sites. This causes the 
phosphorylation of STAT-3 and subsequently translocation of this protein to the 
nucleus where it initiates gene transcription. In turn, STAT-3 induced gene 
transcription negatively regulates IL-6 activity through inhibition of JAKs induced by 
increased SOCS-3 activity. Furthermore, Shp2 binds to activated gp130 resulting 
in pathway activation of Ras-MAPK and PI3-Kinase. (b) In a process known as “IL-
6 trans-signalling”, agonistic sIL-6R may be generated through alternate mRNA 
splicing or via cleavage of the membrane bound IL-6R by metalloproteases 
(referred to as “sheddase” within this figure). IL-6/sIL-6R complex then targets 
gp130 and results in the downstream activation of the fore mentioned pathways.  
 
 
 
1.5 IL-6 in Health and Disease 
In accordance with the true pleiotropic nature of IL-6, the release of this cytokine 
mediates various effects in both health and disease. Contrary to the “pro-
inflammatory cytokine” description many studies have focussed on examining IL-6 
production and release during exercise and the beneficial effects on metabolism 
often associated with this cytokine. It is well established that contracting skeletal 
muscle produces and releases IL-6 (Ostrowski et al., 1998 and Hiscock et al., 
2004). Subsequently, increased release of IL-6 into the circulation provides a 
mechanism by which tissues can “cross-talk” (For review refer to Pedersen and 
Febbraio, 2008), whereby IL-6, produced by other tissues such as skeletal muscle, 
is able to bind to, and elicit effects in, tissues such as liver and adipose. This, in 
turn, leads to IL-6 dependent increases in hepatic glucose output and increased 
lipolysis of adipose (Figure 1.4). Tissue IL-6 dependent cross-talk has also been 
noted in states of inflammation. HFD induced insulin resistance was less in liver of 
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mice with ablated JNK1 in adipose tissue when compared to littermate control mice 
(Sabio et al., 2008). Upon further exploration it was apparent this was IL-6 
dependent. JNK1 ablated mice had suppressed IL-6 production by adipose tissue 
and as a consequence decreased expression of SOCS-3 within the liver, an 
important mediator of hepatic insulin resistance.    
 
Many studies have examined the effect of this cytokine on metabolism in vitro and 
in vivo. In vitro, IL-6 is known to increase glucose uptake in 3T3-L1 adipocytes 
(Stouthard, Elferink and Sauerwein., 1996). In human skeletal muscle cells 
glycogen synthesis is increased through IL-6 dependent activation of Akt at the 
ser473 residue (Weigert et al., 2005). Carey and co-workers (2006) demonstrated 
IL-6 leads to increased glucose uptake and fat oxidation in L6 myotubes. This 
study also implicated AMPK activity in IL-6 dependent increases in metabolism. In 
L6 myotubes infected with an AMPK DN virus, the IL-6 induced increase in glucose 
uptake was ablated. In further support of the notion IL-6 positively regulates 
metabolic processes, infusion of IL-6 into humans increased insulin stimulated 
glucose disposal as determined by hyperinsulinaemic-euglycaemic clamp (Carey 
et al., 2006). This was in accordance with previous research performed by 
Febbraio and colleagues (2004) who discovered recombinant human IL-6 (rh-IL-6) 
infusion increased the rate of contraction induced endogenous production of 
glucose and its rate of disposal.  Recombinant human IL-6 infusion was also 
utilised by Van Hall et al., (2003) to determine the effect of IL-6 on human fat 
metabolism, in vivo. Recombinant human IL-6 infusion increased lipolysis, as 
indicated by increased appearance and elevated sera levels of fatty acids, and fat 
oxidation.  
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Figure 1.4 IL-6 dependent “tissue crosstalk” during exercise. Contracting 
skeletal muscle releases IL-6 into the circulation. IL-6 acts on skeletal muscle and 
other tissues in a paracrine manner, activating Akt and STAT-3 leading to 
increased glucose uptake and fat oxidation in muscle, increased lipolysis of 
adipose tissue and hepatic glucose output (Pedersen and Febbraio, 2008). 
 
 
Contrary to the fore mentioned studies that demonstrate a beneficial role of IL-6 in 
metabolic control, this cytokine has also been implicated in insulin resistance in 
cultured hepatocytes in vitro, causing decreased glucose transport (Senn et al., 
2002) and inhibited insulin stimulated glycogen synthesis (Kanemaki et al., 1998). 
In rats, IL-6 increases production of the acute phase protein α2-macroglobulin and 
causes the degradation of glycogen within the periportal zone of the liver 
(Lienenlüke and Christ, 2007). These changes could possibly contribute to 
decreased glucose production often noted during prolonged acute phase 
inflammation.  
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Interleukin-6 has also been implicated in the pathogenesis of many inflammatory 
conditions. IL-6/sIL-6R complex signalling is an important mediator of such 
inflammatory conditions as arthritis (Nowell et al., 2003), regenerative hyperplasia 
and adenomas of the liver (Maione et al., 1998), AIDS associated Kaposi‟s 
Sarcoma (Miles et al., 1990) and inflammatory bowel diseases such as Crohn‟s 
disease (Jostock et al., 2001), ileitis (Sander et al., 2008) and ulcerative colitis 
(Atreya et al., 2000). It would appear the role of IL-6 in these conditions is through 
directing transition of acute phase inflammation to a chronic state of inflammation. 
This occurs through a change in profile of the subset of the infiltrating cells (Figure 
1.5), a response that is IL-6 trans-signalling dependent as many of the infiltrating 
cells are naturally devoid of the membrane bound IL-6R. Cells migrate from the 
vasculature to the area of infection or damage in an IL-6/gp130/STAT-3 dependent 
manner (Sander et al., 2008). Within the first 24 to 48 hours, the cellular population 
present is predominately leukocytes. The termination of this innate immune 
response is dependent on IL-6 driven activation of STAT-3. If inflammation is not 
resolved within 48 hours, IL-6/gp130/STAT-3 signalling within the neutrophils leads 
to decreased production of chemo-attractants such as CXCL1/KC, thereby 
impairing trafficking of neutrophils to the area (Fielding et al., 2008). In concert with 
increased production of CXCL1/KC, increased neutrophilic apoptosis and shedding 
of the sIL-6R occurs (Chalaris et al., 2007). This leads to the trafficking and 
recruitment of monocytes and T Cells to the area of damaged tissue (Sander et al., 
2008).   
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Figure 1.5 The role of IL-6 in transition from innate immunity to an acquired 
immune response. IL-6 is a central player in the resolution of innate immunity and 
progression to acquired immunity. Central to this concept is the ability of this 
cytokine to regulate the profile of infiltrating immune cells to the area of damage 
(Jones, 2005) 
 
 
Most recently, a study by Briso, Dienz and Rincon (2008) proposed autoimmune 
diseases such as arthritis may be a consequence of sIL-6R produced by auto 
reactive T Cells. In support of this notion their study illustrated both naïve and 
memory CD4+ T Cells are also capable of shedding sIL-6R. Moreover, increases in 
sIL-6R production were highly correlative with expression of the metalloprotease 
ADAM17 within these cells. As memory CD4+ T Cells are paramount to acquired 
immunity this may have implications with regards to autoimmune diseases which 
often have deregulated T Cell expression and function.   
 
Vital to hepatic production of acute phase proteins is the ability of sIL-6R to act in a 
paracrine manner. Using in situ hybridisation, expression patterns of IL-6 and sIL-
6R were examined in transgenic mice expressing either human IL-6 only or human 
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IL-6 and soluble IL-6R under liver specific promoters (Peters et al., 1997). 
Importantly, whilst endogenous murine IL-6 levels remained unaltered, human IL-6 
serum levels were increasingly elevated as the mice aged. Furthermore, human IL-
6 serum concentration was highly correlative with the mRNA expression of the 
acute phase protein haptoglobin, an effect that was potentiated in the double 
transgenic mice. From this study, the investigators concluded that at low 
concentrations, the sIL-6R acts in a paracrine manner. However, when at higher 
circulating concentrations, such as that seen during immune challenge, the sIL-6R 
serves as an important mediator of local and systemic effects. This concept is 
central to the regulation of the immune response.  
 
It is well established upon immune challenge, there is elevated shedding of the sIL-
6R and increased production of IL-6 by immune cells. Importantly, by acting on 
cells in a paracrine manner, increased circulating concentrations of IL-6 induces 
the transcription and production of IL-6, sIL-6R and acute phase proteins by 
hepatocytes (Figure 1.6). Hepatic production of acute phase proteins is important 
in the regulation of the immune response and tissue repair. Acute phase proteins 
serve as mediators of processes central to immunity such as complement, 
phagocytosis, recruitment and trafficking of cellular subset populations to areas of 
inflammation and coagulation to name a few. IL-6 and sIL-6R are key players in 
mediating changes in the kinetic profile of IL-6 inducible acute phase proteins 
(Figure 1.6). C-Reactive Protein (CRP) circulating levels are rapidly increased in 
response to elevated IL-6/sIL-6R concentrations (Zhang et al., 1996), an important 
protein in the activation of the immunological process complement (Black, Kushner 
and Samols, 2004). As CRP levels fall, a concurrent increase in haptoglobin and 
fibrinogen occurs (for review see Gabay, 2006). Haptoglobin is responsible for the 
scavenging of haemoglobin produced upon haemolysis and fibrinogen is a crucial 
player in the tissue repair process due to its coagulation properties. Encoding 
genes for acute phase proteins such as haptoglobin (Oliviero and Cortese, 1989) 
and fibrinogen (Dalmon, Laurent and Courtois, 1993; Zhang, Fuentes and Fuller, 
1995 and Liu and Fuller, 1995) possess IL-6 responsive elements within the 5‟ 
flanking region of their promoter. The acute phase immune response may be 
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inhibited through the use of the naturally occurring antagonist of IL-6 signalling, 
sgp130, preventing production of 1-antichymotrypsin (Jostock et al., 2001), 
haptoglobin (Tenhumberg et al., 2008) and serum amyloid A (Rabe et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6  Kinetic profile of acute phase protein production induced by IL-6 
(Gabay, 2006) 
 
 
1.6 Soluble gp130, the natural antagonist of IL-6 signalling 
In 1993, Narazaki and colleagues discovered the presence of a soluble form of the 
gp130 receptor (sgp130) present within human plasma (Narazaki et al., 1993). 
Soluble gp130 is a glycoprotein of approximately 100 kDa, which lacks the 
transmembrane and cytoplasmic domains the membrane bound form of the 
receptor possesses (Montero-Julian et al. 1997; Diamant et al., 1997; Jostock et 
al., 2001). Like the sIL-6R, the soluble form of the gp130 receptor is produced by 
proteolytic cleavage of membrane bound gp130 (Müllberg et al., 1993; Montero-
Julian et al., 1997) or through alternate splicing of mRNA (Diamant et al., 1997). As 
the CBM of sgp130 remains intact, this receptor still has the ability to form ternary 
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complexes with sIL-6R bound to its ligand. Interestingly, the soluble form of the 
gp130 subunit, via competitive inhibition, is an IL-6 antagonist. sgp130 acts as a 
decoy, decreasing the bioavailability of IL-6/sIL-6R for ternary complex formation 
with gp130 (Figure 1.7, Jostock et al., 2001). However, sgp130 preferentially binds 
to IL-6/sIL-6R and is unable to bind to IL-6 alone, thus inhibiting signalling events 
mediated via the ternary complex only. This leaves IL-6 signalling via membrane 
bound IL-6R unscathed.    
 
    
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Inhibitory mechanism of sgp130. As sgp130 binds to the sIL-6R and 
not IL-6 alone, the cytokine is free to bind to the membrane bound IL-6Rα. Thereby 
eliciting a signalling response mediated via the membrane bound complex of IL-
6Rα/gp130 complex. Competitive inhibition occurs when there is a molar excess of 
sgp130, as sIL-6R is able to bind to both soluble gp130 and its membrane bound 
equivalent. Symbols are as for Figure 1.3 (adapted from Jostock et al., 2001). 
 
 
Many studies have demonstrated sIL-6R signalling inhibition using sgp130 to be a 
biologically relevant phenomenon. Initially, Narazaki et al. (1993) noted that healthy 
human sera contained 390 ng∙ml-1 sgp130. In the murine pro B Cell line 
transduced with human gp130, treatment with human serum supplemented with rh-
IL-6 induced DNA synthesis.  Depleting the sera of sgp130 caused further DNA 
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synthesis. This implies naturally produced sgp130 has the capacity to negatively 
regulate IL-6 signalling mediated via gp130. Studies that followed demonstrated 
sgp130 was able to inhibit IL-6/sIL-6R driven proliferation of gp130 transduced 
BAF3 cells (Müller-Newen et al., 1998) but not that of IL-6 stimulated BAF3 cells 
expressing membrane bound IL-6R and gp130 (Jostock et al., 2001). Thereby 
insinuating sgp130 inhibited signalling mediated via sIL-6R. It is important to note 
the BAF3 cell line is unique as it is naturally devoid of the gp130 receptor 
(Nandurkar et al., 1996) and is therefore a useful tool for exploration of gp130 
targeted therapies. In an experimentally induced form of colitis, Atreya and 
Colleagues (2000) demonstrated that blockade of IL-6/sIL-6R signalling using 
sgp130Fc, sgp130 receptor ligated to the FC portion of IgG (Figure 1.8), showed 
no signs of rectal prolapse, macroscopic evidence of inflammation or wasting 
disease when compared with untreated mice. IL-6 -/- mice induced with an 
experimental model of arthritis using Hyper IL-6, a designer cytokine of IL-6 linked 
to soluble IL-6R, had less severe joint destruction and inflammation when in the 
presence of sgp130 (Nowell et al., 2003). They also noted sgp130 decreased local 
activation of STAT-3 dependent leukocyte migration.  
 
 
 
 
 
 
 
Figure 1.8 Schematic of the structure of sgp130Fc. The sgp130Fc consists of 
the extracellular domains; IgG like domain (grey), the cytoplasmic binding domain 
(white) and the Fibronectin III like domains (black) ligated to the Fc fragment of IgG 
via a synthetic oligonucleotide adapter (Jostock et al., 2001) 
 
 
In experimentally induced murine acute peritonitis, the presence of this soluble 
receptor decreased monocyte and lymphocyte migration to the area of 
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inflammation and increased the presence of neutrophils thereby preventing the 
transition from an early innate immune response to that of acquired immunity 
(Richards et al., 2006). Importantly, using the air pouch model of inflammation in 
transgenic mice with over expression of sgp130 (Rabe et al., 2008), demonstrated 
the transition of an inflammatory response from a neutrophil dominant infiltrate to 
the mononuclear phase is entirely dependent on IL-6 trans-signalling rather than 
classic IL-6 signalling. The fore mentioned studies, compiled, provide 
overwhelming evidence sgp130 inhibits signalling mediated via the sIL-6R. 
 
1.7 The designer cytokine Hyper IL-6  
A great deal of the scientific community‟s understanding of cellular events 
mediated via sIL-6R and sgp130 have arisen through the use of the designer 
cytokine Hyper IL-6 and its antagonist sgp130Fc.  In 1997, a fusion protein of 
recombinant human IL-6 covalently linked via a synthetic polypeptide chain to sIL-
6R was expressed in and secreted from yeast (Figure 1.9, Fischer et al., 1997). 
This “designer cytokine” was 100 to 1000 fold more bioactive than that of IL-6 and 
sIL-6R unlinked. The fusion protein was able to effectively induce the expansion of 
the human hematopoietic progenitor cell line BAF3 transduced with gp130 and 
stimulate the production of the acute phase protein haptoglobin by HepG2 cells in 
a dose dependent manner.  In a later study from the same research group (Peters 
et al., 1998) Hyper IL-6 induced a heightened and prolonged acute phase 
response, as measured by haptoglobin mRNA expression in liver of NMRI mice 
when compared with rh-IL-6 alone. It was hypothesised this marked difference 
between rh-IL-6 and the designer cytokine was due to a) the higher expression of 
gp130 compared to that of membrane bound IL-6R and b) slower internalisation as 
a result of a higher binding affinity between Hyper IL-6 and gp130 than that of IL-6 
to cell surface alone. In support of the later, prolonged elevated Hyper IL-6 serum 
concentration was evident when compared to IL-6 alone.  
 
The heightened and prolonged response to Hyper IL-6 would appear to be, in part, 
a consequence of an enhanced ability to induce nuclear translocation and DNA 
binding by STAT-3 (Rakemann et al., 1999). Many studies ensued exploring the 
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effect of Hyper IL-6 on inflammation within liver (Peters et al., 1998) and 
gastrointestinal derived cell lines (Jostock et al., 2001) and cellular proliferation and 
differentiation of hematopoietic (Fischer et al., 1997), tumourigenic melanoma 
(Özbek et al., 2001) and neural and glial (Islam et al., 2009) derived cell lines. 
However, there is a lack of literature examining the potential effect this designer 
cytokine has within skeletal muscle and adipose tissue. This is surprising given the 
prominent role IL-6 itself plays in skeletal muscle and adipose metabolism. 
 
In summary, IL-6 is an important cytokine involved in the regulation of many 
cellular processes including inflammation and metabolism. It is of great importance 
to note, IL-6 mediated inflammation occurs through an agonistic phenomenon 
known as IL-6 trans-signalling, whereby IL-6 binds to the soluble form of its 
receptor and targets the ubiquitously expressed gp130. Hence, cells naturally 
devoid of the membrane bound IL-6R remain sensitive to this cytokine.  Although 
IL-6 has many beneficial effects on metabolism, it is an unsuitable candidate for 
use as a therapeutic agent in the treatment of metabolic disorders such as 
diabetes due to the dual functionality of this protein. However, sgp130, a naturally 
occurring antagonist of IL-6 trans-signalling, is able to block IL-6 induced 
inflammation through its interaction with IL-6/sIL-6R whilst signalling mediated via 
the membrane receptor remains intact.   
 
Whether it is possible to prevent IL-6 induced inflammation through blockade of IL-
6 trans-signalling using sgp130 whilst maintaining any beneficial effects on 
metabolism mediated via the membrane bound IL-6 receptor has yet to be 
elucidated. Hyper IL-6, a designer cytokine has previously been used as an agent 
to mimic IL-6/sIL-6R signalling in various cell types but the effect this cytokine has 
on skeletal muscle metabolism has yet to be elucidated. Through understanding 
ligand / receptor interactions within metabolically active tissues such as adipose 
and muscle, a “designer cytokine” capable of selectively targetting various 
signalling components may be a useful tool in the war against metabolic diseases 
such as diabetes. One such potential therapeutic anti-obesity agent may be a 
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gp130 receptor/ligand like drug design. This forms the basis of the current 
dissertation.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 The fusion protein Hyper IL-6. a) A molecular model of Hyper IL-6 
illustrating the four helices of IL-6; a,b,c and d (purple) linked via a polypeptide 
linker (grey) to Domain-2 and 3 (DII and DIII)  of the sIL-6R CBM (orange) b) 
Schematic of Hyper IL-6 cDNA used for the expression and secretion of the protein 
in yeast.  (Fischer et al., 1997) 
 
  
a) 
b) 
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CHAPTER TWO 
 
Aims of the Study 
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2.1 Aims of the study 
The significance of IL-6 in the regulation of metabolism is well established, 
however it is not known whether this important biological process occurs via the 
membrane bound IL-6 receptor or via the agonisitic soluble IL-6 receptor, a 
phenomenon most commonly known as “trans-signalling”. The primary aim of this 
study was to elucidate whether IL-6 signalling via the sIL-6R, using the designer 
cytokine Hyper IL-6 to mimic this scenario, is biologically relevant in the regulation 
of common metabolic processes such as mitochondrial oxidative phosphorylation, 
fatty acid oxidation, glucose utilisation and insulin sensitivity within such tissues as 
skeletal muscle, adipose tissue and liver. To investigate this, a variety of analytical 
techniques were utilised including those relevant to gene expression, cell 
signalling, histopathological and physiological studies. 
 
IL-6 regulates activation of Akt, p38 MAPK and AMPK. These proteins have all 
been implicated in metabolism through mediation of fat oxidation, insulin signalling 
and glucose uptake, myogenesis and contraction-induced mitochondrial 
biogenesis. Importantly, PGC-1α, an important mediator of mitochondrial 
metabolism, possesses phosphorylation sites for all three of these proteins. The 
first study of this dissertation (Chapter 3) aimed to determine if sIL-6R signalling, 
using Hyper IL-6, was a transcriptional regulator of PGC-1α and its downstream 
targets in vitro. This study also examined whether intermittent and chronic IL-6 
infusion in male wistar rats regulated mRNA and protein expression of PGC-1α and 
its downstream targets.    
 
There is prolific evidence for IL-6 signalling mediated via the sIL-6R in many 
tissues including synovial fluid, the bowel and liver. However, little evidence of this 
phenomenon occurring in metabolically active tissues such as skeletal muscle and 
adipose tissue is present within the literature. The second study (Chapter 4) 
included in this thesis aimed to determine if this process occurs in L6 myotubes in 
vitro. IL-6 is a predominant player in regulating muscle metabolism, thus it was 
hypothesised that Hyper IL-6 was capable of modulating glucose uptake and fatty 
acid oxidation via pathways previously implicated in metabolic control.  As IL-6 
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would appear to elicit tissue type specific responses, the secondary aim of the 
study included in Chapter 4 of this thesis examined the degree of bioactivity 
induced by membrane bound IL-6 receptor complex signalling in comparison to 
that of IL-6 trans-signalling within CRL1439 hepatocytes and L6 myotubes.  
 
It was established that L6 myotubes are responsive to IL-6 trans-signalling and that 
this phenomena is capable of regulating important physiologically metabolic 
mechanisms such as glucose and fat oxidation and cellular signalling in vitro. It 
was of utmost importance to determine if this scenario translated to an in vivo 
model. This formed the basis of the cohorts in Chapters 5 and 6.  
 
The primary focus of Chapter 5 was to examine the activation of components of 
various cell signalling pathways responsible for inflammation, metabolism and cell 
cycle, in response to acute Hyper IL-6 treatment within skeletal muscle, adipose 
tissue and liver.  
 
Finally, as it was evident Hyper IL-6 was capable of activating signalling pathways 
typically involved in the regulation of metabolism in liver, WAT and skeletal muscle, 
it was proposed that Hyper IL-6 administration over a prolonged period had the 
ability of modulating metabolism (Chapter 6). Hyper IL-6 is often used to induce 
experimental states of inflammation such as arthritis, inflammatory bowel disease 
and hepatocellular carcinoma in vitro. The effect of co-treatment with a naturally 
occurring competitive inhibitor, sgp130Fc was examined with the idea of preventing 
inflammatory signalling associated with Hyper IL-6 treatment whilst maintaining the 
beneficial effects on metabolic signalling.  
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CHAPTER THREE 
 
IL-6 does not mediate transcription 
and translation of the co-transcription 
factor PGC-1α in vitro or in vivo 
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3.1 Introduction 
Peroxisome proliferator activator receptor γ coactivator-1 α (PGC-1α), a coactivator 
of transcription factors, is a key player in metabolic control through the regulation of 
mitochondrial proteins, resulting in increase in mtDNA and hence increased 
replication and translation of mitochondrial oxidative phosphorylation (OXPHOS) 
genes (for reviews refer to Puigserver and Spiegelman, 2003; Houten and Auwerx, 
2004). PGC-1α is expressed in fat, liver, cardiac muscle, skeletal muscle and brain 
and its function appears to be tissue type specific and dependent on its interaction 
with varying transcription factors (Figure 3.1) (Houten and Auwerx, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 PGC-1α transcriptional targets and physiological functions in various 
tissues (adapted from Houten and Auwerx, 2004) 
 
PGC-1α expression is highly responsive to meet cellular energy demands in the 
presence of physiological stimuli such as environmental temperature, nutritional 
status, physical activity and infection (for reviews refer to Puigserver and 
Spiegelman, 2003; Houten and Auwerx, 2004).  In skeletal muscle both exercise, 
and pro-inflammatory cytokines increase PGC-1α regulated transcription of 
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mitochondrial genes for mitochondrial biogenesis, oxidative metabolism and 
respiration (Houten and Auwerx, 2004; Pilegaard, Saltin and Neufer, 2003 and 
Puigserver et al., 2001). However, the signalling pathways by which PGC-1α 
expression and activity are regulated in skeletal muscle remain poorly understood.  
 
Evidence of the role of PGC-1α in metabolic disorders such as Type II Diabetes 
was demonstrated concurrently by Patti and colleagues (2003) and Mootha et al. 
(2003). These studies demonstrate that PGC-1α is significantly reduced in patients 
with Type II Diabetes, as are its downstream targets Nuclear Receptor Factor-1 
(NRF-1), NRF-2 and other OXPHOS genes. PGC-1α mRNA expression is also 
decreased in subcutaneous fat of morbidly obese subjects, whereas in rodents it is 
thought to play a role in the conversion of white adipocytes from fat storing to fat 
oxidising cells (Semple et al., 2003). Cachexia, a chronic wasting of muscle mass 
due to an imbalance in energy expenditure, is often a hallmark of many diseases 
including: cancer, heart failure, HIV-AIDS and infection (for review see von 
Haehling et al., 2002). It is noteworthy that pro-inflammatory cytokines such as 
TNFα, IL-1β, IL-1α and IL-6 are often elevated in these chronic illnesses (von 
Haehling et al., 2002). Spiegelman and co-workers (Puigserver et al., 2001) have 
demonstrated that these pro-inflammatory cytokines can stimulate increased 
respiration and energy expenditure through the activation of PGC-1α in C2C12 
myotubes. Moreover, they showed that pharmacological inhibition of the mitogen 
activated protein kinase p38 MAPK with SB202190 greatly reduced the stimulatory 
effects of cytokines on PGC-1α, thereby implicating p38 MAPK in cytokine 
activation of PGC-1α in states of inflammation (Puigserver et al., 2001). This study 
also verified p38 MAPK phosphorylates PGC-1α on residues Threonine 262, 
Serine 265 and Threonine 298, further insinuating a role for p38 MAPK in the 
regulation of PGC-1α activity (Puigserver et al., 2001).  
 
Endurance training results in increases in PGC-1α transcription and mRNA content 
in human skeletal muscle (Pilegaard, Saltin and Neufer, 2003). Terada and co-
workers (Terada et al., 2002) noted after a 6 h acute bout of low intensity 
swimming exercise, mRNA expression of PGC-1α and AMP-activated protein 
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kinase (AMPK) in the epitrochlearis muscle of Sprague Dawley rats was markedly 
higher than in unexercised, control rats (Terada et al., 2002). Moreover, skeletal 
muscle incubated with 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), 
an AMPK activator, resulted in a 3-fold increase in PGC-1α mRNA expression, 
suggesting that AMPK activation is involved in the induction of PGC-1α during 
exercise. In AMPK WT mice treated with β-guanidinopropionic acid (GPA), a 
pharmacological agent that mimics endurance exercise through the depletion of 
intracellular phospho-creatine and ATP concentrations, increases in PGC-1 gene 
expression, mitochondrial DNA and density were noted. However, these effects 
were abrogated in AMPK dominant negative mice (Zong et al., 2002).  
 
A study by Jäger et al. (2007) demonstrated that in myotubes isolated from PGC-
1α knock out mice treated with AICAR, the expression of the mitochondrial genes 
Cytochrome C, UCP-3, UCP-2, the AMPK target, GLUT-4 and oxidation was lower 
when compared to AICAR treated WT cells.  Furthermore, it was demonstrated 
through co immunoprecipitation studies that AMPKα2 and PGC-1α form a complex 
and identified the AMPK phosphorylated residues on PGC-1α as threonine 177 
and serine 578. These studies establish a role for AMPK in the regulation of 
mitochondrial function through the activation and regulation of PGC-1α and its 
activity.   
 
A recent study (Li et al., 2007) implicated Insulin stimulated activation of Akt in the 
regulation of PGC-1α activity through its serine507 residue.  When primary 
hepatocytes isolated from WT mice received insulin, phosphorylation of PGC-1α 
was increased compared to control treatment, however when Akt2 -/- mice were 
similarly treated this response was ablated. Moreover when cells were infected 
with a constitutively active Akt adenovirus, PGC-1α was increased.  
   
It is well established, that skeletal muscle produces and releases the pro-
inflammatory cytokine Interleukin-6 (IL-6) (for review see Carey and Febbraio, 
2004). Elevated levels of the cytokine have also been observed in patients with 
Type II Diabetes (Carey and Febbraio, 2004). The effect of IL-6 on skeletal muscle 
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and the mechanisms by which it elicits these, remains poorly understood. Previous 
research from the Cellular Molecular Metabolism Laboratory has demonstrated that 
treating L6 myotubes with IL-6 augments AMP-activated protein kinase (AMPK) 
activation and p38 Mitogen Activated Protein Kinase (p38 MAPK) phosphorylation 
(Carey et al., 2006). Others have also implicated IL-6 in the activation and 
phosphorylation of AMPK and p38 MAPK in adipocytes and skeletal muscle cells 
(Senn et al., 2002; Geiger et al., 2005 and Carey et al., 2006). Notwithstanding, 
rhIL-6 infusion in healthy humans resulted in a marked increase in oxidative 
glucose metabolism and VO2 (rate of O2 consumption during exercise) (Carey et 
al., 2006). Interestingly, PGC-1α gene expression and its downstream targets 
NRF-1 and Mitochondrial Transcription Factor A (mtFAM) have been correlated 
with VO2 peak (Garnier et al., 2005). The authors of this study also observed a 
strong correlation existed between VMax, an indication of OXPHOS activity, and 
PGC-1α gene expression. Thus, it is postulated that IL-6 increases OXPHOS 
activity through the induction of PGC-1α protein expression and activity.  
 
Further evidence of IL-6 family cytokines in the regulation of metabolic pathways 
that lead to increased PGC-1α transcription and expression is provided by Watt et 
al. (2006). Administration of the IL-6 family cytokine member, Ciliary Neurotropic 
Factor (CNTF) to C57BL6 mice on a High Fat Diet resulted in increased PGC-1α 
protein expression and weight loss when compared to control mice. Moreover 
CNTF resulted in an increase in phosphorylation of ACC, an important intermediate 
step in fat oxidation. These data (Watt et al., 2006; Carey et al., 2006) along with 
those of Jäger et al. (2007) has led to the hypothesis that IL-6 family cytokines can 
increase fat oxidation in skeletal muscle via AMPK phosphorylation and activation 
of PGC-1α (Febbraio, 2007; Figure 3.2) . 
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Figure 3.2 gp130 ligands mediate fat oxidation in skeletal muscle via an AMPK 
dependent manner (Febbraio, 2007) 
 
As Carey et al. (2006) demonstrated that IL-6 results in increased oxidative 
metabolism and phosphorylation of Akt, p38 MAPK and AMPK and as PGC-1α 
possesses phosphorylation sites for these fore mentioned proteins, it is also 
hypothesised that in IL-6 treated skeletal muscle and liver cells, activity and 
expression of PGC-1α and its downstream targets will be increased and thus result 
in enhanced mitochondrial oxidation and respiration (Figure 3.3). The secondary 
aim of this study was to elucidate by which pathway IL-6 may regulate PGC-1α 
activity and expression.  
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Figure 3.3  Schematic of the signalling pathways that are postulated to be 
involved in the regulation of PGC-1α expression and hence mitochondrial activity 
by IL-6.  
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3.2 Methods 
Cell Culture - L6 myoblasts were cultured on 6 well plastic culture plates containing 
tissue culture growth medium consisting of alpha-Minimal Essential Medium (α-
MEM, SAFC Biosciences, Sigma-Aldrich, Sydney, Australia), 10 % Foetal Bovine 
Serum (FBS, JRH Biosciences SAFC Biosciences, Sigma Aldrich), 1 % (v/v) 
Penicillin-Streptomycin-glutamine (10,000 units·ml-1 Penicillin G Sodium, 10,000 
μg·ml-1 streptomycin sulphate, 0.85 % Saline, Invitrogen, Carlsbad, CA, USA). 
Once L6 myoblasts obtained 60 % confluency, differentiation of myoblastic cultures 
to myotube cultures was initiated by serum withdrawal, replacing the growth media 
with differentiation media (α-MEM, 2 % (v/v) Horse Serum, 1 % (v/v) Penicillin-
Streptomycin-glutamine) for 6 days. After which, L6 myotubes were treated with 
differentiation media containing 100 ng·ml-1 Hyper IL-6 for 2, 6 or 24 h, after which 
cells were harvested for RNA quantitation. In L6 myotube signalling studies, cells 
were treated with 50 ng·ml-1 Hyper IL-6 for 1 hour, after which cells were harvested 
for protein determination by western blotting. CRL1439 liver cells were cultured on 
6 well culture plates containing growth medium consisting of low glucose 
Dulbucco‟s Modified Eagle Medium supplemented with 10 % (v/v) FBS and 1 % 
(v/v) Penicillin-Streptomycin-glutamine. Once cultures had reached approximately 
80 % confluency, the cells were treated with 100 ng·ml-1 Hyper IL-6. Post treatment 
cells were lysed for RNA quantitation. All cultures were stored at 37 °C in a 5 % 
CO2/95 % O2 humidified air cell incubator. 
 
Animals - As previously described (Holmes et al., 2008), Male Wistar rats weighing 
approximately 220 g were housed in the RMIT University animal facility in a 12:12 
hour light:dark cycle. Animals were fed a normal rat chow diet and water ad libitum. 
Animal experiments were performed as approved by the Animal Ethics Committee 
of RMIT University (AEEC #0407). Animals were randomly assigned to be 
administered Saline (control) or IL-6 in an intermittent or chronic manner.   
 
Interleukin-6 treatment - Animals were administered IL-6 as previously described 
(Holmes et al., 2008). For chronic administration of IL-6 or saline, rats were 
surgically implanted with osmotic pumps (Alzet 2ML2; Durect, Cupertino, CA) that 
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had a 14 day pumping capacity. Animals were anaesthetised with 6 mg·100g-1 
sodium pentobarbital and implanted with the pumps into the intrascapular 
subcutaneous space. 
 
Pumps were filled to capacity with 22.5 μg·ml-1 rhIL-6 diluted in 0.1 % (w/v) Bovine 
Serum Albumin (BSA) and 0.9 % (w/v) NaCl. Rats were administered 2400 ng rhIL-
6 per day using an infusion rate 4.5 μl·h-1 over the 14 day treatment period. The 
saline control group received 0.1 % (w/v) BSA and 0.9 % (w/v) NaCl only. Animals 
assigned to the intermittent treatment group were administered 1200 ng rhIL-6 at 
0700 and 1900 daily via intraperitoneal injection for 14 days. At day 15 rats were 
culled and the tissues of interest were harvested, snap frozen in liquid nitrogen and 
stored at -80 °C until required for further analyses. 
 
SDS - PAGE analysis of proteins - Approximately 30 mg of White Adipose Tissue, 
Liver, Extensor Digitorum Longus, Soleus and Tibialis Anterior were homogenised, 
using a motorised homogeniser (Polytron; Brinkman Instruments, New York, NY, 
USA), in ice cold lysis buffer consisting of 50 mM HEPES, 150 mM NaCl, 1 mM 
NaF, 1 mM Na3VO4, 5 mM EDTA, 0.5 % Triton X-100 (v/v), 10 % glycerol (v/v), 1 
mM phenylmethylsulfonyl, 50 mM phosphatase inhibitor and 50 mM protease 
inhibitor. For in vitro experiments, cells were lysed in the fore mentioned lysis 
buffer and the subsequent lysate collected. After which both tissue and cell lysates 
were centrifuged at 13000 g to remove cellular debris. Protein concentrations were 
determined by BCA assay. Forty micrograms of protein were solubilised in 4 x 
Laemmelli‟s Buffer and denatured at 95 °C. Samples were then stored at -20 °C 
until required.  
 
Lysates were resolved using 6-14 % polyacrylamide gels (120 V; stacking gel and 
150 V; resolving gel) followed by transference of protein onto nitrocellulose 
membrane  using a semi-dry transfer unit (Biorad, Melbourne, Australia) at a 
constant ampere of 0.06 per gel for 120 min. Membranes were washed twice in 
TBST (0.05 % Tween 20 (v/v) in Tris Buffered Saline), blocked in 5 % BSA (w/v) 
TBST for 120 min at room temperature, washed thrice in TBST. Membranes were 
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then incubated in primary antibody overnight at 4 °C. The following primary 
antibodies were used; PGC-1α (Santa Cruz Biotechnology, CA, USA), phospho 
Aktser473, phospho AMPKthr172, phospho p38 MAPK thr180/tyr182, total p38 MAPK, β-
actin (Cell Signaling Technology, Beverly, MA, USA) or UCP-3 (Alpha Diagnostics, 
San Antonia, TX, USA).  
 
The following morning membranes were washed three times in TBST and 
incubated in anti rabbit horseradish peroxidase-conjugated secondary antibody 
(1:2000, 2.5 % BSA (w/v) TBST) for 60 min at room temperature. Membranes were 
then thoroughly washed with TBST (6 x 5 min). Membranes were then incubated in 
enhanced chemiluminescence or super chemiluminescence (Amersham, GE 
Health Care Lifesciences, Buckinghamshire, UK) and the immuno-reactive proteins 
were detected by CCD Camera (Chemidoc XRS Unit, Biorad). The digital output 
was analysed for densitometry using Quantity One 1-D Analysis Software Version 
4.5.2 (Biorad).  
       
Real Time PCR 
Primer Design and Optimisation - Forward and Reverse Primer Sequences for β-
Actin, PGC-1α, NRF-1, mtFAM, Cytochrome C and Cox-IV (Table 3.1) were 
designed using Primer Express version software (Applied Biosystems, Foster City, 
CA, USA) using the rat genomic sequence from GenBank/EMBL. The optimal 
primer concentration was determined and these concentrations were used in all 
subsequent gene expression experiments.  
 
RNA Extraction - RNA was extracted from ~ 30 mg tissue, vehicle and cytokine 
treated L6 myotubes and CRL1439 liver cells using an RNeasy minikit as per the 
manufacturer‟s instructions (Qiagen, Melbourne, Australia). Tissue was disrupted 
in Buffer RLT using a hand held homogeniser after which native proteins were 
degraded using proteinase K (Qiagen) at 55°C for 10 min. Residual genomic DNA 
was removed from the sample by DNase digestion using DNase I/Buffer RDD at 
RT for 15 min.  RNA obtained was quantified using a nano-drop 1000 
spectrophotometer (Biolab) and stored at -80°C until required.  
36 
 
Table 3.1: Accession number and forward and reverse primer sequences used for 
genes of interest in real-time PCR analyses. 
 
Target 
Accession 
number 
Forward Primer Reverse Primer 
PGC-1α NM_031347 5‟-TCTGGAACTGCAGGCCTAACTC-3‟ 5‟-GCAAGAGGGCTTCAGCTTTG-3‟ 
NRF-1 NM_001100708 5‟-ATCGATGGGATTCCAGTCTCTGT-3‟ 5‟-TTGAGCATCTCTCTGGGATAAATGC-3‟ 
Cytochrome C NM_001130491 5‟-TCTGTTTGGGCGGAAGACA-3‟ 5‟-CCCAGGTGATACCTTTGTTCTTG-3‟ 
COX IV-1 NM_017202 5‟-CAGGGATGAGAAAGTCCAATTGT-3‟ 5‟-CATTGGTGCCCTTGTTCATCT-3‟ 
mtFAM NM_031326 5‟-CCTCGGTCAGCATATAACATTTACG-3‟ 5‟-TTCAATTTCCCCTGAGCTGAC T-3‟ 
SOCS-3 NM_053565 5‟-TTCTTCACACTGAGCGTCGAGA-3‟ 5‟-CTTGAGTACACAGTCAAAGCGGG-3‟ 
β-Actin NM_031144 5‟-GCCAACACAGTGCTGTCTGG-3‟ 5‟-TACTCCTGCTTGCTGATCCA-3‟ 
 
 
Reverse Transcription - Each RNA sample was reverse transcribed using TaqMan 
Reverse Transcription Reagents (Applied Biosystems). A 10 μl reaction contained 
0.1 μg RNA, 1 μl of 10 x TaqMan RT Buffer, 5.5 mM MgCl2, 500 μM of each dNTP, 
2.5 μM random hexamers, 1.25 u·μl-1 Multiscribe™ Reverse Transcriptase, 0.5 
u·μl-1 RNase Inhibitor. The reverse transcription reaction underwent the following 
conditions using a Perkin Elmer Gene Amp PCR system 2400: 10 min at 25˚C, 30 
min at 48˚C and 5 min at 95˚C to stop the reaction. The subsequent cDNA was 
stored at -20˚C until required for Real-Time PCR. 
 
Real time PCR - Gene expression was quantitated using fluorescent Sybr Green 
(Applied Biosystems) and the comparative critical threshold (CT) method using a 
7500 Fast Real Time PCR System (Applied Biosystems). PCR reactions were 
carried out in duplicate. Reactions consisted of 5 μl 5 x Sybr Green (Applied 
Biosystems), 600 nM forward primer and 600 nM reverse primer for gene of 
interest, 20 ng cDNA and then made to a final volume of 25 μl using DEPC treated 
milliQ H2O. After which the cDNA was amplified using the following conditions: 
50˚C for 2 min, 95˚C for 10 min followed by 50 cycles of 95˚C for 15 s and 58.5˚C 
for 1 min. 
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For each sample β-actin CT values were subtracted from the CT values for the 
gene of interest to derive a Δ CT. The average CT of the saline treatment group or 
vehicle control was then subtracted from each sample of each treatment group, 
thus deriving a Δ Δ CT value. The expression of the genes of interest were then 
expressed relative to the saline group using Δ Δ CT. Data was then expressed as 
fold change in mRNA for the gene of interest when compared to control (=1). 
 
Statistical Analyses - Statistics were computed using the statistical analyses 
software packages SPSS or Sigma Stat. A one way ANOVA with a Tukey‟s Post 
Hoc test was used to determine significant differences between treatments in 
mRNA and protein expression in in vivo intermittent/chronic IL-6 infusion studies. 
Significance was accepted with a p value of < 0.05. In vitro mRNA expression 
Hyper IL-6 treatment time course studies did not undergo statistical analysis due to 
a lack of power as a consequence of the small sample size. Student t-tests were 
used to determine if significant differences in protein abundance existed between 
vehicle and Hyper IL-6 treatment. All data is expressed as mean ± SEM.  
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3.3 Results 
IL-6, irrespective of mode of delivery, does not regulate PGC-1α mRNA expression 
in Tibialis Anterior - In Tibialis Anterior harvested from rats IP injected (intermittent 
treatment group) or infused (chronic treatment group) with rhIL-6, there was no 
change in mRNA levels of PGC-1α, NRF-1, mtFAM, Cox IV or Cytochrome C 
(Table 3.2). The mRNA encoding SOCS-3, an IL-6 inducible protein, increased ~2 
fold with intermittent treatment and ~3 fold with chronic IL-6 treatment in Tibialis 
Anterior (Table 3.2). Contrary to this, SOCS-3 remained unchanged in liver (Table 
3.2).   
 
IL-6 has no effect on PGC-1α protein abundance in Soleus, EDL, Tibialis Anterior, 
Liver or Adipose Tissue in vivo - Intermittent and Chronic treatment with rhIL-6 
caused no change in PGC-1α protein abundance in extensor digitorum longus 
(Figure 3.4b), Tibialis Anterior (Figure 3.4c) or liver (Figure 3.4d). Irrespective of 
mode of delivery, PGC-1α protein expression was decreased to approximately 60 
% of that in soleus from saline infused rats (Figure 3.4a), however upon statistical 
analysis this was not significant (Saline vs. intermittent IL-6; p = 0.2, saline vs. 
chronic IL-6; p = 0.092). Interestingly, in white adipose tissue extracted from the 
intermittent treatment group, PGC-1α abundance had a tendency to be ~ 35 % less 
than that of tissue from saline and chronic IL-6 treated rats (Figure 3.4e). Upon 
statistical analysis this was not a significant difference (saline vs. intermittent IL-6; 
p = 0.711, saline vs. chronic IL-6; p = 0.264 and intermittent IL-6 vs. chronic IL-6; p 
= 0.054).        
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Table 3.2 mRNA expression of PGC-1α and downstream targets remain similar 
in TA from rats administered IL-6, irrespective of mode of delivery 
 
 
 
 
 
 
 
 
 
 
 
 
* p < 0.05 Saline vs. Intermittent IL-6 treatment † p < 0.05 Saline vs. chronic IL-6 
treatment. Data is expressed as mean ± SEM (n=8-12). 
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Figure 3.4 PGC-1α protein expression in tissues harvested from Intermittent and 
Chronic IL-6 infused Rats - Protein abundance of PGC-1α as quantitated by 
densitometry in a) Soleus b) EDL c) Tibialis Anterior d) White Adipose and e) Liver. 
All data are expressed as mean ± SEM, n= 8 for all tissues excluding soleus (n=4). 
Corresponding representative blots for PGC-1α and β-actin (f) are shown. Sal: 
Saline, Int: Intermittent IL-6 treatment, Chr: Chronic IL-6 treatment. 
     
  
  
b) 
a) 
c) 
e) 
d) 
f) 
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Soluble IL-6 receptor signalling does not regulate PGC-1α transcription in L6 
Myotubes or CRL1439 liver cells - To determine if IL-6 regulates transcription of 
PGC-1α and its downstream transcriptional targets in vitro, mRNA expression was 
determined by Real Time PCR over a 24 hour treatment period. In L6 myotubes 
treated with 100 ng·ml-1 Hyper IL-6, no difference in mRNA levels of PGC-1α 
(Figure 3.5a), NRF-1 (Figure 3.5b), mtFAM (Figure 3.5c) and Cytochrome C 
(Figure 3.5d) were detected at 2, 6 and 24 hours, when compared to vehicle 
control.  No changes were noted in mRNA expression of PGC-1α (Figure 3.6a) nor 
mtFAM (Figure 3.6c) and Cox IV (Figure 3.6d) in 100 ng·ml -1 Hyper IL-6 treated 
CRL1439 liver cells. A 0.5 fold and two fold increase in mRNA of NRF-1 (Figure 
3.6b) was noted at 2 and 6 hours respectively in Hyper IL-6 treated CRL1439 liver 
cells when compared to vehicle control treated cells, however statistical analysis 
was not performed due to a lack of power as a consequence of small sample size. 
 
Hyper IL-6 has little effect on phospho AMPKthr172 but increases phospho Aktser473 
and p38 MAPKthr180/tyr182 – Activation of pathways hypothesised to be involved in 
Hyper IL-6 induced increases in PGC-1α and downstream targets was examined in 
L6 myotubes in vitro. Hyper IL-6 had minimal effect on phosphorylation of AMPK at 
Thr 172 residue (Figure 3.7a). However, Hyper IL-6 significantly induced Ser473 
phosphorylation of Akt, with abundance approximately 18 fold that of Vehicle 
treated L6 myotubes (Figure 3.7b; p < 0.001). Furthermore, Hyper IL-6 increased 
phospho p38 MAPKthr180/tyr182 ~3 fold (Figure 3.7c; p < 0.001).  
  
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 PGC-1α and downstream target gene expression in Hyper IL-6 
treated L6 myotubes - mRNA expression of (a) PGC-1α and its downstream 
targets b) NRF-1, c) mtFAM and d) Cytochrome C in L6 myotubes in vehicle and 
100 ng·ml-1 Hyper IL-6 treated cells. Data is expressed as mean ± SEM relative to 
0 hour vehicle control (n=3 experimental replicates from one independent 
experiment). 
  
a) b) 
c) d) 
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Figure 3.6 PGC-1α and downstream target gene expression in Hyper IL-6 
treated CRL1439 hepatocytes - mRNA expression of (a) PGC-1α and its 
downstream targets b) NRF-1, c) mtFAM and d) COX-IV in CRL1439 liver cells in 
vehicle and 100 ng·ml-1 Hyper IL-6 treated cells. Data is expressed as mean ± 
SEM relative to 0 hour vehicle control (n=3 experimental replicates from one 
independent experiment). 
  
a) b) 
c) d) 
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Figure 3.7 Hyper IL-6 has little effect on phosphorylation of AMPK but induces 
that of Akt and p38 MAPK in L6 myotubes – Protein abundance of a) phospho 
AMPKthr172 b) phospho Aktser473 and c) phospho p38 MAPKthr180/tyr182 in L6 
myotubes were treated with 50 ng·ml-1. d) Representative blots for the fore 
mentioned proteins and β-actin. As constitutive expression of corresponding total 
proteins remained unchanged, data is expressed as relative expression of 
phosphorylated protein only. * difference between vehicle and Hyper IL-6; p < 
0.001. All data expressed as mean ± SEM fold change relative to vehicle; n=4 
experimental replicates, representative of two independent experiments. 
  
* 
* 
a) b) 
c) d) 
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3.4 Discussion 
PGC-1α is an important player in metabolic homeostasis through the regulation of 
mitochondrial functions such as mitochondrial biogenesis, β-oxidation of fatty 
acids, cell respiration and adaptive thermogenesis (for review refer to Handschin 
and Spiegelman, 2006).  As previous research has also implicated IL-6 in many of 
these processes, this study sought to examine the effect of IL-6 signalling on PGC-
1α transcription and translation. 
 
IL-6 infused rat tissue was obtained and the PGC-1α mRNA and protein 
expression was examined. Contrary to our hypothesis, there was no significant 
difference in any of the mitochondrial genes measured in Tibialis Anterior. 
However, an increase in mRNA of the IL-6 target SOCS-3 in rats administered IL-
6, irrespective of mode of delivery, was noted, an effect that did not occur in liver. 
The lack of measured effect of IL-6 on PGC-1α mRNA may be explained by the 
following: animals were culled and tissues harvested 24 hours post the last infusion 
of IL-6. This is concurrent with studies by Pilegaard and colleagues (2003), which 
showed the effect of exercise training on PGC-1α mRNA returned to normal 24 
hours post exercise. It is therefore possible that any effect of IL-6 on PGC-1α 
transcription was also missed due to its relatively quick transcriptional turn over.  
 
To determine if IL-6 had an effect on PGC-1α at a translational level, protein 
expression in several metabolically active tissues were examined. There was no 
change in PGC-1α protein of Tibialis Anterior, EDL or liver. By comparison IL-6, 
regardless of mode of delivery, had a tendency to reduce expression of PGC-1α 
protein in soleus compared to the saline counter parts. It is important to note, that 
upon statistical analysis this was not considered significant, a consequence of 
limited sample size. The soleus muscle of rats is described as an oxidative muscle 
as it predominately consists of slow twitch type I oxidative fibres, the remaining 20 
% of fibres are type II glycolytic fibres, whereas Tibialis Anterior and EDL are 
described as fast glycolytic muscles (Pullen, 1977). Tibialis Anterior is known to 
consist of approximately 95 % type IIa and IIb fast twitch glycolytic fibres and only 
5 % type I fibres (Tasić et al., 2003). It is also known that over expression of PGC-
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1α in myotubes results in “fibre type switching” whereby muscle fibres become 
more oxidative and less glycolytic (Lin et al., 2002). 
 
As there is a decrease in PGC-1α protein expression in soleus it may be feasible 
that IL-6 has a regulatory feedback loop thereby preventing further increases in 
oxidative type I fibres. However it is imperative to note this requires further 
investigation and any conclusion reached should be treated with caution for two 
reasons. Firstly, western blotting data obtained should be interpreted with caution 
as commercially available PGC-1α antibodies are, most often than not, of poor 
quality, lacking specificity and as a consequence have a high degree of non 
specific banding. Secondly, it is not known whether this would have been a 
significant difference due to the limitations on power as a result of the small 
amount of animal tissue available for analysis.  
 
The current study suggests in Tibialis Anterior, IL-6 is not a transcriptional regulator 
of PGC-1α as there was no change in the abundance of PGC-1α mRNA or 
downstream genes. Whether IL-6 regulates transcription in other muscles remains 
unknown. In the current studies, the effect of IL-6 on PGC-1α and downstream 
targets was not examined in muscles other than Tibialis Anterior as there was a 
limited amount of tissue available for analysis. Subsequently, it may be of interest 
to examine PGC-1α mRNA expression in other skeletal muscle types to determine 
if IL-6 infusion has a fibre type effect. In support of a fibre specific effect, Ikeda and 
colleagues (2006) concluded mice undergoing endurance training displayed 
muscle type specific responses. It was noted PGC-1α was only increased in 
plantaris and not Tibialis Anterior. Despite the lack of increase in PGC-1α, Ikeda (et 
al., 2006) also noted the mitochondrial proteins Cytochrome C, Cox IV and ATP 
synthase were elevated in Tibialis Anterior. As a result, Ikeda proposed there may 
be mechanisms that result in increases in mitochondrial proteins independently of 
induction of PGC-1α. In accordance with the studies by Ikeda and colleagues, it is 
plausible to suggest that IL-6 may regulate mitochondrial gene expression 
independently of PGC-1α in some tissues, thereby accounting for changes in 
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oxidative capacity often associated with this cytokine (van Hall et al., 2003 and 
Carey et al., 2006).  
 
Previous studies have determined that PGC-1α possesses activation sites that 
may be phosphorylated by AMPK, Akt and p38 MAPK. The fore mentioned players 
have all been implicated in metabolism through mediation of insulin signalling, 
glucose and fat oxidation, myogenesis and contraction induced mitochondrial 
biogenesis. Previously, it has been shown that IL-6 can activate these proteins in 
myotubes and adipocytes (Carey et al., 2006). Moreover, Akimoto et al. (2005) 
demonstrated that a single running bout induced a transient increase in PGC-1α 
transcription in the plantaris muscle of C57BL6 WT mice, which was concurrent 
with an increase in activation of the p38 MAPK pathway. Furthermore, when a 
constitutively active form of the p38 MAPK upstream kinase kinase, MKK6, was 
expressed in a muscle specific manner, protein of PGC-1α and its transcriptional 
target COX- IV, was significantly increased compared to that of WT littermate 
controls (Akimoto et al., 2005).  
 
It has yet to be elucidated by which pathway PGC-1α expression and activity is 
predominately regulated. The crux of this part of the project was to determine if IL-
6 regulates activity and expression of PGC-1α and its downstream targets. 
Subsequently, the protein and mRNA expression of PGC-1α and its known 
mitochondrial targets were examined in two metabolically active tissues in vitro and 
in vivo. In an elegant study by Wu et al. (1999), it was demonstrated that over-
expression of PGC-1α in cultured C2C12 myoblasts and myotubes resulted in 
increases in NRF-1, mtFAM, Cox IV and Cytochrome C. As this study 
demonstrated the induction of these genes occurred via a PGC-1α dependent 
manner, mRNA expression of these were used in all subsequent studies examining 
the effect of IL-6 or Hyper IL-6 on PGC-1α expression and activity.  
 
Previous research has demonstrated that after an acute bout of exercise, an 
increase in PGC-1α mRNA and protein was noted in the skeletal muscle from lean 
subjects. This occurred as soon as 30 min post exercise and remained elevated for 
48 
 
a further 5 hours (De Filippis et al., 2008). Importantly, the previously mentioned 
study also noted, the elevation in PGC-1α was less significant in obese subjects 
than that of lean subjects post exercise. Moreover, Pilegaard, Saltin and Neufer 
(2003) demonstrated that post two legged knee extensor exercises, PGC-1α 
mRNA expression in vastus lateralis was maximal at 2 hours and remained 
elevated for up to 6 hours, after which it returned to baseline. Increases in 
downstream targets such as NRF-1, mtFAM and Cox-IV occur 6 hours post 
treatment with Lipopolysaccharide, a known inducer of oxidative phosphorylation, 
and remain elevated for up to 48 hours within liver (Suliman et al., 2003). These 
fore mentioned studies formed the basis of the design for a preliminary experiment 
in vitro. This preliminary experiment aimed to examine PGC-1α mRNA expression 
in both muscle and liver cells in vitro in response to Hyper IL-6 over time. The 
intent was to use this preliminary experiment to guide the design of future studies 
aimed at examining the effect of Hyper IL-6 on parameters such as PGC-1α 
promoter activity, mitochondrial biogenesis and cell respiration. However, as it was 
determined Hyper IL-6 had little effect on transcription and translation of PGC-1α in 
both cell types examined in vitro. Upon closer examination of the literature, there is 
published evidence that cultured cells have minimal expression of PGC-1α 
(Puigserver et al. 2001), providing a possible explanation as to why limited levels of 
PGC-1 α were detected and why no change was noted. In light of this published 
data regarding minimal PGC-1 α expression in cultured muscle cells, these in vitro 
studies were not continued further.  In future it may be of interest to explore the 
effect of IL-6 on PGC-1 α mRNA expression in cells either transduced or infected 
with PGC-1α over a more detailed time course.  
 
An increase in PGC-1α mRNA and downstream targets was noted with time, 
irrespective of treatment. This is possibly an artefact of the in vitro model used. L6 
myotubes were cultured and differentiation induced upon serum withdrawal. At day 
6 post serum withdrawal, cultures were treated with Hyper IL-6 over a 24 hour 
period. It is important to note, that during differentiation, changes within the 
myogenic gene profile occur. This in turn, leads to the elongation and fusion of the 
cells thereby creating a post-mitotic multinucleated phenotype. In accordance with 
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the notion that PGC-1α may play a role in differentiation, previous research has 
correlated abundance of this protein with myogenic gene expression and enhanced 
differentiation of C2C12 myocytes (Li et al., 2007). Furthermore, it is well 
established that PGC-1α is paramount in fibre type switching, increased expression 
of this protein leads to a more oxidative phenotype (Lin et al., 2003) and muscle 
specific knock out leads to a more glycolytic fibre type (Handschin et al., 2007). As 
myoblastic cultures differentiate, increases in the oxidative capacity of the cells 
may be essential to this process. The fore mentioned studies lend support to the 
notion that, in its capacity as a player within the myogenic program, PGC-1α 
expression may increase as differentiation proceeds, thereby accounting for the 
increased mRNA expression seen in the current cohort.   
 
Hyper IL-6 also had limited effect on phosphorylation of AMPK at the Thr172 
residue in vitro, however this may be a consequence of determining the abundance 
of this protein at one treatment time point only. Secondly, phosphorylation is not 
necessarily a measure of intrinsic AMPK activity. Detailed experiments aimed at 
examining IL-6 family cytokine activation of AMPK on PGC-1α utilising either loss 
or gain of function may provide a definitive answer as to whether this kinase is 
involved in the regulation of this important mediator of mitochondrial activity in 
skeletal muscle. Hyper IL-6 did induce phosphorylation of Akt and p38 MAPK, 
proteins known to phosphorylate and activate PGC-1α. It would be of interest to 
determine the effect of constitutive activation and knock down of the PI3-
Kinase/Akt and p38 MAPK pathways and determine the subsequent effect of 
Hyper IL-6 stimulated PGC-1α activity and expression. If these three proteins act in 
concert, the overexpression or knock out of these proteins may lead to a change in 
PGC-1α activity in response to this cytokine.    
 
This study does not discount the possibility that IL-6 and/or Hyper IL-6 may 
regulate mitochondrial biogenesis and metabolism through post translational 
modification of PGC-1α by the following processes 1) phosphorylation 2) 
methylation or 3) reversible acetylation (For review refer to Ventura-Clapier, 
Garnier and Veksler, 2008). Although beyond the scope of this dissertation, future 
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studies aimed at exploring the effect of these cytokines on these processes may 
provide insight into whether increased OXPHOS associated with elevated IL-6 
occurs in a PGC-1α dependent manner.  
 
PGC-1α possesses phosphorylation sites for p38 MAPK, AMPK and Akt 
(Puigserver et al., 2001, Jäger et al., 2007 and Li et al., 2007). Examining whether 
IL-6 leads to phosphorylation of PGC-1α at these sites would provide evidence as 
to whether IL-6 leads to increased PGC-1α activity through phosphorylation by the 
fore mentioned proteins. Unfortunately, a commercial antibody against these 
specific residues of PGC-1α is not available and as a consequence this was not 
examined in this study.   
 
Another post translational modification that can increase transcriptional activity of 
PGC-1α is methylation. Arginine Methylationtransferase-1 (PRMT-1) interacts with 
PGC-1α, causing the methylation of the co-transcription factor‟s arginine residues. 
This in turn leads to increased activation of PGC-1α target gene promoters, such 
as ERRα and Cytochrome C, involved in mitochondrial biogenesis (Teyssier et al., 
2005). Whilst there is evidence in the osteosarcoma cell line SAOS2 that PRMT-1 
is involved in increased expression of PGC-1α target genes involved in 
mitochondrial biogenesis, there is limited evidence of this protein‟s role in this 
process in skeletal muscle. Moreover, there are no studies in the literature 
examining whether IL-6 leads to increased PGC-1α activity through methylation 
and whether this occurs in a PRMT-1 dependent manner or not. Interestingly, 
PRMT-1 and CARM1, another member of the PRMT family, act synergistically to 
recruit steroid receptor coactivator-2 (SRC-2)/GRIP1. This leads to co-activatation 
of myogenic transcription factors, such as Myocyte Enhancer Factor-2 (MEF-2), 
involved in muscle differentiation (Chen et al., 2002). Given the prominent role  IL-6 
plays in myogenesis and differentiation (Baeza-Raja and Muñoz-Cánoz, 2004) and 
as PRMT-1 and PGC-1α have also been implicated in these processes through 
activation of transcription factors such as MEF-2, it may be of interest to explore 
the effects of this cytokine on PRMT-1 expression and methylation of PGC-1α. 
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Acetylation (the addition of an acetyl group) of PGC-1α inhibits its activity and 
causes a decrease in target genes important to nutrient and stress sensing and 
energy metabolism (For review refer to Ventura-Clapier, Garnier and Veksler, 
2008). It is known that GCN-5, an acetyl transferase, abolishes PGC-1α dependent 
fatty acid utilisation and mitochondrial gene transcription in C2C12s (Lerin et al., 
2006 and Gerhart-Hines et al., 2007).  Conversely, deacetylation (removal of an 
acetyl group) of PGC-1 leads to increased Mitochondrial and fatty acid oxidation 
transcriptional activity (Gerhart-Hines et al., 2007). During fasting, SIRT-1, an 
NAD+ dependent SIRT-1 deacetylase, expression is increased and leads to the 
deacetylation of hepatic PGC-1α. This in turn, promotes hepatic glucose output 
through inhibition of glycolytic gene transcription and activation of gluconeogenic 
genes (Rodgers et al., 2005). In skeletal muscle cells, SIRT-1 activity is known to 
increase in response to low glucose leading to the activation of PGC-1α and 
downstream targets specific to fatty acid oxidation (Gerhart-Hines et al., 2007). 
Whilst there are studies that correlate an increase in SIRT-1 activity with a 
decrease in IL-6 and TNFα production, there is little known about the effects of IL-6 
on SIRT-1 and PGC-1α acetylation/deacetylation and its subsequent transcriptional 
targets. Given the associated effects of IL-6 on metabolism and the prominent role 
SIRT-1 has in regulation of mitochondrial and metabolic transcriptional activity, it 
may be of interest to examine the effect of this cytokine on SIRT-1 dependent 
deacetylation of PGC-1α and its transcriptional targets.   
 
An interesting question arises from this study: as Hyper IL-6 was used, a designer 
cytokine that mimics IL-6/sIL-6R signalling and thought to be pro-inflammatory, is it 
possible that PGC-1α expression and subsequent activity may not be regulated by 
IL-6 trans-signalling events? Moreover is it possible that IL-6 mediates PGC-1α 
expression and activity through the cognate membrane bound IL-6 receptor 
signalling which is thought to be metabolically beneficial? To examine this 
possibility it may be of interest to co-treat liver and muscle in vitro and in vivo with 
IL-6 and the natural inhibitor of soluble IL-6 receptor signalling, sgp130, thereby 
allowing only membrane bound IL-6 receptor signalling to occur.  
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The studies described in this chapter demonstrate that IL-6 signalling through the 
sIL-6 receptor complex, using Hyper IL-6 treatment to mimic this phenomena, does 
not regulate PGC-1α at a transcriptional or translational level in cultured myotubes 
or hepatocytes in vitro. Furthermore, prolonged infusion of IL-6 in rats had little 
effect on mRNA or protein expression of PGC-1α in vivo. It is important to note, 
however, that there was limited tissue available for analysis of PGC-1α expression 
and as a consequence, this aspect to the study was only examined in Tibialis 
Anterior muscle. This does not discount the possibility that IL-6 regulates 
expression of PGC-1α and other mitochondrial genes in muscle types other than 
Tibialis Anterior and requires further investigation. In conclusion, the results of this 
study indicate that neither IL-6 nor Hyper IL-6 regulate transcription or translation 
of PGC-1α.     
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CHAPTER FOUR 
 
Hyper IL-6 augments metabolic cell signalling 
and physiological parameters in myotubes 
and liver cells in vitro 
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4.1 Introduction 
The activation of the JAK/STAT pathway is an important process in the regulation 
of glucose and lipid metabolism. IL-6 may activate the fore mentioned pathway via 
two mechanisms; In the first of the alternatives, IL-6 binds to the transmembrane 
complex of an IL-6 receptor α and gp130β homodimer. This causes auto-
phosphorylation of the associated JAK and the recruitment of STAT-3 resulting in 
pathway activation (for review refer to Febbraio, 2007).  Alternatively JAK/STAT 
activation may occur via a phenomena known as “IL-6 trans-signalling”, whereby 
upon IL-6 interaction with the agonistic soluble IL-6 receptor (sIL-6R), a IL-6/sIL-6R 
complex is formed. This complex then binds to the ubiquitously expressed gp130β, 
resulting in JAK/STAT pathway activation (Rose-John, 2003 and 2006). IL-6 trans-
signalling has broad implications, as cells naturally devoid of the membrane bound 
IL-6 receptor remain responsive to IL-6 due to gp130 being ubiquitously expressed 
(Rose-John, 2003 and 2006).  
 
Whether trans-signalling results in subsequent metabolic signalling is not known. 
To examine the effects that sIL-6R activation elicits on metabolic signalling in 
skeletal muscle in vitro, IL-6 trans-signalling events were mimicked using the 
designer cytokine Hyper IL-6, a fusion protein of the soluble IL-6 receptor fused to 
recombinant human IL-6 by a flexible polypeptide linker (Fischer et al., 1997). As 
IL-6 is a predominant player in regulating muscle metabolism and gp130 is 
ubiquitously expressed it was hypothesised that acute Hyper IL-6 treatment may 
be more efficient than IL-6 alone in modulating glucose uptake and fatty acid 
oxidation via pathways previously implicated in metabolic control. 
 
As discussed in the first chapter of this dissertation, the role of IL-6 in health and 
states of disease remains controversial. Many have described this cytokine as 
functioning in a pro-inflammatory fashion in metabolism, leading to insulin 
resistance within cultured hepatocytes by diminishing glucose transport (Senn et 
al., 2002) and decreasing glycogen synthesis through insulin desensitisation 
(Kanemaki et al., 1998). Contrary to this belief, others have observed that IL-6 
signalling may be executed in the absence of inflammation, resulting in enhanced 
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metabolism and thus allowing it to be described as “anti-inflammatory”. In support 
of this notion, it has previously been noted that IL-6 enhances glucose uptake in 
3T3-L1 adipocytes (Stouthard, Elferink and Sauerwein., 1996) and acts as an 
insulin sensitizer on glycogen synthesis in human skeletal muscle cells (Weigert et 
al., 2005). Further support of this positive metabolic regulator theory was provided 
by Carey and colleagues (2006). When L6 myotubes were treated with IL-6, an 
increase in glucose uptake and fat oxidation was observed. It was proposed that 
this occurred via an AMPK dependent mechanism as, when L6 myotubes were 
transduced with a dominant negative AMPK adenovirus, IL-6 stimulated glucose 
uptake was severely blunted. Notably, this study also demonstrated that infusing 
human subjects with IL-6 resulted in an increase in insulin stimulated glucose 
disposal. Further more, in a study by van Hall and colleagues (van Hall et al., 
2003), IL-6 stimulated lipolysis and fat oxidation in humans. The fore mentioned 
studies depict IL-6 as a multi faceted cytokine that elicits metabolic responses in a 
tissue type dependent manner.  
 
IL-6/sIL-6R complex signalling has been implicated in many animal models of 
inflammatory conditions including arthritis (Nowell et al., 2003), nodular 
regenerative hyperplasia and adenomas of the liver (Maione et al., 1998) and 
colitis (Atreya et al., 2000). This has lead to the general consensus that IL-6 
signalling mediated via trans-signalling events are “pro-inflammatory”. Notably, in a 
study by Rabe and co-workers (2008), transgenic blockade of IL-6/sIL-6R complex 
by over expression of its natural inhibitor, sgp130, led to the abrogation of 
recruitment of mononuclear inflammatory cells in the air pouch model of 
inflammation. Moreover, it was determined that classic signalling via the membrane 
bound IL-6 receptor remained intact. Whether soluble IL-6 receptor signalling plays 
a part in skeletal muscle metabolism, or is purely associated with inflammation has 
yet to be elucidated. Thus, the primary aim of this study was to determine the 
significance of sIL-6R signalling within skeletal muscle in vitro and to examine what 
effect inhibition of IL-6 trans-signalling using the soluble form of gp130 (sgp130), 
would have within these cells. 
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As IL-6 would appear to elicit tissue type specific responses, the secondary aim of 
this study was to determine the degree of bioactivity induced by membrane bound 
IL-6 receptor complex signalling in comparison to that of IL-6 trans-signalling within 
CRL1439 hepatocytes and L6 myotubes. Furthermore, it was hypothesised that the 
degree of bioactivity, as determined by the activation of common signalling targets, 
would be conducted in an inherent cell type specific manner.  
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4.2 Materials and Methods 
Cell Culture - L6 myotubes and CRL1439 hepatic cells were cultured as described 
in Chapter 3.   
 
In vitro treatments - Six days post initiation of serum withdrawal, L6 cultures were 
considered to be fully differentiated myotubes as most cells had fused to form 
multinucleated cells. At this point the cultures were treated with the appropriate 
compound. Eighteen hours prior to treatment, media was replaced with fresh 
differentiation media.  After which, vehicle (0.1 % (w/v) BSA/ PBS), 100 ng·ml-1 
recombinant human IL-6 (referred to as rh-IL-6 from here in), 100 ng·ml-1 
recombinant murine IL-6 (rm-IL-6), 100 ng·ml-1 recombinant rat IL-6 (rr-IL-6) (R and 
D Systems, Minneapolis, MN, USA), or the “designer cytokines” 100 ng·ml-1 Hyper 
IL-6 with or without sgp130Fc  were administered via directly “spiking” the 
compound of interest into the media and incubating for the desired amount of time.     
  
SDS PAGE Analysis of Protein expression - Protein analyses were performed as 
described in Chapter 3. Briefly, 40 μg of protein from cytokine treated lysates were 
subjected to SDS PAGE. The protein expression of phospho AMPKthr172, phospho 
ACCser79, phospho STAT-3tyr705, phospho p38 MAPKthr180/tyr182, phospho Aktser473, 
their corresponding totals, β-actin (Cell Signaling Technology Inc, Beverly, MA, 
USA) and SOCS-3 (Abcam, Cambridge UK) were examined by antibody binding 
and enhanced chemiluminescence as described in Chapter 3.  
 
Glucose Uptake - L6 myotubes were cultured as described above, however cells 
were serum starved for 4 hours prior to stimulation with 50 ng·ml-1 Hyper IL-6 and 
50 ng·ml-1 sgp130Fc for 1 h, the negative control 5 μM Cytochalasin B for 30 min 
or 100 nM Insulin for 15 min.  The treatment media was removed and cells 
equilibrated in fresh α-MEM media containing 100 nM D-deoxy-D-glucose for 5 
min, after which the media was removed and cells were incubated in fresh media 
containing 100 nM D-deoxy-D-glucose and 1μCi mL-1 2-Deoxy-D-[2,6-3H]glucose 
(Amersham, GE Healthcare Life Sciences, Buckinghamshire, UK) for 10 min. Cells 
were lysed in 0.3M NaOH and 400 μl of lysate was placed in 5 ml scintillation fluid 
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and mixed thoroughly. Radioactivity counts were determined for each sample over 
a 5 min period using a Packard TRICARB 1900CA Scintillation Counter (GMI Inc, 
Ramsey, MN, USA). For each sample, counts per minute were corrected for 
protein as determined by BCA assay and then expressed relative to counts for 
cytochalasin B control samples. Final data was expressed as fold change over 
vehicle.           
 
Fatty Acid Oxidation - L6 myotubes were cultured as per above. Cells were 
incubated for 2 hours in differentiation media containing 0.1mM palmitate, 1.6 μCi 
ml-1 tritium labelled palmitate, 2 % (w/v) BSA and either Vehicle, 50 ng·ml-1 Hyper 
IL-6 or 100 nM Insulin (negative control). After which 1 ml of the media was 
collected and incubated with 5 ml Chloroform: Methanol (2:1 v/v), whilst vigorously 
shaken, for 15 min. Two millilitres of 2M KCl: HCl solution was added to the 
media/chloroform mix, subjected to a further vigorous shaking for 15 minutes 
followed by a 5 min centrifuge at 3000 rpm.  This resulted in separation of the 
sample into an inorganic and tritium labelled palmitate containing aqueous phase, 
of which 0.5 ml of the latter was collected and mixed with 5 ml scintillation fluid and 
mixed thoroughly. Radioactivity counts were determined for each sample over a 5 
min period using a Packard TRICARB 1900CA Scintillation Counter (GMI Inc, 
Ramsey, MN, USA).  For each sample, counts per minute were corrected for 
protein amount as determined by BCA assay and then expressed as a function of 
time.  
 
Statistics - Statistics were computed using the statistical analyses software 
packages SPSS 12.0.01 for Windows (Apache Software Foundation, USA) or 
Sigma Stat. In all experiments other than fatty acid oxidation assays, a two way 
(treatment*time) ANOVA was used to determine significant differences. Multiple 
comparisons were made using the Student-Neuman-Keuls post hoc method. For 
the fatty acid uptake assay a one way ANOVA with a Student-Neuman-Keuls post 
hoc test was used to locate significant differences between treatments. Significant 
differences for all experiments were accepted at p <0.05. All data is expressed as 
mean ± SEM.  
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 4.3 Results 
Hyper IL-6 has a greater bioactivity in muscle cells than that of other recombinant 
IL-6 species- The bioactivity of varying species of IL-6 was determined over time in 
L6 myotubes treated with 100 ng·ml-1 rmIL-6, rrIL-6 and hyper IL-6. As a measure 
of bioactivity, the phosphorylation and subsequent activation of IL-6/IL-6R/gp130 
signalling targets STAT-3 and p38 MAPK were examined after 2, 10, 30 and 120 
min exposure to the fore mentioned cytokines. It was noted that in L6 myotubes 
treated with Hyper IL-6 for 2 min phospho STAT-3tyr705 expression was 20 fold 
greater (p = 0.001) than that in cells treated with other species of IL-6 (Figure 
4.1a). Notably, this response peaked after 30 min exposure, to approximately 45 
fold (p <0.001) and was still sustained by 120 min with a 15 fold increase 
compared to vehicle with p < 0.001.  Hyper IL-6 significantly induced phospho p38 
MAPKthr180/tyr182 at 30 min (Figure 4.1b), after which it returned to base line by 120 
min. There were no other significant differences in phospho p38 MAPKthr180/tyr182 
observed.  Hyper IL-6 also activated Akt. After 10 minutes, treatment robustly 
stimulated phospho Aktser473 with an approximately 8 fold increase in this protein 
(Figure 4.2a). At 30 min phospho Akt was still 8 fold higher than that of vehicle 
however, by 120 min expression had returned to levels seen at 2 min exposure 
with Hyper IL-6. There was a trend for phospho AMPKthr172 to be increased in the 
presence of Hyper IL-6 at 120 min (Figure 4.2b). 
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Figure 4.1 Hyper IL-6 has a greater bioactivity than that of other IL-6 species on 
L6 myotubes. L6 myotubes were treated with 100 ng·ml-1 rm IL-6, 100 ng·ml-1 rm 
IL-6 or 100 ng·ml-1 Hyper IL-6. When compared to vehicle control, Hyper IL-6 
increased a) phospho STAT-3tyr705 (p <0.001) and b) phospho p38 MAPKthr180/tyr182.  
c) representative blots for the fore mentioned proteins. † denotes difference 
between vehicle and 100 ng·ml-1 Hyper IL-6. * Difference between vehicle and 100 
ng·ml-1 Hyper IL-6; p < 0.05. As constitutive expression of corresponding total 
proteins remained unchanged, data is expressed as relative expression of 
phosphorylated protein only. All data expressed as mean ± SEM fold change 
relative to vehicle; n=6 (3+3) experimental replicates from 2 independent 
experiments (equal numbers from each experiment). 
  
* b) 
c) 
a) 
† 
† 
† 
† 
* b) 
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Figure 4.2 Hyper IL-6 increases a) phospho Aktser473 but has no significant effect 
on b) phospho AMPKthr172. c) Representative blots for phospho Akt ser473 and 
phospho AMPK thr172 and the corresponding totals. L6 myotubes were treated with 
100 ng·ml-1 rm IL-6, 100 ng·ml-1 rm IL-6 or 100 ng·ml-1 Hyper IL-6. * denotes 
difference vehicle v Hyper IL-6 p <0.01. As constitutive expression of 
corresponding total proteins remained unchanged, data is expressed as relative 
expression of phosphorylated protein only. Data expressed as mean ± SEM fold 
change from Vehicle; n=6 experimental replicates from two independent 
experiments (equal numbers from each experiment). 
a) 
b) 
* * 
a) 
b) 
c) 
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Hyper IL-6 activates STAT-3 in a dose dependent manner in L6 myotubes – As it 
was evident 100 ng·ml-1 Hyper IL-6 significantly increased phosphorylation of 
STAT-3, the effects of time and dose were examined in L6 myotubes to determine 
the optimal dose of Hyper IL-6 to be used in all subsequent in vitro experiments. 
Over the timecourse, it was observed that, when compared with vehicle, 
concentrations of 2, 10, 50 and 100 ng·ml-1 Hyper IL-6 caused significant increases 
(p=0.031; p=0.005; p=0.002; p=0.006 respectively) in phosphorylation of STAT-3 
(Figure 4.3a). Significant differences with time (2 min vs. 30 min; p < 0.001 and 30 
min vs. 120 min; p< 0.001) were also noted. There was no significant interaction 
between dose and time (p=0.836).    
 
In direct contrast to L6 myotubes, membrane bound IL-6R is as biologically active 
as sIL-6R in CRL1439 hepatocytes – To make a direct comparison between 
cognate membrane bound IL-6R signalling and that mediated by the sIL-6R, 
CRL1439 hepatocytes, which express membrane bound IL-6R, and L6 myotubes 
were treated with either 50 ng·ml-1 Hyper IL-6 or 100 ng·ml-1 rh-IL-6 to mimic 
soluble receptor complex signalling or membrane bound receptor signalling, 
respectively. In CRL1439, after 1 h of treatment, Hyper IL-6 induced approximately 
2 fold greater phosphorylation of STAT-3 (Figure 4.4a) when compared with that of 
rh-IL-6 (vehicle vs. Hyper IL-6; p<0.001, vehicle vs. rh-IL-6; p<0.001, rh-IL-6 vs. 
hyper IL-6; p<0.001). However as treatment time was prolonged, hyper IL-6 and rh-
IL-6 induced phosphorylation of STAT-3 to a similar degree when compared to that 
of vehicle treated cells, with this bioactivity being sustained for as long as 48 h post 
initiation of treatment.  Moreover, there was a significant difference between 
treatments over time (p<0.001). By contrast, in L6 myotubes  after 1 h of treatment 
phosphorylation of STAT-3 at the tyr705 residue was increased by 4 fold in 
response to rh-IL-6 (vehicle vs. rh-IL-6; p<0.001) and this effect was sustained for 
as long as the 48 h treatment period (Figure 4.4b). In the case of Hyper IL-6 
treatment, increased phospho STAT-3tyr705 was ~20 fold (p<0.001) and by 12 h this 
had decreased to approximately a 12 fold increase when compared to vehicle 
(p<0.001). Again, this was sustained over the remaining treatment period. Co-
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treatment with 100 nM Insulin had no effect on phosphorylation of STAT-3 in 
response to the various treatments. 
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Figure 4.3 Hyper IL-6 phosphorylates STAT-3 in a dose-dependent manner. a) 
Quantitation of phospho STAT-3 protein abundance in L6 myotubes treated with 
varying concentrations of Hyper IL-6 b) Representative blots for phospho STAT-3, 
its corresponding total and β-actin in L6 myotubes. * at 30 min, vehicle vs. 2, 10, 50 
and 100 ng·ml-1 Hyper IL-6; p = 0.031; p=0.005; p=0.002; p=0.006 respectively † 
differences with time 2 min vs. 30 min; p < 0.001 # 30 min vs. 120 min; p< 0.001. 
As constitutive expression of corresponding total proteins remained unchanged, 
data is expressed as relative expression of phosphorylated protein only. Data 
expressed as mean ± SEM fold change relative to vehicle at 2 minute time point, 
n=6 experimental replicates from two independent experiments (equal numbers 
from each experiment). 
  
a) 
b) 
* † # 
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Figure 4.4  Membrane bound IL-6Rα signalling has greater bioactivity in 
CRL1439s than in L6 myotubes a) membrane bound versus soluble receptor 
signalling in myotubes and in b) CRL1439. c) phospho STAT-3tyr705 representative 
blots. L6 myotubes were treated with 100 ng·mL-1 rh-IL-6 or 50 ng·mL-1 Hyper IL-6 
with or without 15 minute 100 nM Insulin stimulation. As constitutive expression of 
corresponding total proteins remained unchanged, data is expressed as relative 
expression of phosphorylated protein only. Data expressed as mean ± SEM fold 
change in phospho STAT-3tyr705 compared with vehicle, n=3 experimental 
replicates from one experiment. 
a) 
b) 
c) 
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Hyper IL-6 co-treatment potentiates Insulin stimulated glucose uptake – Glucose 
uptake was significantly increased ~ 0.75 fold in L6 myotubes stimulated with 100 
nM Insulin when compared to vehicle treated cells (vehicle vs. Insulin; p <0.001, 
Figure 4.5). A similar effect on glucose uptake was seen in L6 myotubes treated 
with 50 ng·mL ml-1 Hyper IL-6 with a 0.75 fold increase in glucose uptake (vehicle 
vs. Hyper IL-6; p = 0.003). Co-treatment with 50 ng·ml-1 Hyper IL-6 potentiated 
Insulin stimulated glucose uptake by approximately 3 fold when compared to 
vehicle control (vehicle vs. Hyper IL-6 + Insulin; p <0.001).  
 
Hyper IL-6 induces SOCS-3 protein and potentiates the increase in insulin 
stimulated phospho-p38 MAPKthr180/tyr182 in L6 myotubes. The effects of Hyper IL-6 
on signalling pathway components were examined under the conditions used in the 
glucose uptake assay. Under these conditions, regardless of the presence of 
insulin, 50 ng·ml-1 Hyper IL-6 increased phospho-STAT3tyr705 approximately 13 fold 
(Figure 4.6a; vehicle vs. Hyper IL-6; p < 0.001). A protein band at a molecular 
weight consistent with that predicted for SOCS-3 was apparent at 25 kDa. The IL-6 
inducible protein SOCS-3, was significantly increased by 5 fold (Figure 4.6b; 
vehicle vs. Hyper IL-6; p <0.001). In cultures co-treated with 100 nM Insulin, a 
tendency for potentiation of Hyper IL-6 induced SOCS-3 protein abundance was 
apparent, albeit not statistically significant.  
 
In L6 myotubes under basal conditions, Hyper IL-6 induced a 2 fold increase in 
phospho-p38 MAPKthr180/tyr182 when compared to vehicle with p < 0.001 (Figure 
4.7a). When stimulated with insulin, protein expression of phospho-p38 
MAPKthr180/tyr182 was augmented by 0.5 fold in vehicle treated cells (p = 0.02) 
compared to 3 fold in those cells co-treated with Hyper IL-6 (vehicle vs. Hyper IL-6 
+ Insulin; p <0.001). In the presence of insulin, there is also a significant 
potentiation of Hyper IL-6 induced activation of p38 MAPK (Hyper IL-6 vs. Hyper 
IL-6 + Insulin; p = 0.032). A significant increase in insulin stimulated 
phosphorylation of Akt at the ser473 residue was observed (p < 0.001). However, 
there was no change in expression of this protein in response to Hyper IL-6 (Figure 
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4.7b). Although Hyper IL-6 had no effect on phospho-AMPKthr172, Insulin reduced 
its expression with and without Hyper IL-6 treatment (p = 0.037, Figure 4.8).  
  
68 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Hyper IL-6 co-treatment results in potentiation of Insulin stimulated 
glucose uptake in L6 myotubes. L6 myotubes were treated for 2 hours with 50 ng· 
mL-1 Hyper IL-6, during the final 15 minutes of the period cells were stimulated with 
100 nM Insulin and glucose uptake determined.   * denotes significant difference 
between Vehicle Basal v Vehicle + 100 nM Insulin; p <0.001, † significant 
difference between Vehicle and 50 ng·ml-1 Hyper IL-6; p=0.003, # difference 
between Vehicle and 50 ng·ml-1 Hyper IL-6 + 100 nM Insulin; p <0.001. Data 
expressed as fold change in glucose uptake expressed relative to vehicle under 
basal conditions, mean ± SEM, n=6 experimental replicates from two independent 
experiments (equal numbers from each experiment). 
 
 
 
  
* † 
# 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Hyper IL-6 activates STAT-3 and induces SOCS-3 protein in L6 
myotubes under conditions used in the glucose uptake assay a) quantitation of 
phospho STAT-3tyr705 protein abundance b) SOCS-3 protein expression c) 
representative blots for protein expression of phospho STAT-3, its corresponding 
total, SOCS-3 and β-actin. * difference between vehicle and Hyper IL-6; p < 0.001. 
As constitutive expression of corresponding total proteins remained unchanged, 
data is expressed as relative expression of phosphorylated protein only. Data 
expressed as mean ± SEM fold change in protein expression from vehicle; n=6 
experimental replicates from two independent experiments (equal numbers from 
each experiment). 
* 
* 
a) 
b) 
c) 
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Figure 4.7 Insulin stimulated activation of Akt remains unchanged with Hyper IL-
6 co-treatment where as phosphorylation of p38 MAPK is potentiated under these 
conditions. Quantitation of a) phospho p38 MAPKthr190/tyr182 and b) phospho 
Aktser473. * Vehicle versus Insulin stimulation; p = 0.02 (phospho p38 
MAPKthr180/tyr182); p < 0.001 (phospho Aktser473), † difference between vehicle and 
Hyper IL-6 + Insulin; p < 0.001, # Hyper IL-6 versus Hyper IL-6 + Insulin p = 0.032. 
As constitutive expression of corresponding total proteins remained unchanged, 
data is expressed as relative expression of phosphorylated protein only. Data 
expressed as mean ± SEM fold change in protein expression from vehicle; n=6 
experimental replicates from two independent experiments (equal numbers from 
each experiment). 
# 
* 
* 
† a) 
* 
b) 
c) 
* 
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Figure 4.8 Hyper IL-6 has no effect on a) phospho AMPKthr172 protein 
abundance under conditions used in the glucose uptake assay. b) Representative 
blots for phospho AMPK thr172 and β-actin. * basal versus Insulin; p = 0.037. As 
constitutive expression of corresponding total proteins remained unchanged, data 
is expressed as relative expression of phosphorylated protein only. Data expressed 
as mean ± SEM fold change in protein expression from vehicle; n=6 experimental 
replicates from two independent experiments (equal numbers from each 
experiment).  
* 
a) 
b) 
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Hyper IL-6 attenuates fatty acid oxidation – Oxidation of palmitic acid was 
decreased by approximately 27 % in L6 myotubes treated with 50 ng·ml-1 Hyper IL-
6 when compared with vehicle treated cells (Figure 4.9; vehicle vs. Hyper IL-6; p = 
0.046).  When compared with vehicle control, treatment with the negative control, 
100 nM Insulin, significantly attenuated palmitate oxidation by approximately 70 % 
with p < 0.001. 
 
sgp130Fc augments Hyper IL-6 insulin stimulated glucose uptake – Co-treating 
with 50 ng·ml-1 of the natural inhibitor of Hyper IL-6, sgp130Fc, had a tendency to 
attenuate Hyper IL-6 stimulated glucose uptake, however this was not considered 
significant (Figure 4.10).  Insulin stimulated glucose uptake was increased 2 fold 
when compared to vehicle (p = 0.043), interestingly insulin stimulated Hyper IL-6 
induced glucose uptake was heightened 3 fold, this was considered significant 
compared to that induced by the Hyper IL-6/sgp130Fc co-treatment (p < 0.001). 
 
sgp130Fc has no effect on phosphorylation of STAT-3, p38 MAPK or Akt under 
basal conditions .The effect of 50 ng·ml-1 sgp130Fc on basal expression of 
phospho STAT-3tyr705, phospho p38 MAPKthr180/tyr182 and phospho Aktser473 was 
examined in L6 myotubes (Figures 4.11 and 4.12). In the absence of Hyper IL-6 
there was no significant effect of 50 ng·ml-1 sgp130Fc on basal expression of these 
proteins.  A dose of 50 ng·ml-1 Hyper IL-6 caused an approximate 24 fold increase 
in phospho STAT-3tyr705 when compared to vehicle treated cells (p < 0.001; Figure 
4.11a). Co-treatment with 50 ng·ml-1 Hyper IL-6 and 50 ng·ml-1 sgp130Fc did not 
decrease phosphorylation of STAT-3 at the tyr705 residue when compared to 
treatment with Hyper IL-6 alone. A similar observation of protein expression for 
phospho p38 MAPK thr180/tyr182 and phospho Akt ser473 was noted (Figure 4.12a and 
4.12b, respectively).  
 
There was no significant effect of 50 ng·ml-1 sgp130Fc alone on abundance of 
phospho p38 MAPKthr180/tyr182 when compared to vehicle treated cells (Figure 
4.12a). In L6 myotubes treated with 50 ng·ml-1 Hyper IL-6 a 3.5 fold increase in 
phospho p38 MAPK thr180/tyr182 was evident (Vehicle vs Hyper IL-6; p < 0.001). 
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There was no significant difference in protein abundance of phospho p38 
MAPKthr180/tyr182 in cells treated with 50 ng·ml-1 Hyper IL-6 alone and those co-
treated with 50 ng·ml-1 Hyper IL-6 and 50 ng·ml-1 sgp130Fc (50 ng·ml-1 Hyper IL-6 
vs 50 ng·ml-1 Hyper IL-6 + 50 ng·ml-1 sgp130Fc; p = 0.399).   
 
Cells treated with sgp130Fc alone had a similar level of phospho Aktser473 
abundance as that of vehicle treated cells (Figure 4.12b). A significant difference 
was evident between Vehicle and 50 ng·ml-1 Hyper IL-6, with an approximate 17 
fold difference (p < 0.001). There was no significant difference between cells 
treated with 50 ng·ml-1 Hyper IL-6 and those treated with 50 ng·ml-1 Hyper IL-6 + 
50 ng·ml-1 sgp130Fc (p = 0.217).  As 50 ng·mL-1 sgp130Fc had no significant 
effect on Hyper IL-6 induced phosphorylation of STAT-3, p38 MAPK or Akt in L6 
myotubes, the effects of sgp130Fc on Hyper IL-6 induced bioactivity were 
examined in a dose dependent manner in cultured myotubes and hepatocytes. 
   
Inhibition of Hyper IL-6 bioactivity by sgp130Fc occurs in a tissue specific manner 
in vitro – L6 myotubes and CRL1439 hepatocytes were co treated with 25 ng·mL-1 
Hyper IL-6 with or without varying concentrations of sgp130Fc (Figure 4.13a). 
Regardless of the presence of sgp130Fc at any given dose, no difference in Hyper 
IL-6 induced phospho STAT-3tyr705 was observed in L6 myotubes. Contrary to this, 
bioactivity was diminished in CRL1439 hepatocytes treated with 25 ng·mL-1 Hyper 
IL-6 plus 500 ng·mL-1 sgp130Fc as indicated by approximately a 25 % reduction in 
phospho STAT-3 tyr705 protein abundance (Hyper IL-6 + 50 ng·mL-1 sgp130Fc vs. 
Hyper IL-6 + 500 ng·mL-1 sgp130Fc; p = 0.041, Hyper IL-6 + 100 ng·mL-1 
sgp130Fc vs. 500 ng·mL-1 sgp130Fc; p = 0.031). When compared to cells 
administered Hyper IL-6 + 200 ng·mL-1 sgp130Fc, there was a non significant 
propensity for Hyper IL-6 induced phosphorylation of STAT-3 to be reduced by co-
treatment with 500 ng·mL-1 sgp130Fc (p=0.073).  
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Figure 4.9 IL-6/sIL-6R signalling attenuates palmitate oxidation in L6 myotubes. 
* difference in fatty acid oxidation between vehicle and Hyper IL-6 treated 
myotubes; p = 0.046, † Difference between vehicle and Insulin stimulated L6 
myotubes; p <0.001. Data expressed as mean ± SEM, n = 6 experimental 
replicates from one experiment. 
  
* 
† 
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Figure 4.10 Co-treatment with sgp130Fc augments Hyper IL-6, Insulin stimulated 
glucose uptake. A significant difference between basal and insulin stimulation 
exists; p <0.001. * difference between basal and insulin stimulated glucose uptake 
in vehicle treated cells; p = 0.043; # Hyper IL-6 + Insulin vs Hyper IL-6 + sgp130Fc 
† difference between Hyper IL-6 + sgp130Fc and Hyper IL-6 +  sgp130Fc + Insulin; 
p <0.001. Data expressed as mean ± SEM, n=6 experimental replicates from one 
experiment.  
  
* 
† 
# 
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Figure 4.11 sgp130Fc has no effect on basal phosphorylation of STAT-3 in L6 
myotubes.    a) Quantitation of phospho STAT-3tyr705. b) Representative blots for 
phospho STAT-3tyr705, total STAT-3 and β-actin. * difference between basal vehicle 
and Hyper IL-6 treated cells; p < 0.001; †  Hyper IL-6 vs sgp130Fc; p <0.001; # 
sgp130Fc vs Hyper IL-6 + sgp130Fc; p < 0.001. As constitutive expression of 
corresponding total proteins remained unchanged, data is expressed as relative 
expression of phosphorylated protein only. Data expressed as mean ± SEM fold 
change in protein expression from vehicle; n=4 experimental replicates from one 
experiment  
  
a) 
b) 
* 
† 
# 
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Figure 4.12 sgp130Fc has no effect on basal phosphorylation of p38 MAPK or 
Akt in L6 myotubes. a) Quantitation of phosphorylation of p38 MAPK in L6 
myotubes treated with 50 ng∙ml-1 sgp130Fc alone or in combination with 50 ng∙ml-1 
Hyper IL-6. b) Quantitation of phosphorylation of Akt in L6 myotubes treated with 
50 ng∙ml-1 sgp130Fc alone or in combination with 50 ng∙ml-1 Hyper IL-6. c) 
Representative blots of phospho p38 MAPKthr180/tyr182, phospho Aktser473 and β-actin 
expression in L6 myotubes.  Difference in phospho p38 MAPK and Akt between  
* basal vehicle and Hyper IL-6 (p <0.001); † Hyper IL-6 vs sgp130Fc; p < 0.001; #  
sgp130Fc vs sgp130Fc + Hyper IL-6; p < 0.001.  As expression of corresponding 
a) 
b) 
c) 
* 
* 
† 
† 
# 
# 
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β-actin remained unchanged, data is expressed as relative expression of 
phosphorylated protein only. Data is expressed as ± SEM fold change in protein 
expression from vehicle; n = 4 experimental replicates from one experiment.   
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Figure 4.13 sgp130Fc inhibits Hyper IL-6 in a cell type dependent manner. a) 
Quantitation of phosphorylation of STAT-3 in L6 myotubes and CRL1439 myotubes 
treated with varying concentrations of sgp130Fc. b) Representative blots of 
phospho STAT-3tyr705 and β-actin expression in L6 myotubes and CRL1439 
hepatocytes. Difference in phospho STAT-3tyr705 expression between vehicle and 
Hyper IL-6 ± sgp130Fc at varying concentrations exists in both cell lines (p < 
0.001). * difference between Hyper IL-6 + 50 ng·ml-1 sgp130Fc and Hyper IL-6 + 
500 ng·ml-1 sgp130Fc ; p = 0.041. † difference between Hyper IL-6 + 100 ng·ml-1 
sgp130Fc and Hyper IL-6 + 500 ng·ml-1 sgp130Fc; p = 0.036. As constitutive 
expression of corresponding total proteins remained unchanged, data is expressed 
as relative expression of phosphorylated protein only. Data expressed as mean ± 
SEM fold change in protein expression from vehicle; n=6 experimental replicates 
from two independent experiments (equal numbers from each experiment). 
4.3 Discussion 
* 
† 
a) 
b) 
80 
 
The current study aimed to determine whether IL-6 trans-signalling events 
occurred within skeletal muscle in vitro using the designer cytokine Hyper IL-6 to 
emulate the activity of the sIL-6/sIL-6R complex. Throughout the studies 
undertaken in this chapter it was demonstrated that Hyper IL-6 was highly bioactive 
within the rat skeletal muscle cell line L6, using phosphorylation of the common 
targets of IL-6 signalling, STAT-3 and p38 MAPK, as a measure of bioactivity. 
Expression of total SOCS-3 was also induced upon Hyper IL-6 treatment. SOCS-3, 
is an IL-6 induced protein that regulates IL-6 signalling through a negative 
autoregulatory loop that prevents autophosphorylation of gp130 or by targeting the 
receptor complex for proteosomal degradation by ubiquitination (Krebs and Hilton, 
2001). This cell line was treated with either 100 ng·ml-1of recombinant IL-6 derived 
from mice or rats or the designer cytokine Hyper IL-6 (human IL-6). It is important 
to note that L6 myotubes remain responsive to the fore mentioned species of IL-6 
as there is a high level of conservation of sequence between species. When 
compared with that of human IL-6, murine IL-6 sequence homology for the 
nucleotide sequence and amino acid sequence is 60 % and 42 %, respectively. 
Similarly, other studies have shown that Rat IL-6 shares sequence homology of 68 
% for nucleotides and 58 % for amino acids (Tanabe et al. 1988; Northemann et al. 
1989). Furthermore rat and murine IL-6 also share a high degree of nucleotide (92 
%) and amino acid (93 %) sequence homology (Northemann et al. 1989). 
 
Hyper IL-6 does not rely on the abundance of the membrane bound IL-6Rα but 
instead binds to the ubiquitously expressed gp130β receptor, resulting in pathway 
activation. It is plausible to suggest that in L6 myotubes the expression of the 
membrane bound form of the receptor is of less abundance than gp130β, thereby 
accounting for the heightened activity of this cytokine when compared with that of 
murine, rat and human IL-6 (Figures 3.1 and 3.3). This requires further 
examination. This supports a notion proposed by Peters and co-workers (1998) 
that the prolonged affect of Hyper IL-6, when compared with IL-6 alone, on 
haptoglobin mRNA (a downstream target of IL-6) was due to the higher expression 
of gp130 than the IL-6 receptor within liver. The Peters et al., (1998) study also 
noted that internalisation of Hyper IL-6 was impaired and it had a greater affinity 
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than IL-6 for its receptor, which possibly contributes to the prolonged and 
increased bioactivity of Hyper IL-6.  
 
In a study by Kami et al. (2000), in skeletal muscle undergoing regeneration after 
contusion, mRNA of the IL-6R was only expressed in mononuclear cells and not in 
multi nucleated myofibres. As the L6 cultures in the present study were 
differentiated for 7 days ensuring a population of mostly multi-nucleated and fused 
myofibre colonies, this may insinuate that the IL-6 receptor is of low abundance 
due to the low numbers of IL-6R mRNA and protein expressing mononuclear cells 
present within these cultures. This may also explain the lack of response to the 
recombinant forms of IL-6 used in the comparative studies (Figure 4.1), as these 
species target cognate receptor signalling and naturally occurring trans-signalling, 
rather than gp130β which is more likely to be of higher abundance within L6 
myotube colonies.   
 
The lack of effect of the cytokines on AMPK phosphorylation in L6 myotubes was 
surprising given that every measure possible was taken to ensure the integrity of 
cytokines used in these experiments remained intact. This included adhering to 
manufacturer‟s instructions stringently. Before cytokine reconstitution the vial was 
briefly centrifuged ensuring any cytokine stuck to the walls of the vial would be 
pelleted at the bottom of the vial. Secondly, cytokine was reconstituted with the 
carrier protein BSA. Recombinant rat -IL-6 and rm-IL-6 was used immediately after 
reconstitution and was never freeze / thawed ensuring that the cytokine did not 
denature as a consequence of this process. Experiments examining the effect of rr-
IL-6 and rm-IL-6 were repeated numerous times, using different batches of 
cytokine from different commercial companies and consistently provided similar 
results. 
 
Contrary to previous studies examining IL-6 signalling (Carey et al., 2006), Hyper 
IL-6 did not markedly increase phosphorylation of AMPK at the thr172 residue. A 
possible explanation is that over time, myogenic differentiation as a result of serum 
starvation increases the basal level of AMPK activity, possibly due to lower 
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amounts of metabolic substrates for glucose utilisation available for the ever 
increasing energy demands of these cells. Moreover, the cells in the present study 
were cultured in low glucose α-MEM. This may have implications for basal 
phosphorylation and subsequent activation of this protein as AMPK activity is 
induced in glucose deprived states due to a shift in the AMP/ADP ratio. This may 
result in a metabolic shift allowing the cell to maintain energy homeostasis through 
the induction of β-oxidation. In support of this, a study by Niesler, Myburgh and 
Moore (2006) demonstrated that C2C12 myotubes displayed a higher basal level 
and stimulated activation of AMPK and this activity was greater than that seen in 
myoblasts. In addition, induction of apoptosis due to serum starvation was less in 
C2C12 myotubes than that of undifferentiated myoblasts, most likely due to the 
increased expression of AMPK within these cells. If IL-6 does indeed activate 
AMPK, one may argue that the culture conditions used within this study would be 
adverse for exploring this. AMPK expression and activity may be exponentially 
elevated with increases in post mitotic fused multi nucleated myotubes within cell 
populations thus masking any changes induced by cytokine treatment.  
  
It has previously been shown that IL-6 is an important regulatory component of the 
myogenic differentiation program of C2C12 cells (Baeza-Raja and Muñoz-Cánoz, 
2004). Under conditions considered unfavourable for C2C12 differentiation, 
administration of sIL-6 resulted in an increase in markers of myogenic 
programming including α-actin and myogenin. More recently, in a study by the 
same group, IL-6 release was increased over time during muscle hypertrophy 
(Serrano et al., 2008) and behaved in both an autocrine and paracrine manner. 
Importantly, this study also demonstrated that IL-6 Receptor shedding may occur in 
skeletal muscle both in vitro and in vivo as evident by the presence of sIL-6R in cell 
culture media and in plantaris muscle extracts, thus providing support to the 
current study‟s findings IL-6/sIL-6R induced signalling is physiologically relevant 
within skeletal muscle. As this is the case, it may be of interest to examine IL-6 
receptor expression in both its transmembrane complex form and sIL-6R as well as 
metalloprotease activity, throughout the myogenic cycle.  
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As previous research has alluded that the physiological response to IL-6 is unique 
according to the cell type‟s intrinsic properties, it was hypothesised that activation 
of the JAK/STAT pathway by the two types of IL-6 receptor complexes would also 
be inherently different according to cell type. Thus, the response of L6 myotubes 
and CRL1439 hepatocytes to either recombinant human IL-6 or Hyper IL-6 was 
examined (Figure 4.4). It was evident that membrane bound receptor signalling 
was as biologically relevant as that of soluble IL-6 receptor signalling within liver 
cells in vitro. By contrast, L6 myotubes were highly responsive to Hyper IL-6, an 
effect that was not so apparent in cells treated with rhIL-6.  It is not inconceivable 
that the differences in response to the cytokines are due to disparity in the relative 
expression of gp130 and membrane bound IL-6Rα within these two cell types and 
would certainly account for the heightened activity of this cytokine within L6 
myotubes when compared to that of other species of IL-6. In support of this, a 
study by Schwabe, Zhao and Kung (1994) demonstrated that cell lines responded 
differently according to the relative expression of the membrane bound IL-6R.  
 
IL-6 has previously been implicated in potentiating the dynamic cellular response of 
insulin stimulated glucose uptake (Carey et al., 2006). In concurrence with this 
study, it was determined that Hyper IL-6 stimulated glucose uptake to a similar 
level as that induced by Insulin. Furthermore, co-treatment with Hyper IL-6 
potentiated insulin stimulated glucose uptake, suggesting that Hyper IL-6 increases 
glucose uptake by Insulin independent pathways. These changes in glucose 
uptake were associated with increases in the dual phosphorylation of p38 MAPK. 
This is in accordance with previous research that implicates p38 MAPK in the 
regulation of glucose uptake within adipocytes and skeletal muscle (Lee et al., 
2008; Lemieux et al., 2003; Niu et al., 2003; Sweeney et al., 1999).  The exact role 
of p38 MAPK in glucose uptake remains controversial. Previous research indicates 
that Insulin stimulated glucose uptake in L6 myotubes occurs independently of p38 
MAPK (Antonescu et al., 2005). However, this does not exclude the possible effect 
p38 MAPK may have in IL-6 induced glucose uptake, independently of insulin.  
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Akt substrate of 160 kDa (AS160), a Rab GTPase binding protein, plays an integral 
part in Insulin and Contraction induced glucose uptake (Kramer et al., 2006). 
During the basal state AS160 is bound to GLUT 4, upon insulin stimulation Akt 
phosphorylates AS160, causing the protein to dissociate from GLUT4, leading to 
vesicular exocytosis to the plasma membrane and increased glucose uptake 
(Larance et al., 2005). It should be noted that, AS160 also possesses 
phosphorylation sites for AMPK (Treebak et al., 2006). These sites would appear 
to be important in the regulation of contraction mediated AS160 dissociation and 
glucose uptake (Kramer et al., 2006). Whether p38 MAPK has the ability to induce 
dissociation of AS160 has yet to be elucidated. It would be of great interest to 
determine if Hyper IL-6 potentiates glucose uptake via mediating p38 MAPK 
induced dissociation of AS160 and subsequently increased exocytosis of GLUT4. 
Alternatively, the increased glucose uptake due to Hyper IL-6 may be a result of 
increased intrinsic activity of GLUT4. This requires further investigation.  
 
Contrary to previous studies, under the conditions used in the glucose uptake, 
AMPK activation via phosphorylation of residue thr172 did not appear to be 
affected by Hyper IL-6. Thus, it is proposed that AMPK is not required for sIL-6/sIL-
6Rα induced glucose uptake within skeletal muscle. Further studies involving 
knock down of AMPK activity would provide a definitive answer to this supposition. 
As AMPK is activated during metabolic stress resulting in a shift of metabolism 
from ATP utilising to ATP generating processes and as glucose uptake was 
attenuated in these studies, palmitate oxidation was also examined.  In support of 
this “metabolic switch” hypothesis, palmitate oxidation was less in L6 myotubes 
treated with Hyper IL-6 compared with vehicle treated cells. It is known that upon 
exercise, skeletal muscle releases IL-6 into the circulation thereby providing tissue 
cross talk which, in turn, alters metabolism within the liver by reducing hepatic 
glucose output (Febbraio and Pedersen, 2008) and increasing lipolysis in adipose 
tissue (van Hall et al., 2003). As transient increases in IL-6 occur during exercise, 
perhaps IL-6 trans-signalling also plays a beneficial role in an acute manner 
through the regulation of glucose utilisation and modulation of lipid metabolism. IL-
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6 is often chronically elevated in states of disease and perhaps this chronic 
elevation results in aberrant metabolism and inflammation.   
 
Unexpectedly, when co-treated with Hyper IL-6 and the natural competitive 
inhibitor of IL-6 trans-signalling, sgp130Fc, insulin stimulated glucose uptake was 
potentiated (Figure 4.10). Whether sgp130Fc is capable of mediating glucose 
uptake through alternate signalling pathways is not known and the mechanism by 
which this may occur remains elusive and requires further investigation. It is of 
great importance to note that classical IL-6 signalling mediated through the 
membrane receptor complex remains unaffected by sgp130 (Jostock et al., 2001). 
This was confirmed in these studies, whereby 50 ng∙mL-1 sgp130Fc did not 
stimulate phosphorylation of STAT-3, p38 MAPK or Akt. Upon review of the 
literature, previous studies have demonstrated a molar excess of sgp130 is 
required for inhibition of sIL-6/sIL-6R complex signalling due to the comparative 
differences in molecular weight of the two molecules (Jostock et al., 2001). sgp130 
has a molecular weight of approx 130 kDa, whereas sIL-6/sIL-6R complex is 70 
kDa in size (Ward et al., 1994), thus explaining the necessity for molar excess in 
inhibition of the designer cytokine. Thus under the conditions used in the glucose 
uptake assay only partial inhibition, would occur. As it would appear that 50 ng·ml-1 
sgp130Fc was unable to inhibit Hyper IL-6 potentiated insulin stimulated glucose 
uptake or Hyper IL-6 induced cell signalling, a cell signalling dose response was 
examined in both L6 myotubes and the CRL1439 cell line. It was determined that 
sgp130Fc was ineffective, even at higher concentrations, for inhibiting the action of 
Hyper IL-6 in L6 myotubes.  However, contrary to the response of L6 myotubes, 
sgp130Fc was able to inhibit Hyper IL-6 action within CRL1439s with a 25 % 
reduction in activation of STAT-3 in the presence of 500 ng·mL-1 sgp130Fc. This 
may also be due to the relative expression of mIL-6Rα, gp130 and the action of 
trans-signalling in these two cell types.  
 
In conclusion, using Hyper IL-6 to mimic the action of IL-6/sIL-6R, it was 
determined that L6 myotubes are indeed responsive to the IL-6 trans-signalling 
phenomena. Furthermore, Hyper IL-6 regulates important physiologically activities 
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such as glucose and fat oxidation, through the activation of the JAK/STAT pathway 
and its downstream targets.  Moreover, these studies insinuate IL-6/sIL-6R has a 
cell type dependent effect causing diverse levels of bioactivity within L6 myotubes 
and CRL1439 hepatocytes. This is likely due to the variable expression of 
membrane bound IL-6Rα and gp130β within different cell types. 
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CHAPTER FIVE 
 
Acute Hyper IL-6 administration has 
tissue specific effects on metabolic 
signalling pathways in vivo 
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5.1 Introduction 
As discussed previously in this dissertation, it is well established within the 
literature that IL-6 is increased in a transient manner during exercise and is 
associated with increased fat oxidation and glucose utilisation within skeletal 
muscle, lipolysis within adipose tissue and increased hepatic glucose output (refer 
to Chapter 1). Contrary to the beneficial outcomes arising from transient increases 
in IL-6, prolonged elevated levels of this cytokine and the soluble receptor are often 
associated with chronic inflammatory conditions and described as a common 
hallmark of such diseases as arthritis, hepatocellular adenomas and colitis (Nowell 
et al., 2003; Maione et al., 1998, and Atreya et al., 2000) 
 
In 1997, Fischer and co-workers designed and produced a bioactive fusion protein 
that consisted of 16 N terminal amino acid residues of human IL-6 linked to the sIL-
6R via a flexible 13 residue polypeptide linker rich in glycine and serine.  From this 
work and subsequent studies it was determined that this designer cytokine 
mimicked IL-6/sIL-6R trans-signalling and had greater bioactivity than that of IL-6, 
as it was required at a concentration of 100 to 1000 fold less than regular IL-6 to 
elicit expansion of human haematopoietic cells and induce mRNA for the acute 
phase protein haptoglobin (Fischer et al., 1997; Peters et al., 1998). The greater 
bioactivity of this designer cytokine was attributed to its distinct biochemical ability 
to target gp130β, which is of greater abundance and ubiquitously expressed, rather 
than the lowly abundant and atypically expressed membrane bound IL-6 Receptor 
(Rose-John et al., 2006).   
 
Previous research has elucidated transient increases in IL-6 release from adipose 
tissue and skeletal muscle (Keller et al., 2003; Ostrowski et al., 1998; Hiscock et 
al., 2004) that occur during exercise. It is not known whether this is in concert with 
escalating concentrations of sIL-6R in the circulation and thus frequency of IL-6 
trans-signalling events. It is known that IL-6 release leads to enhanced metabolic 
signalling and subsequently altered physiological function within liver, adipose 
tissue and skeletal muscle (Pedersen and Febbraio, 2008). Further support of the 
probable importance of IL-6 trans-signalling events in metabolic regulation was 
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provided by Chapter 4 of this dissertation whereby acute Hyper IL-6 treatment, 
used to mimic IL-6/sIL-6R complex signalling, regulated metabolic processes in 
cultured myotubes and hepatocytes in vitro. As a consequence, it was 
hypothesised that the IL-6 trans-signalling events seen in vitro would be 
biologically relevant within an in vivo context. Therefore, the primary aim of this 
study was to examine the effect of an acute administration (45 min) of 4 μg Hyper 
IL-6 to C57BL6 WT mice on metabolic pathway signalling within muscle, liver and 
adipose tissue. Furthermore, as Hyper IL-6 treatment has been implicated in 
progression of inflammation, inflammatory signalling pathways were examined in 
the fore mentioned tissues.  
 
It is of importance to note that the sIL-6R activity may be inhibited by binding of the 
naturally occurring soluble form of gp130β (sgp130) (Jostock et al., 2002). Soluble 
gp130 is present in human sera where it binds to the soluble form of the IL-6 
receptor in complex with IL-6 (Narazaki et al., 1993; Jostock et al., 2002). This 
prevents the IL-6/sIL-6R complex from binding to membrane bound gp130 and 
forming the high affinity ternary complex. An artificial form of this naturally 
occurring inhibitor was produced by linking the extra cellular portion of sgp130 to 
the heavy chain region (Fc fragment) of human IgG (Jostock et al., 2002). This 
recombinant protein had the ability to inhibit sIL-6R mediated signalling whilst 
membrane bound receptor signalling remained intact. Thus the secondary aim of 
the study was to explore the effects of sgp130Fc on Hyper IL-6 mediated signalling 
events in liver, white adipose tissue and skeletal muscle. As IL-6 trans-signalling is 
known to cause inflammation within liver and various other tissues, it was proposed 
that co-treatment with sgp130Fc would prevent inflammatory signalling mediated 
by Hyper IL-6, particularly within the liver, whilst maintaining the beneficial effects 
associated with membrane bound IL-6 receptor signalling, as previously 
demonstrated in Chapter 4, on metabolic signalling within skeletal muscle and 
WAT in vivo.    
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5.2 Methods 
Animals - Male C57BL6 mice of 12 weeks of age weighing approximately 25 g 
were housed in the AMREP precinct animal facility in a 12:12 hour light:dark cycle. 
Animals were fed a standard mouse chow diet and water ad libitum. All animal 
experiments were performed as approved by the Animal Ethics Committee of the 
AMREP (ethics application approval number E/0679/2008/B). Animals were 
randomly assigned to be administered Saline (control), 4 μg Hyper IL-6 or 4 μg 
Hyper IL-6 + 40 μg sgp130Fc by intraperitoneal injection using a 25 gauge needle 
under basal or insulin stimulated conditions.  Mice assigned to the fore mentioned 
groups that were to undergo 3 minute insulin stimulation before being culled, 
received 1.5 U/kg Insulin (Actrapid®, Novo Nordisk, Bagsraerd, Denmark) via 
intraperitoneal injection. Animals were culled by cervical dislocation, 45 minutes 
post administration of the assigned compounds, after which the tissues of interest 
were promptly excised, snap frozen in liquid nitrogen and stored at -80°C until 
required for further analyses.  
 
Extraction of protein from harvested tissue - Approximately 50 mg of liver, soleus, 
EDL or white adipose tissue were cut from the excised tissues by scalpel blade 
whilst in a pre-chilled ceramic bowl. samples were then placed in a microfuge tube 
containing ice cold lysis buffer (consisting of 50 mM HEPES, 150 mM NaCl, 1 mM 
NaF, 1 mM Na3VO4, 5 mM EDTA, 0.5 % Triton X-100 (v/v), 10 % glycerol (v/v), 1 
mM phenylmethylsulfonyl, 50 mM phosphatase inhibitor and 50 mM protease 
inhibitor). Samples were then ground using a plastic handheld homogeniser tip and 
the subsequent lysates were centrifuged at 13000 g for 60 min at 4°C. The 
supernatant was placed in a fresh microfuge tube and the debris containing pellet 
was discarded. Protein concentration was determined by BCA assay and 40 μg of 
protein was solubilised in Laemmelli‟s Buffer as described in Chapter 3. 
 
SDS-PAGE analysis of protein expression - The expression of proteins of interest 
was examined using Western Blotting as previously described in Chapter 3 of this 
dissertation. Briefly, after proteins of each sample were separated by 
electrophoresis, proteins were transferred to nitrocellulose membranes by semi dry 
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transfer. Membranes were incubated overnight in either phospho STAT-3 tyr705, 
phospho Akt ser473, phospho ACC ser79, phospho AMPK thr172, PGC-1α, β-
actin (Cell Signaling Technology, Beverly, MA, USA), total STAT-3 (Upstate 
Biotechnology Incorporated, Lake Placid, NY, USA) or SOCS-3 (Abcam, 
Cambridge, UK). The relative expression of the proteins of interest was determined 
by antibody binding and enhanced chemiluminescence as described in Chapter 3. 
β-actin was used as a loading control, to ensure equal amounts of protein had 
been analysed for each sample.  
 
Statistics - Statistics were computed using the statistical analysis software package 
SPSS 12.0.01 for Windows to identify significant differences using either a one way 
or two way ANOVA. Multiple comparisons were made using the Tukey‟s post hoc 
test to locate significant differences between treatments. Significant differences for 
all experiments were accepted at p < 0.05. All data is expressed as mean fold 
change of protein expression compared to the expression of the protein of interest 
in tissues harvested from saline treated mice (Saline Control =1).  
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5.3 Results 
Hyper IL-6 modulates STAT signalling in metabolically active tissues in vivo – As 
previous studies have determined that 4 μg Hyper IL-6 is effective in inducing an 
acute phase response for 48 hours in mice (Peters et al., 1998) the bioactivity of 4 
μg Hyper IL-6 was examined in various tissues important in metabolic regulation. 
Phospho STAT-3 tyr705 was used as a measure of JAK/STAT pathway activation 
and hence used as an indicator of efficiency of the cytokine to induce a biological 
response within muscle, adipose tissue and liver. This was also examined in the 
presence and absence of 40 μg sgp130Fc. It is important to note, administration of 
40 μg sgp130Fc alone had little effect on any of the biomarkers examined in the 
tissues of interest and as a consequence has not been included in the current data 
set. To determine if Hyper IL-6 had the potential to influence insulin signalling, the 
level of phosphorylation of Akt at the ser473 residue was examined under basal 
and insulin stimulated conditions. In liver (Figure 5.1a), in the presence of Hyper IL-
6, phospho STAT-3 tyr705 was increased approximately 5.5 fold when compared 
with saline (Saline vs. Hyper IL-6, p < 0.001). In the presence of 40 μg sgp130Fc, 
the level of phosphorylation was 3.5 fold less (approx. 35 % of Hyper IL-6 induced 
phosphorylation) than that of Hyper IL-6 treatment (Hyper IL-6 vs. Hyper IL-6 + 
sgp130Fc, p <0.001) only increasing phospho-STAT-3 tyr705 by 2 fold when 
compared saline (Saline vs. Hyper IL-6 + sgp130Fc; p = 0.042). 
 
Hyper IL-6, had a tendency to increase phospho Akt ser473 (Figure 5.1b) and in the 
presence of sgp130Fc resulted in a 2 fold increase (Saline vs. Hyper IL-6 + 
sgp130Fc; p < 0.01) in liver. The difference in phospho Akt ser473 between saline 
and saline under Insulin stimulated conditions was not quite significant (saline vs. 
Insulin; p = 0.088). Hyper IL-6 and Insulin co-administration increased phospho Akt 
ser473 5 fold (Saline vs. Hyper IL-6 + Insulin; p < 0.001, Hyper IL-6 vs. Hyper IL-6 + 
Insulin; p = 0.003). In liver harvested from Insulin stimulated mice administered 
Hyper IL-6 and sgp130Fc, phospho Akt ser473 had a tendency to be reduced when 
compared to livers of insulin stimulated animals administered Hyper IL-6 (Saline 
vs. Hyper IL-6 + sgp130Fc + Insulin; p = 0.005).  
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Figure 5.1 Hyper IL-6 increases a) STAT-3 activation and has a propensity to 
increase basal and potentiate insulin stimulated b) phospho Aktser473 in liver.  
c) Representative blots for proteins of interest. † denotes difference between 
Saline vs. Hyper IL-6; p < 0.001, # Saline vs. Hyper IL-6 + sgp130Fc; p = 0.042 
and Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p < 0.001.  * denotes difference 
between Saline vs. Hyper IL-6 + Insulin; p < 0.001, Hyper IL-6 vs. Hyper IL-6 + 
Insulin; p = 0.003, ** Saline vs. Hyper IL-6 + sgp130Fc; p < 0.01, *** Saline vs. 
Hyper IL-6 + sgp130Fc + Insulin; p = 0.005. As constitutive expression of 
corresponding total proteins and β-actin remained unchanged, data is expressed 
as relative expression of phosphorylated protein only. Data expressed as mean ± 
SEM, n = 12 and n = 6 for phospho STAT-3tyr705 and phospho Aktser473, 
respectively.   
a) 
b) 
c) 
† 
# 
* 
** 
*** 
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In white adipose tissue (Figure 5.2a), phospho STAT-3 tyr705 was significantly 
increased by ~11 fold (Saline vs. Hyper IL-6 p = 0.004). There was no significant 
difference in animals co-administered sgp130Fc (Saline vs. Hyper IL-6 + 
sgp130Fc; p = 0.442, Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p = 0.065).  There 
was no significant difference between treatment groups in phospho Akt ser473, under 
basal or insulin stimulated conditions (Figure 5.2b). A slight tendency for this 
protein to be increased was noted under insulin stimulated conditions, however 
upon analysis this was not considered to be significant.       
 
In skeletal muscle co-treatment with sgp130Fc diminished Hyper IL-6 induced 
phospho STAT-3 tyr705 by approximately 40 %, regardless of the fibre type of the 
muscle. In soleus (Figure 5.3a), Hyper IL-6 elevated phospho STAT-3 tyr705 ~ 4 fold 
(Saline vs. Hyper IL-6; p < 0.001) and this was reduced to ~ 2.5 fold in the 
presence of sgp130Fc (Saline vs. Hyper IL-6 + sgp130Fc; p = 0.001, Hyper IL-6 
vs. Hyper IL-6 + sgp130Fc; p = 0.001).   A 5 fold increase in phospho STAT-3 tyr705 
in the EDL (Figure 5.4a) of mice administered Hyper IL-6 was noted (Saline vs. 
Hyper IL-6; p < 0.001). Upon co-administration with sgp130Fc this was decreased 
by approximately 40 % to 3 fold that of phospho STAT-3 tyr705 protein expression in 
EDL harvested from Saline treated animals (Saline vs. Hyper IL-6 + sgp130Fc; p = 
0.023, Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p = 0.038). In soleus (Figure 5.3b), 
Hyper IL-6 + sgp130Fc increased phospho Akt ser473 under basal conditions (saline 
vs. Hyper IL-6 + sgp130Fc; p = 0.006, Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p = 
0.040). There was no difference between treatment groups under insulin stimulated 
conditions. There was no significant change in phospho Akt ser473 under basal nor 
insulin stimulated conditions within EDL (Figure 5.4b).  
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Figure 5.2 IL-6 trans-signalling events occur in WAT in vivo - Hyper IL-6 is 
bioactive in white adipose tissue, as determined by increases in a) phospho STAT-
3tyr705 (n=12) with 4 μg Hyper IL-6 treatment, an affect that is not ameliorated in the 
presence of 40 μg sgp130Fc. However Hyper IL-6 does not significantly induce b) 
Akt activation under basal or insulin stimulated conditions (n=6) as determined by 
phospho Aktser473 c) Representative blots for the fore mentioned proteins. * denotes 
Saline vs. Hyper IL-6; p < 0.005. As constitutive expression of corresponding total 
proteins and β-actin remained unchanged, data is expressed as relative expression 
of phosphorylated protein only. Data expressed as mean ± SEM. 
  
* a) 
b) 
c) 
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Figure 5.3 IL-6 trans-signalling occurs in Soleus muscle in vivo - a) Quantitation 
of phospho STAT-3tyr705, which is increased in response to 4 μg Hyper IL-6 but 
displays a moderated increase with 40 μg sgp130Fc co-treatment (n=12). b) 
Quantitation of phospho Aktser473 (n=6) in soleus. c) Representative western blots. * 
Saline vs. Hyper IL-6; p < 0.001, † Saline vs. Hyper IL-6 + sgp130Fc; p = 0.001, 
Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p = 0.001. # Saline vs. Hyper IL-6 + 
sgp130Fc; p = 0.006; Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p = 0.04.  As 
constitutive expression of corresponding total proteins and β-actin remained 
unchanged, data is expressed as relative expression of phosphorylated protein 
only. Data expressed as mean ± SEM, n = 12 and n = 6 for phospho STAT-3tyr705 
and phospho Aktser473 
  
c) 
* 
† 
# 
a) 
b) 
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Figure 5.4 Hyper IL-6 trans-signalling is bioactive in EDL in vivo but displays 
moderated increases upon co- administration with sgp130Fc - Quantitation of a) 
phospho STAT-3tyr705 (n=12) and b) phospho Aktser473 (n=6) protein expression in 
EDL and c) the corresponding representative blots for these proteins. * denotes 
Saline vs. Hyper IL-6; p < 0.001, † Saline vs. Hyper IL-6 + sgp130Fc; p = 0.023, 
Hyper IL-6 vs. Hyper IL-6 + sgp130Fc; p = 0.038.  As constitutive expression of 
corresponding total proteins and β-actin remained unchanged, data is expressed 
* 
† 
a) 
b) 
c) 
98 
 
as relative expression of phosphorylated protein only. Data expressed as mean ± 
SEM. 
 
Hyper IL-6 regulates proteins involved in signalling associated with fat oxidation in 
liver and white adipose tissue – Protein levels of important mediators of fat 
oxidation were measured in liver and WAT of mice that received Hyper IL-6 ± 
sgp130Fc. In liver, phospho ACC ser79 (Figure 5.5b) was increased with Hyper IL-6 
(Saline vs. Hyper IL-6; p = 0.012). Soluble gp130Fc was unable to impede Hyper 
IL-6 action on phospho ACC ser79 (Saline vs. Hyper IL-6 + sgp130Fc; p = 0.007). 
There was a tendency for protein expression of phospho AMPK thr172, to be 
increased by 50 % in liver from mice administered Hyper IL-6, regardless of the 
presence of sgp130Fc (Figure 5.5a). Concomitantly, the downstream target of the 
fore mentioned proteins, the co-transcription factor PGC-1α (Figure 5.5c) had a 
tendency to be increased by 50 % in liver of animals administered Hyper IL-6 and 
was significantly increased by 2 fold in those animals that received Hyper IL-6 + 
sgp130Fc (Saline vs. Hyper IL-6; p = 0.222, Saline vs. Hyper IL-6 + sgp130Fc; p = 
0.036) . 
 
There was a trend for slight increases in phospho ACC ser79 and phospho AMPK 
thr172 in WAT, however upon statistical analysis, these were not considered to be 
significantly different to the levels found in WAT from control mice (Figure 5.6a and 
5.6b). However, a significant increase of approximately 2 fold was noted in PGC-1α 
(Figure 5.7c) in WAT of C57BL6 mice administered Hyper IL-6 (Saline vs. Hyper 
IL-6; p = 0.013). However not statistically significant, it was of interest to note that 
upon co-administration with sgp130Fc, PGC-1α protein had a tendency to be 
decreased by approximately 25 %.  
 
Hyper IL-6 affects mediators of fat oxidation in a skeletal muscle fibre type 
dependent manner – activation of proteins that are known to modulate fat oxidation 
were examined including phospho ACC ser79, phospho AMPK thr172 and PGC-1α 
within Soleus and EDL. Hyper IL-6 had a tendency to increase phospho ACC ser79 
protein by approximately 50 % in Soleus (Figure 5.7b), however this was not 
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statistically significant. Phospho AMPK thr172 (Figure 5.7a) was reduced by 25 % in 
Soleus of mice administered Hyper IL-6 (Saline vs. Hyper IL-6; p = 0.018). In EDL, 
Hyper IL-6 had a tendency to increase phospho AMPK thr172 (Figure 5.8a). 
However, there was no significant difference in protein expression of either 
phospho ACC ser79 (Figure 5.8b) or phospho AMPK thr172. PGC-1α was not 
detectable in soleus and EDL. This could reflect its rather transient nature of 
expression (Pilegaard, Saltin and Neufer, 2003).  
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Figure 5.5 In liver, Hyper IL-6 trans-signalling has a tendency of regulating 
proteins that mediate fat oxidation regardless of the presence of sgp130Fc - 
Quantitation of a) phospho AMPKthr172, b) phospho ACCser79 and c) PGC-1α in liver 
of mice administered either 4 μg Hyper IL-6 in the presence or absence of 40 μg 
sgp130Fc. d) Representative western blots for phospho AMPKthr172, phospho 
ACCser79, PGC-1α and β-actin in liver. * denotes Saline vs. Hyper IL-6; p = 0.012, # 
Saline vs. Hyper IL-6 + sgp130Fc; p = 0.007, † Saline vs. Hyper IL-6 + sgp130Fc; 
p = 0.036. As constitutive expression of corresponding total proteins and β-actin 
remained unchanged, data is expressed as relative expression of phosphorylated 
protein only for AMPK and ACC. All data expressed as mean ± SEM; n = 6.  
 
  
* # 
† 
a) b) 
c) d) 
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Figure 5.6 Hyper IL-6 has a tendency to increase signalling proteins associated 
with β- Oxidation and significantly increases protein expression of PGC-1α in WAT. 
Quantitation of protein levels of a) phospho AMPKthr172, b) phospho ACCser79 and c) 
PGC-1α in white adipose tissue collected from mice administered 4 μg Hyper IL-6 
or 40 μg sgp130Fc. d) Representative blots for the proteins of interest. * denotes 
the difference between Saline vs. Hyper IL-6; p = 0.013. As constitutive expression 
of corresponding total proteins and β-actin remained unchanged, data is expressed 
as relative expression of phosphorylated protein only for AMPK and ACC. All data 
expressed as mean ± SEM; n = 6.  
 
  
* 
a) b) 
c) d) 
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 Hyper IL-6 induces proteins associated with inflammation in a tissue specific 
manner – As soluble IL-6 receptor signalling is often associated with states of 
inflammation and IL-6 is described as a pro inflammatory cytokine, proteins 
typically induced in acute phase inflammation were examined.  There was no 
significant change in phospho IKKα ser180/IKKβ ser181 or phospho JNK thr183/tyr185 in 
liver (Figure 5.9a and 5.9b), soleus (Figure 5.11a) or EDL (Figure 5.11b) (data for 
JNK thr183/tyr185 is not shown as it was not detectable within skeletal muscle). Of 
great interest is the significant increase noted in the 46 kDa subunit of phospho 
JNK thr183/tyr185, an important  mediator of inflammatory signalling, with Hyper IL-6 
treatment (Saline vs. Hyper IL-6; p < 0.001) within WAT, an affect that was 
ameliorated with sgp130Fc co-administration (Figure 5.10b; Hyper IL-6 vs. Hyper 
IL-6 + sgp130Fc; p = 0.005). Phospho IKKβ ser181 had a tendency to be increased 
in WAT with Hyper IL-6 treatment (Figure 5.10a).  
 
Suppressor of Cytokine Signalling-3 has a tendency to be induced with IL-6/sIL-6R 
complex mediated signalling – As another measure of bioactivity the protein 
expression of SOCS-3 was examined in the 4 tissue types. It was determined that 
mimicking IL-6/sIL-6R complex JAK/STAT signalling had a tendency to induce 
SOCS-3 protein expression in liver (Figure 5.12a), WAT (Figure 5.12b) and EDL 
(Figure 5.12d) regardless of the presence of sgp130Fc. Counter to that pattern, a 
trend of reduced expression of this protein upon administration of Hyper IL-6 was 
noted in soleus (Figure 5.12c). However upon statistical analyses any differences 
noted in protein expression of SOCS-3 were not considered significant. 
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Figure 5.7 Hyper IL-6 has a tendency to increase phospho ACCser79 but in 
contrast decreases phospho AMPKthr172 in soleus in vivo - Quantitation of protein 
expression of a) phospho AMPKthr172 and b) phospho ACCser79 c) Representative 
blots. * denotes difference between Saline vs. Hyper IL-6; p = 0.018. As 
constitutive expression of corresponding total proteins and β-actin remained 
unchanged, data is expressed as relative expression of phosphorylated protein 
only for AMPK and ACC. All data expressed as mean ± SEM; n = 6.  
 
  
* 
a) 
b) 
c) 
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Figure 5.8 Hyper IL-6 mediates fat oxidation signalling in a fibre type specific 
manner as demonstrated by the contrast in signalling between EDL and that of 
soleus – Quantitation of protein expression of a) phospho AMPKthr172 and b) 
phospho ACCser79 in EDL.  As constitutive expression of corresponding total 
proteins and β-actin remained unchanged, data is expressed as relative expression 
of phosphorylated protein only for AMPK and ACC. All data expressed as mean ± 
SEM; n = 6.  
 
 
  
a) 
b) 
c) 
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Figure 5.9 In liver, acute Hyper IL-6 treatment does not stimulate robust 
activation of a) IKK or b) JNK, proteins implicated in the induction of inflammation - 
a) phospho IKKβser181 remains unchanged in liver from mice that were administered 
4 μg Hyper IL-6 ± 40 μg sgp130Fc when compared to saline. b) Four micrograms 
Hyper IL-6, regardless of the presence of 40 μg sgp130Fc had a tendency to 
increase phospho JNKthr183/tyr185 at both the 46 kDa and 54 kDa subunits. c) 
Representative western blots. Data is expressed as mean ± SEM, n = 6.       
 
 
  
a) 
b) 
c) 
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Figure 5.10 Markers of inflammatory signalling are induced in WAT of mice 
administered Hyper IL-6. a) Quantitation of phospho IKKβser181 demonstrating a 
trend of increased phosphorylation in WAT harvested from mice administered 4 μg 
Hyper IL-6, this had a tendency to be decreased by approximately 25 % when co-
administered 40 μg sgp130Fc. b) phospho JNK thr183/tyr185 was significantly elevated 
at the 46 kDa subunit, which was inhibited upon the co-administration of 40 μg 
sgp130Fc. There was no significant change in the 54 kDa subunit c) 
Representative blots for the fore mentioned proteins and the loading control β-
actin. * denotes Saline vs. Hyper IL-6; p < 0.001, ** Hyper IL-6 vs. Hyper IL-6 + 
sgp130Fc; p = 0.005.  Data expressed as mean ± SEM, n = 6. 
  
* 
** 
a) 
b) 
c) 
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Figure 5.11 Inflammatory signalling was not induced in skeletal muscle upon 
administration of Hyper IL-6. Quantitation of phospho IKKα/βser180/181 in a) soleus 
and b) EDL and c) the corresponding representative blots for these muscle types. 
Data is expressed as mean ± SEM, n = 6.   
  
  
a) 
b) 
c) 
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Figure 5.12 SOCS-3 protein expression has a tendency to be induced with acute 
IL-6/sIL-6R complex mediated signalling events. Expression of SOCS-3, an IL-6 
inducible protein, had a tendency to be increased in a) liver, b) white adipose, c) 
soleus and d) EDL in mice administered 4 μg Hyper IL-6 ± 40 μg sgp130Fc. 
SOCS-3 protein remained relatively consistent in c) Soleus regardless of treatment 
group. Note: SOCS-3 is expressed as a doublet in liver. Data expressed as mean ± 
SEM, n = 6.   
a) b) 
c) d) 
e) 
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5.4 Discussion 
The primary aim of this study was to examine the effect of an acute dose of Hyper 
IL-6 on trans-signalling events in various metabolically active tissues in vivo 
including liver, white adipose tissue, soleus and extensor digitorum longus. Using 
Hyper IL-6 to mimic IL-6/sIL-6R activation of gp130 and the subsequent 
downstream targeted JAK/STAT pathway, it was hypothesised that these trans-
signalling events would not only be biologically relevant as previously illustrated in 
L6 myotubes and CRL1439 hepatocytes in vitro, but also in skeletal muscle and 
adipose tissue as well in vivo.  
 
To date there have been no studies that have formally examined the role sIL-6R 
signalling has on metabolism. To mimic sIL-6R signalling, the designer cytokine 
Hyper IL-6, a fusion protein of rh-IL-6 and sIL-6R, was used to induce “trans-
signalling”, i.e. sIL-6R mediated signalling events. However, it is noteworthy that IL-
6 trans-signalling is known to cause inflammation within liver and various other 
tissues as demonstrated within several studies (Miles et al., 1990; Maione et al., 
1998; Atreya et al., 2000; Jostock et al., 2001; Nowell et al., 2003; Rabe et al., 
2008; Sander et al., 2008). Thus, it was proposed that co-treatment with the 
inhibitor of Hyper IL-6, sgp130Fc, would prevent inflammatory signalling, 
particularly within the liver, thereby preventing inflammation within other tissues, 
whilst maintaining the beneficial effects of this designer cytokine on metabolic cell 
signalling within skeletal muscle in vivo.    
 
To examine the effect that acute IL-6 trans-signalling events have on proteins 
commonly implicated in exercise induced regulation of metabolism, C57BL6 mice 
were administered 4 μg of Hyper IL-6 ± 40 μg sgp130Fc via intraperitoneal 
injection. Forty five minutes post injection, the animals were culled and tissues 
were promptly excised. The dose and time used in these experiments have 
previously been used to induce functional changes in downstream targets of 
JAK/STAT-3 signalling and were thus considered biologically active (Peters et al., 
1998).  
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As the functional role of IL-6/sIL-6R complex signalling in skeletal muscle and WAT 
remains elusive, the activation of STAT-3 was examined to ensure this 
phenomenon was biologically relevant within these tissues. Mice were also 
administered these cytokines in the presence of insulin, however this hormone had 
little effect on phospho STAT-3tyr705. Subsequently, mice assigned to receive Hyper 
IL-6 ± sgp130Fc and insulin stimulation prior to harvest were included in the 
corresponding cytokine treatment group under basal conditions thereby increasing 
the sample size (to n=12). Clearly, phosphorylation of STAT-3 at the tyr705 residue 
was increased upon treatment with Hyper IL-6 within liver, an effect that was 
conserved across skeletal muscle and WAT. The inhibition of Hyper IL-6 induced 
phospho STAT-3tyr705, using sgp130Fc, occurred in a tissue type specific manner 
as demonstrated by a reduction of ~60 % in liver compared to that of ~ 40 % in 
Soleus and EDL. Notwithstanding, no significant change of this protein was evident 
in WAT upon co-administration of Hyper IL-6 and sgp130Fc. The varying 
responses of individual tissues to sgp130Fc may possibly occur as a result of the 
relative expression of gp130β and the naturally occurring sIL-6R and soluble gp130 
within the circulation. Varying signalling responses resulting from limitations of the 
experimental design can not be excluded. Previous research in NMRI mice has 
demonstrated that the concentration of Hyper IL-6 within sera peaks at 1 – 3 hours 
post intraperitoneal administration of the cytokine (Peters et al., 1998) but in culture 
the Hyper IL-6 activity, as indicated by the phosphorylation of STAT-3, was 
maximal at 30 min post injection (refer to Chapter 4). The time point of 45 minutes 
was selected because it fell between the two experimentally determined maxima. 
As animals were culled at only one time point post administration of the cytokines, 
it is not inconceivable that signalling events which took place either prior to or post 
45 minutes were consequently missed. Moreover, given the cytokines were 
administered by IP injection, the possibility that the Hyper IL-6 was administered 
directly into the epidydimal fat mass can not be ignored. This may have resulted in 
saturation of WAT with Hyper IL-6 and as a consequence sgp130Fc unable to 
prevent trans-signalling events via competitive inhibition, thus explaining the limited 
inhibition of STAT-3 activation in the WAT of mice administered Hyper IL-6 + 
sgp130Fc. Further experiments covering a broader span of treatment periods 
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and/or utilising alternative routes of administration would readily verify whether the 
experimental constraints impacted the results.  
   
It is well established in the literature that many physiological changes occur upon 
exercise within many tissues. These include; increased glucose oxidation and 
endogenous glucose production, decreased insulin release by the pancreas, 
increased lipolysis and fat oxidation. During exercise, many of the fore mentioned 
physiological processes are concurrent with an increase in IL-6 release from 
skeletal muscle and for this reason IL-6 is often described as a myokine (Ostrowski 
et al., 1998; Hisckock et al., 2004). Research from Febbraio et al. (2004) provided 
insight into the role of IL-6 within muscle metabolism, demonstrating recombinant 
human IL-6 infusion into humans increased the rate of contraction induced 
endogenous production and disposal rate of glucose, without changes in hormones 
such as glucagon, insulin and epinephrine. This was supported by later research 
that demonstrated rhIL-6 infusion into healthy men increased Insulin stimulated 
glucose disposal during a hyperinsulinaemic-euglycemic clamp (Carey et al., 
2006). Further evidence of the role IL-6 plays in metabolic regulation is provided in 
an elegant study by van Hall and colleagues (2003) who noted IL-6 increases fatty 
acid oxidation and lipolysis. Healthy young men were infused with either a low 
dose (mean concentration in plasma ~143 pg/mL) or a high dose (mean 
concentration in plasma ~319 pg/mL) of rhIL-6 for 90 min, at which point an 
increase in the rate of appearance of endogenous free fatty acid and elevated fatty 
acid concentration was evident compared to those who received saline. It is 
important to note, skeletal muscle utilises free fatty acids generated upon the 
hydrolysis of ester linkages of triglycerides from triglyceride storages to generate 
ATP through β-oxidation. These studies are suggestive of a positive role for IL-6 in 
metabolic regulation during exercise and are thus contrary to the popular notion 
within the literature that this cytokine is a mediator of inflammation.  Hence forth 
the effect of Hyper IL-6 ± sgp130Fc was examined on common signalling pathways 
that have previously been implicated in these processes and IL-6 action.  
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Akt activation is an important mediator of many processes including cell cycle 
progression and survival, glucose metabolism, protein synthesis and Nitric Oxide 
production (for review refer to Ždychová and Komers, 2005). The trend of basal 
increases in phospho Aktser473 in most tissues of mice that received Hyper IL-6 was 
therefore of great interest. The presence of sgp130Fc would appear to have no 
effect on basal increases in phospho Aktser473 and even potentiated it within soleus. 
No significant effect of these designer cytokines were noted in the insulin 
stimulated state. This was not anticipated considering the results obtained in vitro 
(Chapter 4) whereby Insulin stimulated glucose uptake was potentiated in L6 
myotubes treated with Hyper IL-6 + sgp130Fc. This increase in basal activity of Akt 
may have many implications on many cellular processes including protein 
synthesis and proliferation and would certainly be a reflection upon the multi-
faceted nature of IL-6. Whether IL-6/sIL-6R complex truly regulates insulin 
signalling in an acute fashion remains undetermined. To elucidate the role of the 
IL-6/sIL-6R complex in Insulin signalling regulation it would be necessary to 
examine upstream mediators of this metabolic pathway such as PI3-Kinase and 
IRS-1 and downstream targets such as AS160 and GLUT4 translocation.  
 
AMPK is thought to be a metabolic regulator through modulation of its activity 
through changes in cellular [AMP]/[ATP] ratio. Activation of AMPK leads to the 
suppression of anaerobic pathways that require the use of ATP and subsequently 
causes a switch to ATP generating aerobic pathways such as β-oxidation, thereby 
providing metabolic substrates for cells undergoing metabolic stress (for review 
refer to Hardie and Sakamoto, 2006).  Inhibition of ACC activity occurs by AMPK 
phosphorylation of ACC at the serine 79 residue. This in turn causes inhibition of 
malonyl CoA synthesis or increased degradation of this protein. This relieves the 
allosteric inhibition of the mitochondrial fatty acid transporter, CPT1. CPT-1 activity 
is increased causing increased uptake of long chain fatty acids and thus fat 
oxidation (for reviews refer to Ruderman, Saha and Kraegen, 2003 and Steinberg 
and Jørgensen, 2007). It is well established that exercise increases AMPK activity. 
In rodents, it has previously been shown that a positive correlation exists between 
contraction intensity induced activation of AMPK and fatty acid uptake and 
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oxidation (Raney and Turcotte, 2006). Furthermore it has been demonstrated that 
during exercise, AMPK activity is diminished in skeletal muscle of IL-6 KO mice 
when compared to that of WT (Kelly et al., 2004) and increases in IL-6 within the 
circulation correlate positively with AMPK activity within human skeletal muscle 
(MacDonald et al., 2003). This is in accordance with Carey and co-workers (2006) 
who demonstrated that IL-6 mediated increases in glucose uptake and fatty acid 
oxidation occurred in an AMPK dependent manner, further insinuating this 
cytokine‟s importance in fat metabolism. In agreement with these previous studies, 
four micrograms of Hyper IL-6 injected into mice resulted in a significant increase 
in phospho ACC in liver, an effect that was not influenced by co-treatment with 40 
μg sgp130Fc. In WAT and EDL Hyper IL-6 had a propensity to increase ACC and 
AMPK phosphorylation, however in soleus phospho AMPKthr172 was significantly 
reduced upon Hyper IL-6 treatment and co-treatment with sgp130Fc, ablated this 
effect. A similar response was seen in soleus of rats infused with IL-6 in a chronic 
or intermittent manner (refer to Chapter 3), whereby protein expression of PGC-1α, 
a downstream target of AMPK, was reduced.   
 
It is noteworthy that AMPK is a multifaceted kinase that is not only a master 
regulator of metabolism but also involved in cell cycle progression through the 
regulation of protein synthesis, de novo fatty acid synthesis, G1 cell cycle arrest 
and autophagy through the TSC1/2-mTOR pathway and the p53-p21 axis (for 
review refer to Motoshima et al., 2006). During periods of energy deprivation, 
AMPK suppresses cell growth and biosynthetic processes through its negative 
modulation of the rapamycin sensitive mTOR (mTORC1) pathway, a regulator of 
protein synthesis (Kimura et al., 2003). Although the present study did not examine 
mTOR pathway activity, it may be of interest to do so in future studies given the 
potential effect Hyper IL-6 has on AMPK and cell growth and differentiation, 
particularly within the liver. In the current study, Hyper IL-6 also stimulated basal 
increases in phospho-Aktser473 in vivo. Upon stimulation with growth factors, 
activation of Akt results in the phosphorylation of TSC2 and subsequent loss of 
activity of the TSC1/2 complex, thereby preventing Rheb binding to the complex 
and subsequent inhibition of the mTOR complex. Upon activation of mTOR, 
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increased protein synthesis occurs through the recruitment of its downstream 
effectors p70S6K1 and eukaryotic translation initiation factor 4E (eIF4E)-binding 
protein 1 (4E-BP1) to its binding partner raptor (Fingar et al., 2002).   
 
Many studies have also implicated AMPK activity in the inhibition of cell cycle 
progression through the regulation of the tumour suppressor, p53 during periods of 
glucose depletion (Jones et al., 2005; Okoshi et al., 2008). The fore mentioned 
studies have implicated AMPK in the phosphorylation and accumulation of p53, 
activation of the pro-apoptotic protein Bax, preventing progression of cell cycle 
from G1 to S phase thus impeding cellular proliferation.  This is of great importance 
as it promotes cellular survival and maintains cellular viability during periods of 
glucose deprivation. Given the ability of Hyper IL-6 to regulate proliferation of 
progenitor cells and other studies insinuating a role for IL-6 in cellular proliferation 
and differentiation, it is certainly plausible that AMPK activation in response to 
Hyper IL-6 as seen in this study, particularly within the liver, would result in 
inhibition of protein synthesis through the mTOR pathway and G1 cell cycle arrest 
through accumulation and activation of p53. Any aberrant AMPK or Akt pathway 
activity in response to prolonged Hyper IL-6 administration may lead to either 
cellular senescence or excessive proliferation. Future studies aimed at examining 
protein synthesis and cell cycle arrest in response to Hyper IL-6 would provide 
further insight into the purpose of this important regulatory kinase. 
   
As previously mentioned in Chapter 3 of this dissertation, PGC-1α is a co-
transcription factor whose physiological function occurs in a tissue type dependent 
manner and that expression is abnormal in many diseased states. PGC-1α is an 
important player in metabolism through the regulation of OXPHOS genes and thus 
mitochondrial biogenesis and uncoupling, cellular respiration and fat oxidation. 
Previous research from Watt et al. (2006) and Al-Kahlili et al. (2006) have 
implicated IL-6 family cytokines in the regulation of this protein, whereby PGC-1α 
expression was increased compared to saline control animals in C57BL6 mice on a 
HFD treated with the IL-6 family member CNTF; this in turn was concomitant with a 
decrease in fat mass. In the later study PGC-1α mRNA in human skeletal muscle 
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was increased over an 8 day IL-6 treatment period, an effect that was abrogated 
when transduced with AMPK α1/2 siRNA. It is well established that PGC-1α mRNA 
is transiently increased upon endurance exercise training (Goto et al., 2000; 
Pilegaard, Saltin and Neufer, 2003; Mathai et al., 2008) and has previously been 
proposed to occur via an AMPK signalling dependent manner in rat epitrochlearis 
muscle (Terada et al., 2002). Furthermore, endurance training in male Sprague 
Dawley rats increased LKB1 (upstream of AMPK) activity with concomitant 
increases in PGC-1α and citrate synthase, an indicator of mitochondrial activity 
(Taylor et al., 2005). In support of the fore mentioned notion, Lee and colleagues 
(2006) demonstrated that AMPK activation increases fatty acid oxidation in C2C12 
myotubes via a PGC-1α dependent mechanism. Most recently, using point 
mutations and mass spectrometry, it was established that within skeletal muscle, 
AMPK directly interacts with PGC-1α via phosphorylating thr177 and ser538 
residues (Jäger et al., 2007). As there is an abundance of literature supporting a 
role for exercise and IL-6 family cytokines in the regulation of PGC-1α mRNA and 
protein, most likely via an AMPK dependent mechanism, this was explored within 
tissues from animals that received an acute dose of Hyper IL-6. In the current 
study design, by administering mice with an acute dose of Hyper IL-6, the role of 
IL-6/sIL-6R/gp130 mediated signalling in the regulation of this protein was studied 
independently of other exercise related mechanisms that may influence expression 
of this protein in various tissues.    
 
There was no difference between groups of PGC-1α abundance in either skeletal 
muscle type examined (soleus and EDL, data not shown). The change in PGC-1α 
protein may be dependent on the particular fibre phenotype of the muscle under 
investigation. This would certainly be in accordance with previous studies 
insinuating that PGC-1α expression occurs in a fibre type phenotypic manner 
within skeletal muscle. Ikeda and colleagues (2006) proposed that increases in 
PGC-1α occurred in a muscle fibre type specific manner as mice undergoing wheel 
exercise training over an 8 week period had increases in PGC-1α protein in 
plantaris muscle but protein expression remained unchanged in Tibialis Anterior or 
soleus. It is also possible that the lack of change seen in PGC-1α protein 
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abundance may be due to the inability of Hyper IL-6 to regulate transcription and 
translation of PGC-1α within EDL and soleus. It may also be possible that the 
acute time point examined in this cohort may be inappropriate for detection of 
changes of this protein within skeletal muscle. This is feasible as previous studies 
show an increase in mRNA at 2 hours post exercise and is sustained for at least 6 
hours after cessation of exercise (Pilegaard, Saltin and Neufer, 2003). Future 
experiments examining a detailed time response experiment of PGC-1α mRNA 
and protein in skeletal muscle in response to Hyper IL-6 treatment would elucidate 
whether IL-6/sIL-6R complex signalling is a regulator of this important mediator of 
mitochondrial metabolism.  
 
Metabolic regulation within liver is a complex system of compensatory mechanisms 
during periods of fasting and feeding and this concept is pertinent to whole body 
physiology ensuring energy homeostasis is maintained. This is of central 
importance as aberrant signalling within metabolic tissues such as the liver forms 
the basis of metabolic disease. In liver, during periods of fasting, PGC-1α is 
activated through its interaction with FoxO1 and increased pyruvate stimulated 
deactylation by SIRT-1 (Puigserver et al., 2003, Rodgers et al., 2005). This 
enables the induction of transcription factors including Hepatocyte Nuclear Factor 
4α (HNF4α) and activation of gene transcription for important mediators of 
gluconeogenesis, including glucose-6-phosphatase (G-6-Pase) and 
phosphoenolpyruvate carboxykinase 1 (PEPCK) (Yoon et al., 2001). Moreover, 
PGC-1α activation also regulates lipoprotein metabolism via activation of HNF4α 
(Rhee et al., 2006). Further evidence of PGC-1α involvement in hepatic glucose 
output is provided by Koo and colleagues (2005) who demonstrated that glucagon, 
a hormone released during periods of fasting, increased CREB in an AMPK 
dependent manner and led to greater transcription of PGC-1α. It has also recently 
been discovered that PGC-1α possesses an Akt phosphorylation site at ser570 
and when activated causes an attenuation of gluconeogenesis and fatty acid 
oxidation (Li et al., 2007). This is consistent with a previous study that showed 
upon insulin stimulation, increases in phospho Akt ser473 occurred in concert with 
a decrease in PGC-1α, thus in turn leading to suppression of transcriptional activity 
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of the co-transcription factor (Koo et al., 2005). These studies suggest insulin is a 
key player in hepatic glucose production via inhibition of PGC-1α and 
transcriptional control of its downstream gluconeogenic genes.  
 
During exercise, hepatic glucose production is increased, due to a combination of 
increased circulating IL-6, lactate and pyruvate and raised AMP/ATP ratio. Of great 
interest is the aberrant regulation of gluconeogenesis within diabetic patients 
resulting in hyperglycaemia. During the fed state, increases in insulin results in the 
activation of Akt, the sequestration of FoxO1 from the nucleus and subsequent 
inhibition of PGC-1α activity, thus preventing gluconeogenesis. However, in insulin 
resistant states such as that seen in diabetes there is a loss of insulin dependent 
suppression of gluconeogenesis and increased triglyceride synthesis and 
accumulation resulting in steatosis within the liver (Matsumoto et al., 2006). 
Contrary to the above study, in the present research, livers from mice co-
administered Hyper IL-6 and sgp130Fc had elevated basal levels of phospho 
Aktser473 with a simultaneous increase in PGC-1α protein. It may be of interest to 
determine whether in healthy mice, the elevation of Akt activity in response to 
Hyper IL-6 occurs as a compensatory mechanism in response to increased PGC-
1α induced by AMPK and hence is aimed at preventing hyperglycaemia.   
 
Acute treatment with Hyper IL-6, regardless of the presence of sgp130Fc, had a 
tendency to increase PGC-1α protein within liver and WAT. It is not unreasonable 
to suggest that in an acute manner such as that seen during exercise, the increase 
in PGC-1α may occur as a consequence of transient increases of IL-6 within the 
circulation, leading to an increase in hepatic glucose output, thereby providing an 
alternate source of energy for working muscles. Whether the increase in PGC-1α 
protein is mediated via the membrane bound IL-6 Receptor or the sIL-6R requires 
further investigation. In this current study, it was evident Hyper IL-6, used to mimic 
IL-6/sIL-6R signalling, induced increases in PGC-1α protein in the liver which were 
unable to be attenuated in the presence of its inhibitor sgp130Fc. This implies that 
the induction of PGC-1α in liver occurs via membrane bound IL-6 receptor 
signalling. Moreover, IL-6/gp130/JAK/STAT-3 induced PGC-1α in liver may have 
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broader implications in a chronic scenario whereby persistently elevated IL-6 within 
the plasma leads to hyperglycaemia through increased PGC-1α abundance and 
enhanced gluconeogenic gene transcription.           
 
It is known that insulin sensitivity in vivo correlates with PGC-1α mRNA and protein 
expression in adipose tissue and expression of this protein was reduced in adipose 
tissue from insulin resistant individuals (Hammarstedt et al., 2003). Moreover, the 
exact consequence of IL-6 signalling within adipose metabolism remains elusive, 
as it has previously been associated with both insulin sensitivity and insulin 
resistance in adipose tissue. The results obtained in Figure 5.6 supports IL-6/sIL-
6R complex as a promoter of mitochondrial metabolism as treatment with Hyper IL-
6 significantly increased PGC-1α protein expression. Contrary to that of liver, it 
would appear that this affect was entirely mediated by IL-6/sIL-6R/gp130 signalling 
as in the presence of sgp130Fc, Hyper IL-6 treatment was unable to increase 
PGC-1α protein. These studies insinuate induction of this protein is mediated via 
distinct biochemical mechanisms (ie. membrane bound receptor v soluble receptor 
signalling) in a tissue type dependent manner.    
 
It was noteworthy that Hyper IL-6 induced significant increases in the 46kDa 
subunit of phospho-JNK1 and had a tendency to increase phospho IKKβ within 
WAT, these affects were ameliorated upon co-treatment with sgp130Fc. Contrary 
to this, Hyper IL-6 administered murine liver had a tendency for increased phospho 
JNK at both sub units regardless of the presence of sgp130Fc. No change in IKK 
and JNK were noted in either skeletal muscle type, this was not surprising as 
muscle has to undergo severe assault before inflammation is induced (unpublished 
observations, Cellular and Molecular Metabolism Laboratory). A recent study by 
Sabio and colleagues (2008) provided evidence of metabolic cross-talk between 
WAT and Liver in an IL-6 dependent manner. Ablation of JNK1 in WAT caused 
suppression of HFD induced insulin resistance and restored insulin sensitivity in 
the liver of these mice. They also noted that secretion of IL-6 by WAT was 
increased upon activation of JNK1 in response to free fatty acids and IL-6, in turn 
causing a concomitant increase in SOCS-3 expression within the liver. It would be 
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of interest to examine whether IL-6 secretion from adipose tissue occurs in 
response to Hyper IL-6 treatment in mice, thereby increasing IL-6 within the 
circulation, possibly leading to increased membrane bound IL-6 signalling within 
the liver. This would certainly account for the increased abundance of phospho 
ACCser79 and PGC-1α noted in liver of Hyper IL-6 treated mice, an effect that 
occurred regardless of the presence of sgp130Fc. 
 
Many studies have suggested that SOCS-3 induction may lead to the pathogenesis 
of insulin resistance via its ability to inhibit IRS-1 and IRS-2 activation by binding to 
the Insulin Receptor at Tyr960, the key residue for IRS recognition (Torisu et al., 
2007 and Ueki, Kondo and Kahn, 2004). Over-expression of SOCS-3 in the liver of 
mice leads to inhibition of IRS-1 and IRS-2, in turn leading to a reduction in activity 
of PI3-kinase and Akt (Ueki, Kondo and Kahn, 2004). Torisu and colleagues found 
insulin sensitivity, in mice with a hepatocyte specific SOCS-3 deficiency, was 
improved as, during an euglycaemic - insulinaemic clamp, hepatic glucose 
production rate was lower in these mice compared with that of wild type mice. In 
hepatocytes isolated from SOCS-3 deficient mice, phosphorylation of IRS-1 and 
IRS-2 and the downstream target Akt was enhanced compared to those from WT 
mice. More over, when hepatocytes from wild type mice were administered insulin 
or IL-6 for 16 h, an increase in SOCS-3 protein with a simultaneous decrease in 
phospho IRS1 and Akt was noted. When mice deficient in hepatic SOCS-3 are 
aged, regardless of whether they consume normal chow or high fat diet (HFD), a 
metabolic syndrome like phenotype is evident. These mice became obese, had fat 
deposits in the liver and had elevated blood glucose, insulin, serum triglycerides 
and total cholesterol levels. Furthermore, in the muscle of these mice, insulin 
stimulated phosphorylation of Akt was less than that of WT mice. It was also 
evident these mice had increased serum levels of the acute phase proteins serum 
amyloid A and C-reactive protein. The authors hypothesised that in mice deficient 
in hepatic SOCS-3, insulin resistance develops as a consequence of the inability to 
inhibit STAT-3, this in turn leads to hyper activation of this protein and thus mimics 
a state of chronic inflammation. This will be discussed further in Chapter 6 of this 
dissertation.  
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The consequences of SOCS-3 induction in skeletal muscle remains poorly 
understood. In 2006, a study by Spagenburg aimed to examine the effects of 
exercise training on SOCS-3 expression and the potential role of this protein within 
skeletal muscle. Upon treadmill training for 12 weeks, increased expression of 
SOCS-3 and IL-6 mRNA occurred within the Soleus and Plantaris muscle of 
female Sprague Dawley rats when compared to that of sedentary untrained 
animals.  This study also emphasises that the IL-6 gene promoter contains a NFκB 
consensus site thereby increasing IL-6 upon NFκB activation. Using luciferase 
reporter assays, SOCS-3 overexpression in C2C12 myotubes drives NFκB 
transcriptional activity thus increasing IL-6. This effect would appear to be NFκB 
dependent as co-transfection with an NFκB mutant led to failure of SOCS-3 to 
induce IL-6 expression. Further more, SOCS-3 has been implicated in leptin 
resistance through its interaction with the leptin receptor at Tyr985 (Bjørbæk et al., 
1998) and augmenting leptin activation of AMPK within skeletal muscle of morbidly 
obese humans (Steinberg et al., 2006).  
 
The present study does not show significant increases in SOCS-3 induced by 
Hyper IL-6 in skeletal muscle of lean mice, thus SOCS-3 induced leptin resistance 
may only be of importance in a chronic model of inflammation, not acute 
stimulation. Although a one hour treatment with Hyper IL-6 significantly increased 
SOCS-3 in L6 myotubes in vitro (Chapter 4), in the present study this designer 
cytokine had a tendency to induce SOCS-3 in WAT, liver and EDL. It is possible 
that for a significant induction of this protein to occur, longer administration of the 
designer cytokine may be required. It was also of great interest to note that in 
response to Hyper IL-6 administration, there was a trend for increased SOCS-3 in 
the liver and this was in concert with significant elevations in phospho JNK1 in 
WAT. This supports the notion presented by Sabio and colleagues (2008).   
 
In summary, the findings of this study demonstrate that IL-6 trans-signalling events, 
using Hyper IL-6 to mimic IL-6/sIL-6R complex signalling, occur in liver, muscle 
and epidydimal WAT in vivo, in a tissue type dependent manner. More over, it was 
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demonstrated that the inhibitor of Hyper IL-6, sgp130Fc was bioactive within these 
tissues. However, the degree to which inhibition occurred was tissue type 
dependent. IL-6 trans-signalling events led to the activation of JAK/STAT-3, AMPK 
and JNK pathways, also in a tissue type dependent manner. The exact mechanism 
by which the tissue type dependency occurs remains unknown and requires further 
investigation.  Due to the findings of this study using Hyper IL-6 to mimic IL-6/sIL-
6R complex signalling, it is proposed that trans-signalling may be considered 
beneficial in an acute manner. For example, during exercise, IL-6 is released in a 
transient manner and acts as a mediator of metabolic regulation via signalling 
pathways involved in glucose oxidation and disposal and fat oxidation. However, 
contrary to the transient release seen during exercise, states of disease are often 
associated with chronically elevated levels of IL-6 and and/or sIL-6R within the 
circulation (refer to Chapter 1). This may lead to aberrant pathway activation and 
inflammation within many tissues. As this paradox exists, the next chapter explores 
the effect of prolonged Hyper IL-6 administration on inflammation and whole body 
energy metabolism in vivo.              
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CHAPTER SIX 
 
Prolonged Hyper IL-6 treatment 
perturbs insulin sensitivity and 
induces liver injury in mice on a high 
fat diet 
 
123 
 
6.1 Introduction 
IL-6 signalling mediated via the sIL-6R leads to the activation of STAT-3, ERK and 
PI3-kinase/Akt pathway activation (Weigel et al., 2008; Leu et al., 2003 and 
Heinrich et al., 2003). These pathways are mediators of many important cellular 
processes including cell survival and proliferation, metabolism and inflammation. 
The role of IL-6 in health and disease remains poorly understood, let alone that of 
signalling via the soluble IL-6 Receptor. This cytokine is often described as pro-
inflammatory, yet it also modulates many metabolic processes including fat 
oxidation and glucose utilisation within metabolically active tissues such as 
adipose, skeletal muscle and liver (Pedersen and Febbraio, 2008). Many studies 
have focussed on prolonged IL-6 trans-signalling and the effect this phenomena 
has on inflammation (Miles et al., 1990; Maione et al., 1998; Atreya et al., 2000; 
Jostock et al., 2001; Nowell et al., 2003 and Sander et al., 2008). In contrast, there 
is little evidence within the literature implicating prolonged IL-6 trans-signalling in 
the regulation of metabolism. It is well established that transient IL-6 release leads 
to increased fat oxidation, glucose utilisation, lipolysis and suppressed hepatic 
glucose output (Stouthard, Elferink and Sauerwein, 1996; van Hall et al., 2003; 
Weigert et al. 2005; Carey et al., 2006; Pedersen and Febbraio, 2008). Contrary to 
the fore mentioned beneficial functions, there is also mounting evidence that this 
cytokine is chronically elevated during many states of inflammation, including 
metabolic syndrome and diabetes (Targher et al., 2001; Kelley et al., 2003; 
Pradhan et al., 2003). Subsequently, aberrant signalling pathway activation occurs 
due to chronically elevated IL-6 within the circulation and the inherent 
consequences are often dire. Thus the primary aim of this study was to examine 
the effects of prolonged IL-6 trans-signalling on metabolism in vivo.  
 
IL-6 is known to be a key player in the development of such diseases as 
hepatocellular carcinoma, Kaposi‟s sarcoma, inflammatory bowel diseases and 
arthritis to name a few (Miles et al., 1990; Maione et al., 1998; Atreya et al., 2000; 
Jostock et al., 2001; Nowell et al., 2003 and Sander et al., 2008). Furthermore, it 
has been illustrated that IL-6/sIL-6R signalling is efficacious at inducing 
experimental models of inflammatory bowel disease, arthritis and hyperplasic 
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nodules of the liver (Atreya et al., 2000; Nowell et al., 2003; Maione et al., 1998). 
These studies surmise that sIL-6R targeted signalling is not a suitable therapeutic 
candidate treatment in metabolic disorders due to the highly likely odds of the 
patient developing undesirable side effects. Specifically, these unwanted attributes 
would make the designer cytokine an unsuitable stand-alone agent for the 
therapeutic treatment of metabolic disorders. As this is the case, it was proposed 
that ill effects, as a consequence of prolonged treatment with this cytokine, could 
be abrogated by co-treating with sgp130Fc. It was hypothesised that the beneficial 
effects associated with IL-6 signalling through the membrane bound IL-6 receptor 
such as fat oxidation, increased glucose clearance and insulin sensitivity would be 
maintained whilst counteracting the detrimental inflammatory processes that are 
associated with prolonged Hyper IL-6 treatment.  
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6.2 Materials and Methods 
Animals - Male C57BL6 mice of 8 weeks of age weighing approximately 27 grams 
were housed in the AMREP precinct animal facility in a 12:12 hour light:dark cycle. 
Animals were fed a high caloric diet (approx 60 % of calories from fat) and water 
ad libitum for 6 weeks. All animal experiments were performed as approved by the 
Animal Ethics Committee of AMREP (ethics application approval number 
E/0573/2007/B). At 14 weeks of age, animals were randomly assigned to treatment 
groups and administered Saline (referred to control here on in), 4 μg Hyper IL-6 or 
4 μg Hyper IL-6 + 40 μg sgp130Fc by intraperitoneal injection using a 25 gauge 
needle every alternate day for 16 days (Figure 6.1). Food intake and body mass 
was monitored throughout treatment period.  
 
Figure 6.1 Schematic of the experimental design. HFD: High Fat Diet; GTT: 
Glucose Tolerance Test; ITT: Insulin Tolerance Test.  
 
Twenty four hours post the last injection of the treatment period, mice were food 
restricted for 4 h, after which they were anaesthetised with 60-80 mg/kg sodium 
pentobarbital. Upon loss of pedal and blink reflex, basal state tissue was promptly 
excised. Mice were then administered 1.5 U/kg Insulin (Actrapid®, Novo Nordisk, 
Bagsraerd, Denmark) via abdominal aortic injection. Three minutes post insulin 
administration tissues were excised from the contralateral side (referred to as 
insulin stimulated from here on in). A small amount of liver and gastrocnemius 
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were collected for histological sectioning. Blood was collected from the heart of the 
mice and placed in a centrifuge tube containing heparin for further analyses by 
ELISA. After excision, all tissues were snap frozen in liquid nitrogen and animals 
were euthanased upon removal of the heart.  
 
1H Magnetic Resonance Imaging – On the day of insulin sensitivity and glucose 
tolerance testing, lean and fat mass of each individual mouse was determined by 
MRI. Mice were placed within a tube within the 1H Magnetic Resonance Imaging 
Unit (Columbus Instruments, Columbus, OH, USA) and a digital output was 
obtained. The volume of insulin and glucose required for GTT and ITT for each 
individual animal were calculated relative to its corresponding lean body mass. 
  
Insulin Sensitivity and Glucose Tolerance Tests – At the conclusion of week 4 of 
HFD and day 11 of the treatment period, whole body glucose tolerance was 
examined. Insulin sensitivity was determined on days 6 and 13 of the treatment 
period. Prior to testing, mice were fasted for 6 h. Using a hand held glucometer 
(Accu-check®, Roche Diagnostics, Mannheim, Germany), basal (t = 0) blood 
glucose concentration were obtained via tail cut. For Glucose tolerance testing, 
following determination of basal glucose levels the mice were administered 1 g kg-1 
glucose diluted in saline via an injection into the intraperitoneal (IP) space. Glucose 
concentration was determined in blood obtained at 15, 30, 45, 60, 90 and 120 min 
post glucose injection. For insulin sensitivity testing, after basal (t = 0) blood 
glucose concentrations were determined, 0.75 U kg-1 insulin (recombinant human 
insulin, Actrapid®, Novo Nordisk, Bagsraerd, Denmark) was administered IP. As for 
the GTT, blood glucose concentrations were determined at 15, 30, 45, 60, 90 and 
120 min.        
  
Comprehensive Laboratory Animal Monitoring System (CLAMS) – Before initiation 
of, and at day 13 of treatment, metabolic parameters such as VO2, RER, food 
intake, heat output and individual activity, were monitored over a 24 h period by 
CLAMS (Columbus Instruments, Columbus, OH, USA). Briefly, mice were placed 
in individual chambers containing sensors for O2 and CO2 interfaced with a 
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computer thereby providing a digital output for parameters of interest. Ambulatory 
movement of each mouse was monitored through the use of infra red beams on 
the x, y and z planes. Upon a break of the infra red beam by animal activity a 
movement event was recorded by the system. Feeding was monitored over this 24 
h period by recording the difference in weight of the centre feeder between time 
points.   
 
Enzyme Linked Immunosorbent Assay (ELISA) analyses of Sera- On the day of 
harvest, the blood samples taken from each animal for each treatment group were 
spun in a centrifuge at 3000 g for 10 min, after which the sera containing 
supernatant was placed in a fresh centrifuge tube and stored at -80 °C until 
required for ELISA. The concentration of C-reactive protein and Haptoglobin, 
markers of IL-6 induced acute phase inflammation, were determined using 
commercially available ELISA kits (Immunology Consultants Laboratory, Inc., 
Newberg, OR, USA). Briefly, samples were diluted in diluent (for Haptoglobin 
assay; 1:10000; C - reactive protein; 1:20) and 100 μl of each diluted sample and 
standards were transferred onto a 96 well plate pre coated with either anti- CRP or 
anti-haptoglobin antibody. After incubation at room temperature for 15 min, the 
wells were washed four times using wash solution to remove unbound protein 
followed by the addition of 100 μl of Enzyme Antibody Conjugate to each well. The 
plate was incubated for a further 15 min at room temperature followed by thorough 
washing. One hundred micro litres of TMB Substrate was added to each well, 
incubated for 10 min and the reaction was stopped upon the addition of 100 μl of 
the provided stop solution to each well. The absorbance of the reaction was 
determined by spectrophotometry at 450 nm. The concentration of the sera 
samples were then interpolated using the standard curve followed by correction for 
the dilution factor used in the assay.   
 
The concentration of AST and ALT in the sera from each mouse were analysed by 
the Pathology unit of The Alfred Hospital, Melbourne, Australia.    
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Histology – Liver lipid content was visualised using Oil Red O staining. Livers 
mounted in OCT Compound (Tissue Tek, Sakura Finetek, Torrance, CA, USA) 
were sectioned using a microtome and placed on a glass microscope slide. Slides 
were then subjected to staining for 15 min using a working solution of 1.5:1; Oil 
Red O Stock solution (0.5 % (w/v) Oil Red O in dH2O)-dH2O. Slides were then 
rinsed in dH2O for 15 minutes, mounted in glycerine jelly and allowed to air dry. 
After which time, images of random fields of view for each section were obtained 
using a digital SLR camera interfaced with an Olympus image pro microscope. The 
lipid droplet sizes of 10 random droplets, from 3 representative animals were 
determined by counting the number of pixels within a square field drawn 
surrounding the droplet using Adobe Image Ready. Images used were all of the 
same magnification. The pixel counts for each section for the individual treatment 
groups were then averaged providing a representative droplet size.     
 
Architecture of the livers harvested from the animals was determined by 
Haemotoxylin and Eosin (H & E) Staining. After excision, a small amount of liver 
was removed and placed in Carnoy‟s Fixative (60 % (v/v) Ethanol, 30 % (v/v) 
Chloroform and 10 % (v/v) Glacial Acid). Liver samples were then stored in 50 % 
Ethanol until embedded in paraffin. Following embedding, the livers were sectioned 
by microtome and placed on a glass microscope slide. Slides were de-waxed by 
immersion in Xylene for 5 min twice followed by 100 % Ethanol for 5 min, twice and 
finally 95 % Ethanol for 2 min. Residual xylene and ethanol was removed from the 
slide by rinsing in dH2O for 5 min. Tissue sections were then stained by immersing 
in Haemotoxylin for 2 min, washed for 3 min, followed by staining with Eosin for 30 
s. Excess stain was removed by washing thoroughly for 5 min with dH2O. Sections 
were then subjected to a dehydration process involving 2 minute immersions in 95 
% Ethanol; 100 % Ethanol twice and Xylene twice. Sections were then mounted 
using DEPEX and allowed to air dry. After which, images of random fields of view 
for each section were obtained using a digital SLR camera interfaced with an 
Olympus image pro microscope.   
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Western Blotting – Endogenous levels of the proteins of interest were determined 
by western blotting as described in Chapter 3 of this dissertation. Whilst in a pre-
chilled ceramic bowl, approximately 50 mg of liver, soleus, EDL or white adipose 
tissue were cut from the excised tissues by scalpel blade. Samples were then 
placed in lysis buffer and ground using a plastic handheld homogeniser tip. The 
subsequent lysates were then centrifuged at 13000 g for 60 min at 4°C. The 
supernatant was placed in a fresh microfuge tube and the protein concentration 
was determined by BCA assay. For each sample, 40 μg of protein was solubilised 
in Laemmelli‟s Buffer. 
 
After the constitutive proteins of each sample were separated by electrophoresis, 
the proteins were transferred to nitrocellulose membrane by semi dry transfer. 
Membranes were incubated overnight in antibodies for either phospho Akt ser473, 
phospho Akt thr308, phospho ACC ser79, phospho AMPK thr172, TNFα, β-actin 
(Cell Signaling Technology, Beverly, CA, USA) or SOCS-3 (Abcam, Cambridge, 
UK). The relative expression of the proteins of interest was determined by antibody 
binding and enhanced chemiluminescence. To ensure equal amounts of protein 
had been analysed for each sample, β-actin protein was evaluated for each 
sample.  
 
Statistics - Statistics were computed using the statistical analyses software 
package Sigma Stat to analyse significant differences using a either a one way or 
two way ANOVA. Multiple comparisons were made using the Student Newman 
Kuehl‟s or Tukey‟s post hoc test to locate significant differences between 
treatments. Significant differences for all experiments were accepted at p < 0.05. 
All data are expressed as mean fold change of protein expression compared with 
the expression of the protein of interest in tissues harvested from saline treated 
mice (Saline Control =1).  
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6.3 Results 
Prolonged Hyper IL-6 administration has no effect on food intake or body mass – 
C57BL6 mice whole body mass was monitored throughout the experimental 
period, there was no difference in over all body mass between mice of randomly 
assigned groups, similar amounts of weight were gained over the 6 weeks of high 
fat feeding (data not shown).  To ensure that any changes noted in body mass over 
the treatment period were not due to differences between groups in habitual 
feeding, food intake was monitored (Figure 6.2a). There was no significant 
difference in food intake between mice that received saline injections and those 
administered Hyper IL-6 ± sgp130Fc over the 16 day cytokine administration 
period (Figure 6.2a). A similar loss of total body mass was noted in mice 
administered saline and Hyper IL-6 + sgp130Fc (Figure 6.2b). The percentage of 
lean body mass to total body mass (Figure 6.2c) remained unchanged in all groups 
over the treatment period. At the end of the treatment period, all mice had a lower 
fat mass to total mass ratio then at the beginning of the treatment (Figure 6.2d). 
Moreover the loss of fat mass in mice administered Hyper IL-6 alone had a 
tendency to be greater than that of other treatment groups (25 % vs 10 % 
respectively), however, upon analysis none of the trends were statistically 
significant.   
 
 
Prolonged Hyper IL-6 treatment, regardless of the presence of sgp130Fc, has no 
effect on glucose tolerance but impedes insulin sensitivity – After 6 weeks of high 
fat feeding, glucose tolerance was examined in all mice (Figure 6.3a). All animals 
displayed signs of developing an insulin resistant phenotype as demonstrated by 
high basal levels of blood glucose of approximately 10 mmol·l-1 compared with 
blood glucose levels typically seen in age matched chow fed C57BL6 mice 
(unpublished observations, Cellular and Molecular Metabolism Laboratory). 
Glucose tolerance remained unchanged in all experimental groups after 11 days of 
cytokine administration (Figure 6.3b and Figure 6.3c). Insulin Sensitivity was 
examined at day 6 and 13 of treatment period. There was no significant difference 
in insulin sensitivity between groups after 6 days of treatment (Figure 6.4a). 
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However, by day 13 (Figure 6.4b) mice that received Hyper IL-6 ± sgp130Fc had 
impaired insulin sensitivity when compared with control animals (Figure 6.4c, 
Saline vs Hyper IL-6; p = 0.021; Saline vs Hyper IL-6; p = 0.008). 
 
Prolonged Hyper IL-6 administration has no effect on VO2, RER, food intake and 
activity as determined by CLAMS – Hyper IL-6 had no effect on the oxidative 
capacity of animals as determined by measuring VO2 (Figure 6.5a). The respiratory 
exchange rate also remained unchanged (Figure 6.5b) and there was no significant 
difference in food intake (Figure 6.5c) between treatment groups over a 24 h 
period. Activity of mice had a tendency to be higher in those animals administered 
Hyper IL-6 alone (Figure 6.5d), however this was not of statistical significance 
(Saline vs Hyper IL-6 p = 0.078).  
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Figure 6.2 Prolonged Hyper IL-6 treatment has no effect on food intake or lean 
body mass but decreases fat mass relative to whole body weight. a) Food intake 
remained similar between mice of each treatment group pre and post treatment. b) 
Total body mass before initiation of treatment and at the end of the treatment 
period. c) Lean body mass as a percentage of total body mass pre-initiation and 
post treatment. d) Amount of fat mass lost over entire treatment period as indicated 
by fat mass/total body mass relative to starting fat mass/total body mass. Data 
expressed as mean ± SEM, n = 6. 
  
a) b) 
c) d) 
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Figure 6.3 Hyper IL-6, regardless of the presence of sgp130Fc, has no effect on 
glucose tolerance. a) Area under curve for Day 0 and Day 11 for the Saline 
treatment group only, demonstrating no significant difference in glucose tolerance 
with time in response to Saline treatment. Glucose Tolerance Test of C57Bl/6 mice 
b) day 11 of treatment period. c) The area under the curve for each treatment 
group calculated for day 11 GTT. Data expressed as mean ± SEM, n = 6.  
  
a) 
b) 
c) 
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Figure 6.4 Continued Hyper IL-6 treatment decreases insulin sensitivity with 
time as determined by ITT. Concentration of Blood glucose over time as 
determined by an insulin tolerance test on a) day 6 and b) day 13 of Hyper IL-6 ± 
sgp130Fc treatment. Area under curve for Insulin tolerance test performed on c) 
day 6 and d) day 13 of the treatment period. * Saline vs Hyper IL-6; p = 0.021, † 
Saline vs Hyper IL-6 + sgp130Fc; p = 0.008. Data expressed as mean ± SEM, n = 
6. 
 
  
* † 
a) 
b) 
c) d) 
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Figure 6.5 Hyper IL-6 treatment has little or no effect on metabolic parameters 
as determined by CLAMS. Analysis of a) VO2, b) RER, c) food intake and d) 
ambulatory movement as determined using the Comprehensive Laboratory Animal 
Monitoring System. Data expressed as mean ± SEM, n = 3 - 4. 
a) b) 
c) d) 
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Mice administered Hyper IL-6 only have a higher circulating concentration of ALT 
and AST, an indication of hepatocellular damage – Circulating levels of AST and 
ALT, indicators of hepatocellular damage, were determined by ELISA. Animals 
administered Hyper IL-6 in isolation had a tendency to have higher serum levels of 
AST (Figure 6.6a) than control animals (Hyper IL-6; 552.3 U/l compared with 
Saline; 177.6 U/l), an effect that was abrogated upon co-treatment with sgp130Fc 
(267.3 U/l). Furthermore, mice that received Hyper IL-6 had greater serum 
concentrations of ALT than control mice or those co-administered sgp130Fc (37.2, 
310.5, 42.3 U/l respectively, Figure 6.6b; Saline vs Hyper IL-6). Due to technical 
difficulties an insufficient amount of sera was collected at time of harvest to perform 
all necessary analyses. As a consequence many samples were pooled thus 
limiting group numbers (n=3-5) for analysis of AST and ALT. 
 
Acute phase proteins, C-reactive protein and Haptoglobin, were not induced with 
prolonged Hyper IL-6 treatment – As previous studies have implicated Hyper IL-6 
in acute phase inflammatory protein induction, C-reactive protein and Haptoglobin 
were examined by ELISA. There was no significant difference in concentration of 
C-reactive protein between treatment groups (Figure 6.6c). Surprisingly, although 
Hyper IL-6 had a tendency to increase circulating Haptoglobin concentrations, it 
was only significantly induced upon co - stimulation with sgp130Fc (Figure 6.6d; 
Saline vs Hyper IL-6 + sgp130Fc; p = 0.035, Hyper IL-6 vs Hyper IL-6 + sgp130Fc; 
p = 0.083). 
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Figure 6.6 Hyper IL-6 administration had little effect on acute phase protein 
production but a tendency to induce chronic liver injury. Sera concentrations of the 
markers of hepatocellular damage a) AST, and b) ALT as determined by ELISA. 
Prolonged Hyper IL-6 treatment did not increase sera concentrations of c) C-
Reactive protein and, in the case of d) Haptoglobin, only in the presence of 
sgp130Fc as determined by ELISA. * Saline vs Hyper IL-6 + sgp130Fc; p = 0.035. 
Data expressed as mean + SEM. n = 3 - 5 for AST and ALT analysis and n = 6 for 
C-reactive protein and Haptoglobin analysis.       
c) 
a) b) 
d) 
* 
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Saline and co- treated mice on a HFD develop macrovesicular steatosis where as 
mice administered Hyper IL-6 had greater progenitor cell infiltration plus smaller & 
uniform lipid droplets – Oil Red O staining was used to examine the extent of 
steatosis in mice of all treatment groups (Figure 6.7a). Mice in the control and 
Hyper IL-6 + sgp130Fc treatment groups demonstrated a mixed phenotype 
steatosis as annotated by the deposition of small and large lipid droplets. By 
contrast, a difference in lipid droplet size was evident in Hyper IL-6 mice which had 
an average pixel count of ~400 compared with control and Hyper IL-6 + sgp130Fc 
treated mice which averaged 550 – 600 pixels in size (Figure 6.7a; saline vs Hyper 
IL-6; p = 0.002; Hyper IL-6 vs Hyper IL-6 + sgp130Fc; p = 0.035).  
 
Haemotoxylin and Eosin staining was used to examine morphology of the liver 
sections obtained. Saline treated mice showed demarcated lobules around central 
veins, an effect not seen in mice administered Hyper IL-6 only, which maintained 
classic radial lobule organisation (Figure 6.7b). In mice co-administered sgp130Fc 
the integrity of the lobules were maintained, however, to a lesser degree than 
those administered Hyper IL-6 alone. Control mice on the high fat diet showed a 
steatotic phenotype as illustrated by the increased lipid deposition as determined 
by oil red o staining, lobular inflammation, hepatocyte ballooning and cytoplasmic 
reticulation by small aggregates of steatosis in the parenchyma of acinar zone 3 
and large vacuole spaces  (Figure 6.7a and 6.7c respectively). Mice administered 
Hyper IL-6 had greater progenitor cell infiltration and larger numbers of fibroblastic 
stellate cells in the space of disse than either of the other experimental treatment 
groups. This is an indication that Hyper IL-6 treated mice were undergoing 
regeneration after liver injury (Figure 6.7c). Hyper IL-6 + sgp130Fc mice appeared 
to display morphological symptoms of liver disease intermediate to that of mice of 
the control and Hyper IL-6 experimental treatment groups. 
  
139 
 
S 
P 
S 
P 
S 
P 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Livers from Saline treated C57Bl6 mice on a HFD have disrupted 
morphology and macro-steatosis whereas Hyper IL-6 treated livers have infiltration 
of progenitor cells indicating regeneration - a) Quantitation of average number of 
pixels (size of) for lipid droplets as stained by Oil Red O. Representative 
histological sections for treatment groups stained with b) Oil Red O, Haemotoxylin 
and Eosin at magnification x20 and x40. Significant difference * saline vs Hyper IL-
6; p = 0.002; Hyper IL-6 vs Hyper IL-6 + sgp130Fc; p = 0.035 V; Vacuoles, B; 
Hepatocellular Cytoplasmic Ballooning, S; Stellate Cells, P; Progenitor Cells
V 
V B 
a) 
b) 
* 
V 
V  
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Prolonged Hyper IL-6 administration modulates phospho Aktser473 and Aktthr308 in a 
tissue type dependent manner – Prolonged Hyper IL-6 administration had a 
tendency to attenuate basal phosphorylation of Akt at the serine 473 residue in the 
liver (Figure 6.8a), however in the presence of sgp130Fc this effect was abrogated 
and thus comparative to the basal levels of control animals. In soleus muscle 
(Figure 6.8b), upon insulin stimulation, expression of phospho Aktser473 was 
increased by 60 % in Hyper IL-6 treated mice (p=0.01) and control animals 
(p=0.043), however upon statistical analysis there was no significant change 
between the basal and insulin stimulated state in co-treated mice (p=0.072). There 
was no significant difference in basal expression between the treatment groups. In 
the WAT of Hyper IL-6 and Hyper IL-6 + sgp130Fc treated mice basal expression 
of phospho Aktser473 had a tendency to be approximately 50 % greater than that of 
control mice (Figure 6.8c) although upon analysis this was not statistically 
significant. There was an increase of approximately 2 fold in phospho Akt  ser473 
under insulin stimulated conditions in all treatment groups.         
 
In liver, there was no significant difference in phospho Aktthr308 between treatment 
groups under basal or insulin stimulated conditions (Figure 6.9a). By contrast, in 
soleus (Figure 6.9b), insulin stimulation caused an increase of approximately 2.5 - 
3 fold in the abundance of phospho Aktthr308 when compared to that of basal state 
(Saline vs Saline + Insulin; p = 0.001, Hyper IL-6 vs Hyper IL-6 + Insulin; p = 0.016 
and Hyper IL-6 + sgp130Fc vs Hyper IL-6 + sgp130Fc + Insulin; p = 0.019). 
However, there was no statistically significant difference between the treatment 
groups.   
 
Expression of phospho AMPKthr172 remains similar between treatment groups 
however Hyper IL-6 + sgp130Fc decreased phospho ACCser79 abundance in liver – 
Hyper IL-6 administration had no effect on the activation of AMPK (Figure 6.10a) 
within the liver. The abundance of phospho ACCser79 was reduced by 
approximately 70 % upon co - treatment with Hyper IL-6 and sgp130Fc (Figure 
6.10b; Saline vs Hyper IL-6 + sgp130Fc; p = 0.004, Hyper IL-6 vs Hyper IL-6 + 
sgp130Fc; p = 0.007).  
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Prolonged Hyper IL-6 administration does not induce increases in membrane 
bound TNFα or SOCS-3 protein – There was no significant difference in pro TNFα 
(Figures 6.11a and 6.11b) nor SOCS-3 (Figure 6.11a) in any of the tissues 
examined.   Although a slight increase in proTNFα in the soleus (Figure 6.11a) of 
mice administered Hyper IL-6 was evident. 
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Figure 6.8 High basal expression of phospho Aktser473 is evident in liver of mice 
regardless of compound administered, an affect that is not conserved in all tissue 
types. Furthermore, insulin stimulation does not result in a significant increase in 
phosphorylation of Akt at the ser473 residue in liver of mice treated with saline or 
Hyper IL-6 ± sgp130Fc - a) Quantitation of phospho Aktser473 under basal and 
insulin stimulated conditions in a) liver, b) soleus and c) WAT. d) Representative 
immunoblots of phospho Aktser473 in the fore mentioned tissues. For soleus the 
difference in expression; * Saline vs Saline + Insulin; p = 0.043, ** Hyper IL-6 vs 
Hyper IL+ Insulin; p = 0.010. Data expressed as fold change from saline control =1, 
mean ± SEM, n = 6.  
  
 
  
  
c) d) 
a) b) 
* ** 
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Figure 6.9 Prolonged hyper IL-6 treatment has little effect on phospho Aktthr308 
protein abundance in liver, Soleus or WAT. Densitometry quantitation of protein 
abundance of phospho Aktthr308 as determined by western blotting in a) liver, b) 
soleus and c) WAT. Representative immunoblots for phospho Aktthr308 in the fore 
mentioned tissues. Difference in protein expression of phospho Aktthr308 within 
soleus; * Saline vs Saline + Insulin; p = 0.001, † Hyper IL-6 vs Hyper IL-6 + Insulin; 
p = 0.016, # Hyper IL-6 + sgp130Fc vs Hyper IL-6 + sgp130Fc + Insulin; p = 0.019.  
Data calculated as fold change from saline control animals under basal conditions 
(=1). Data expressed as mean ± SEM; n = 6. 
 
  
a) b) 
c) d) 
* 
† 
# 
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Figure 6.10 Hyper IL-6 has no effect on the activation of AMPK but in the 
presence of sgp130Fc reduces phosphorylation of ACC in liver. Quantitation of 
abundance of phospho a) AMPKthr172 and b) ACCser79 as determined by western 
blotting within the liver of Hyper IL-6 ± sgp130Fc treated mice on a HFD. c) 
Representative immunoblots of phospho AMPKthr172 and ACCser79. * Difference 
between Saline vs Hyper IL-6; p = 0.004, Hyper IL-6 vs Hyper IL-6 + sgp130Fc; p = 
0.007. Data expressed as mean + SEM fold change relative to Saline control;n = 6.  
a) 
b) 
c) 
* 
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Figure 6.11 Prolonged Hyper IL-6 treatment does not significantly alter protein 
abundance of pro TNFα or SOCS-3 in tissues of interest in mice on a HFD. 
Representative immunoblots of pro TNFα in a) Liver and soleus, b) EDL and WAT, 
c) SOCS-3 protein in Liver, Soleus, EDL and WAT and d) β-actin in fore mentioned 
tissues.  
 
 
a) b) 
c) d) 
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6.4 Discussion 
It is well established IL-6 signalling events are able to modulate metabolism in an 
acute manner. This occurs through the activation of cellular signalling pathways 
commonly associated with physiological processes such as fat oxidation and 
glucose utilisation both in vitro and in vivo. Studies within this dissertation 
demonstrate acute Hyper IL-6 treatment is capable of regulating glucose uptake 
and fat oxidation in myotubes in vitro and signalling pathways implicated in 
metabolic processes and inflammation in various tissues in vivo. Importantly, these 
studies also demonstrate inhibition of Hyper IL-6 using sgp130Fc, occurs in a 
tissue type dependent manner. The prolonged effect of Hyper IL-6 on metabolism 
has yet to be examined. However, it is imperative to note prolonged IL-6/sIL-6R 
treatment is known to cause inflammation (Maione et al., 1998; Atreya et al., 2000; 
Jostock et al., 2001; Nowell et al., 2003), thereby making it an unsuitable candidate 
as a stand alone therapeutic agent for the treatment of metabolic disorders such as 
obesity and diabetes.  As this paradigm exists, the main thrust of this study was to 
examine the effect of prolonged co-treatment with Hyper IL-6 and its competitive 
inhibitor sgp130Fc on compromised metabolism and inflammation in vivo.  
 
To examine the fore mentioned hypotheses, C57Bl6 mice were placed on a HFD, 
whereby a high percentage of caloric intake originates from dietary trans fats. This 
ensured mice displayed signs of metabolic syndrome, such as increased fat mass, 
glucose intolerance and insulin resistance. After 6 weeks of HFD, mice were 
randomly assigned to a treatment group and administered via IP injection saline, 
Hyper IL-6 or Hyper IL-6 + sgp130Fc every alternate day for 16 days. Cytokine was 
administered every alternate day as Hyper IL-6 remains bioactive for 48 h inclusive 
(Peters et al., 1998). As discussed in Chapter 5 of this dissertation, 40 μg of 
sgp130Fc was used to ensure that there was a molar excess of the inhibitor in the 
presence of Hyper IL-6. 
 
To determine if Hyper IL-6 had detrimental side effects many parameters were 
monitored through out the entire experimental period, including fat mass and lean 
body mass and food intake. Monitoring body mass was of particular importance to 
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determine if the designer cytokine possessed anti-obesigenic properties. The food 
intake of each mouse was monitored daily to ensure that any perturbation in body 
mass was due to the cytokine affecting whole body metabolism and not due to a 
change in habitual feeding associated with treatment. It was noted that feeding 
patterns remained similar between all treatment groups. Despite this, mice 
administered Hyper IL-6 had a tendency towards greater loss of fat mass over the 
treatment period than those mice assigned to receive saline or co-treatment with 
sgp130Fc. The fat mass loss could not be attributed to improved glucose tolerance 
or improved insulin sensitivity, as mice that received prolonged treatment with 
Hyper IL-6 displayed evidence of compromised insulin sensitivity and glucose 
tolerance.  
 
In the current study, mice that received prolonged Hyper IL-6 treatment had little 
change in lean body mass. This was surprising, given elevated IL-6 as a result of 
aberrant secretion from tumours such as breast and prostate carcinoma, correlates 
positively with loss of lean body mass in humans (Evans et al., 2008). 
Subsequently, the presence of IL-6 and CRP are often used in the diagnosis of 
cancer induced cachexia (Evans et al., 2008). An additional factor may be required 
for the onset of cancer induced cachexia, one such candidate may be the protein 
proteolysis inducing factor (Hussey et al., 2000).  Hyper IL-6 may not induce the 
expression of the necessary co-factor for cachexia to occur, thus explaining why 
there is little change in lean body mass over time with treatment.    
 
The tendency towards greater fat mass loss could not be attributed to increased 
activity or improved oxidative capacity, as these remained similar across the three 
treatment groups. Prolonged Hyper IL-6 administration within these animals, even 
in the presence of sgp130Fc, had comparatively similar VO2, RER, ambulation and 
heat production (unpublished observation). It is noteworthy, a symptomatic 
hallmark of chronic inflammatory bowel disease is weight loss, attributed to the loss 
of protein, water and most notably, fat stores (Powell-Tuck, 1986). As Hyper IL-6 
has previously been used to induce experimental models of colitis it is feasible to 
suggest that in the current cohort mice suffered from cytokine induced chronic 
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inflammation of the gastrointestinal tract, inadvertently accounting for the trend of 
reduced fat mass (Figure 6.2). In future experiments, it may be of interest to 
observe if animals treated with Hyper IL-6 are indeed suffering from IBD by 
examining stool consistency and blood content, rectal health and histological 
examination of the colon and determining cell population subsets within the tissue 
through the use of immunohistochemistry.     
 
IL-6 induces and modulates the production of acute phase proteins by hepatocytes 
(Stoyan et al., 1993; Weiergräber et al., 1995; Lienenlüke and Christ, 2007; Rabe 
et al., 2008). In the current study, upon prolonged stimulation with Hyper IL-6 
alone, the sera concentration of the acute phase proteins CRP and Haptoglobin 
remained similar to that of control mice. Surprisingly, mice that were co-
administered Hyper IL-6 and sgp130Fc had no change in CRP yet significantly 
increased levels of Haptoglobin. This suggests that, unlike their experimental 
counterparts, co-treated mice were in a state of acute phase inflammation.  
  
Raised sera concentrations of the amino transferases aspartate amino transferase 
(AST) and alanine amino transferase (ALT), is a consequence of increased 
proteolysis and is indicative of chronic liver assault (Bugianesi et al., 2005; Yin et 
al., 2008).  In the present cohort, a trend of elevated sera concentrations of AST 
and ALT from Hyper IL-6 treated mice was evident when compared with controls. It 
is important to note however, this result was not considered statistically significant, 
likely due to a lack of power as there was a limited volume of serum obtained for 
analysis. To obtain enough volume for analysis, some samples were pooled. AST 
and ALT results combined with the minimal change in levels of acute phase 
proteins in saline control and Hyper IL-6 treated mice are suggestive of chronic 
liver injury, providing support to the notion that Hyper IL-6 is a hepatocellular 
cytotoxic agent. Further more, it is evident from this data set that sgp130Fc was 
able to impair the onset of chronic liver disease induced by Hyper IL-6, as co-
administration did not augment circulating amino transferases. Importantly, 
although not as deleterious to the liver as prolonged Hyper IL-6 administration, 
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prolonged exposure to the designer cytokine and its inhibitor sgp130Fc is still able 
to induce an acute phase inflammatory response.           
 
Histological staining was utilised to examine the general health of the liver within 
these animals. It is well established that chronic injury of the liver results in 
inflammation and increased cytokine production such as TNFα, IFNγ and IL-6, 
which in turn causes proliferation of progenitor cells (Knight et al., 2005). 
Progenitor cells are stem cells that differentiate into hepatocytes, replacing injured 
parenchyma. Thus progenitor cell infiltration is often considered indicative of 
severity of liver disease (Lowes et al., 1999).  In the current study, using 
Haemotoxylin and Eosin staining, further evidence of chronic liver injury was 
provided by increased progenitor cell infiltration in livers from Hyper IL-6 treated 
mice, an anomaly not seen in saline treated nor Hyper IL-6 + sgp130Fc co-treated 
mice. This is in accordance with previous studies which demonstrate progenitor 
cell infiltrate and liver regeneration is induced by IL-6/Hyper IL-6 signalling (Yeoh et 
al., 2007 and Galun et al., 2000) It is unlikely that the increased infiltration of 
progenitor cells was induced by TNFα, as there was no increase in the pro form of 
this cytokine in the liver of Hyper IL-6 treated mice compared to that of animals 
assigned to the control group.  
 
Furthermore, there was no significant change in proTNFα in EDL or WAT but there 
was a strong trend for elevated proTNFα in soleus with Hyper IL-6 treatment, an 
effect that was abrogated in the presence of sgp130Fc (Figure 6.11). The current 
data suggest Hyper IL-6 has differential effects on proTNFα expression according 
to tissue type. This is in accordance with Yuen et al. (2009), who demonstrate cell 
specific effects occur in response to IL-6 with elevated production of TNFα in 
human aortic endothelial cells but not within mixed hindlimb skeletal muscle.       
 
Insulin resistance is associated with increased hepatic glucose and lipid 
production, leading to intrahepatic accumulation of fat due to perturbed fat 
oxidation, a condition known as Steatosis. Using Oil red O staining of liver 
sections, macro-vesicular steatosis, characterised by accumulation of mixed small 
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and large lipid droplets (Brunt, 2007), was evident in saline control and Hyper IL-6 
and sgp130Fc co-administered mice. By contrast, mice administered Hyper IL-6 
had micro-steatosis as demonstrated by small uniform lipid droplets. Microsteatosis 
is considered to be a manifestation of chronic liver injury (Brunt, 2007). Steatotic 
classification suggests that in saline control and co-treated mice, steatosis is a 
manifestation of fatty acid influx and triglyceride accumulation (Reddy and Rao, 
2007). By comparison, in Hyper IL-6 treated mice steatosis is likely due to localised 
hepatocellular damage causing inherent mitochondrial and peroxisomal β-oxidation 
deficiencies (Reddy and Rao, 2007). In liver of mice treated with Hyper IL-6, there 
is also evidence of an increased stellate cell population, indicative of liver 
regeneration and increased fibrosis, an effect not seen in saline control and Hyper 
IL-6 + sgp130Fc co-treated mice. However, to confirm that there is indeed 
increased fibrosis it would be necessary to examine sections using specific 
histochemical stains.  
 
As Oil Red O staining of liver sections demonstrated a perturbation in fatty acid 
metabolism existed, AMPK pathway signalling was examined. There was little 
change in protein abundance of phospho AMPKthr172. Surprisingly, a significant 
reduction in phospho ACCser79 abundance in livers of mice co-administered Hyper 
IL-6 and sgp130Fc compared with control mice was evident. As to why this 
occured remains unknown and requires further investigation. Conversely, this 
reduction was not seen in mice administered Hyper IL-6 alone who displayed 
similar levels of phospho ACC ser79 abundance compared with control mice. This 
suggests that fat oxidation potential is comparative between the Hyper IL-6 treated 
and control mice.   
 
Hyper IL-6 treated mice display signs of insulin resistance as indicated by an 
impaired response to insulin during an insulin tolerance test. Co-treating with 
sgp130Fc was unable to rescue Hyper IL-6 induced insulin resistance. This is in 
accordance with other studies that suggest IL-6 signalling leads to insulin 
resistance (Senn et al., 2002 and Kanemaki et al., 1998). The data obtained in the 
current study suggest Hyper IL-6 promotes the insulin resistant phenotype typically 
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seen within mice fed a HFD. Furthermore, chronically elevated IL-6/sIL-6R 
complex within the circulation of C57BL6 mice may exacerbate any insulin 
resistant phenotype associated with pre existing diet induced metabolic syndrome. 
 
 In support of the insulin resistant phenotype, in liver the of Hyper IL-6 treated 
mice, Akt activation at both residues seemed equivocally regulated. Hyper IL-6 had 
a tendency to increase basal expression of phospho Aktser473 but, upon insulin 
stimulation was not further potentiated. Basal abundance of phospho Aktser473 was 
elevated compared to saline control in soleus and adipose. However, converse to 
that of liver signalling appeared to remain responsive to insulin with a 50 % 
increase in this protein evident (Figures 6.8 and 6.9). In all tissues, activation of Akt 
at the Thr308 residue closely reflected that of phosphorylation at the Ser473 
residues. These signalling data suggest that the insulin resistance seen in all mice 
treated with Hyper IL-6 may be attributed to impaired liver function rather than 
metabolic perturbations of skeletal muscle. 
 
SOCS-3 protein expression is induced by IL-6 activation of STAT-3 and inhibits the 
activity of Janus kinases. It is important to note in the current study there was no 
change in SOCS-3 protein with any of the treatments. This may be a reflection of 
a) the relative short half life, 1-2 hours, of SOCS-3 (Siewart et al., 1999) or b) 
increased proteosomal degradation of the protein. JAK induced phosphorylation of 
SOCS-3 at the SOCS box, prevents the protein from forming a complex with 
Elongin C, thereby decreasing stability and accelerating proteosomal degradation 
of the protein (Haan et al., 2003). It is plausible to suggest Hyper IL-6 results in 
chronic activation of JAK/STAT-3 and subsequently increased binding of JAK to 
SOCS-3, leading to instability and accelerated proteosomal degradation of this 
protein.  
 
In summary, in line with the hypothesis, this current study provides further 
experimental evidence that sgp130Fc is able to prevent severe injury and chronic 
inflammation of the liver induced by prolonged Hyper IL-6 treatment. Mice co-
administered Hyper IL-6 and sgp130Fc show little sign of chronic liver injury per se. 
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However, it is apparent these mice suffered from acute inflammation with elevated 
levels of the IL-6 inducible acute phase protein Haptoglobin and hepatocyte 
degeneration noted. Mice administered Hyper IL-6 lost fat mass over the treatment 
period but also demonstrated overt insulin resistance. sgp130Fc was unable to 
ameliorate insulin resistance associated with prolonged Hyper IL-6 treatment. 
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CHAPTER SEVEN 
 
Conclusions and Future Directions 
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7.1 Conclusions and Future Directions 
The primary aim of this dissertation was to elucidate whether IL-6 signalling 
mediated via the agonistic sIL-6R (IL-6 trans-signalling) can be considered 
biologically relevant in the regulation of common metabolic processes such as 
mitochondrial oxidative phosphorylation, fatty acid oxidation, glucose utilisation and 
insulin sensitivity within skeletal muscle, adipose and liver.  
 
Chapter Three sought to examine IL-6 trans-signalling, using the designer cytokine 
Hyper IL-6, in the regulation of transcription and translation of PGC-1α, an 
important mediator of mitochondrial function through its ability to modulate 
OXPHOS gene expression, mitochondrial biogenesis and adaptive thermogenesis. 
In vitro, Hyper IL-6 was not a transcriptional or translational regulator of PGC-1α as 
evidenced by little change in mRNA or protein expression of PGC-1α in response 
to the designer cytokine within the cell types examined. Furthermore, prolonged 
treatment with IL-6 had little effect on mRNA or protein expression of PGC-1α in 
vivo. It is important to note, however, that there was limited tissue available for 
analysis of PGC-1α expression and as a consequence, this aspect of the study 
was only examined in Tibialis Anterior muscle. This does not discount the 
possibility that IL-6 regulates expression of PGC-1α and other mitochondrial genes 
in muscle types other than Tibialis Anterior and requires further investigation.  
 
An abundance of studies examining IL-6 signalling mediated via the sIL-6R in 
many tissues including synovial fluid, the bowel and liver is evident within the 
literature. Conversely, there is little evidence of this phenomenon occurring in 
metabolically active tissues such as skeletal muscle and adipose tissue. This may 
be considered as surprising given the prominent role acute release of IL-6 plays in 
the regulation of metabolism within such tissues as adipose and skeletal muscle 
during exercise. Consequently this formed the basis of Chapter 4, whereby acute 
IL-6 trans-signalling events were examined in L6 myotubes and CRL1439 
hepatocytes in vitro. Using Hyper IL-6 to mimic IL-6/sIL-6R/gp130 activation, the 
signalling pathways activated and the biological consequences of acute IL-6 trans-
signalling in L6 myotubes in vitro were explored.  This study illustrated L6 
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myotubes are responsive to IL-6 trans-signalling events as indicated by the 
phosphorylation of such proteins as STAT-3 and Akt. Moreover, IL-6/sIL-6R 
complex signalling was adept at regulating glucose uptake and fat oxidation in L6 
myotubes in vitro. Although it was apparent Hyper IL-6 increased glucose uptake, 
the direct mechanism by which this occurred requires further experimentation.  
 
A comparison between IL-6 and Hyper IL-6 induced cell signalling in L6 myotubes 
and CRL1439s provides further support to the notion IL-6/sIL-6R occurs in a cell 
type dependent manner. The degree to which STAT-3 and Akt were 
phosphorylated in response to Hyper IL-6 was variable between the two cell types 
examined. The diverse effects of Hyper IL-6 is likely to be a reflection of its 
bioactivity within individual cell types and is most likely due to the relative 
expression of membrane bound IL-6Rα and gp130β within these cells. Not 
withstanding the naturally occurring competitive inhibitor of sIL-6R signalling, 
sgp130 also had a tissue specific effect, with partial inhibition of phospho STAT-3 
evident in CRL1439 but not L6 myotubes. This too, is likely due to the relative 
abundance of the membrane IL-6R and gp130. 
 
As Chapter 4 established L6 myotubes were responsive to IL-6 trans-signalling, 
and that Hyper IL-6 was proficient at regulating glucose uptake and fat oxidation in 
vitro, it was of utmost importance to determine if this scenario translated to an in 
vivo model. Chapter 5 examined components of various cell signalling pathways 
involved in inflammation, metabolism and cell cycle, in response to an acute Hyper 
IL-6 treatment within skeletal muscle, adipose tissue and liver, in vivo. It was 
evident that activation of proteins involved in the fore mentioned processes 
occurred in a tissue type dependent manner as evident by the relative 
phosphorylation of STAT-3, AMPK and JNK within liver, muscle and WAT.   
 
Due to observations made by previous investigators and those of the current 
cohort, it was proposed IL-6 trans-signalling may be beneficial in an acute manner. 
For example, during exercise, IL-6 is released into the circulation in a transient 
manner and acts as a mediator of metabolic regulation via signalling pathways 
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involved in glucose oxidation and disposal and fat oxidation. However, it is also 
well established that states of disease are often associated with chronically 
elevated levels of IL-6 and and/or sIL-6R within the circulation. This may lead to 
aberrant pathway activation and inflammation within many tissues. As this paradox 
exists, Chapter 6 explored prolonged Hyper IL-6 administration on inflammation 
and whole body energy metabolism in vivo.  
 
Mice administered Hyper IL-6 over a prolonged period lost fat mass over the 
treatment period, had overt insulin resistance and severe liver injury. With the ideal 
of preventing any associated inflammatory signalling whilst maintaining any 
beneficial effect Hyper IL-6 treatment had on metabolism, mice were co-treated 
with Hyper IL-6 and sgp130Fc. Although sgp130Fc prevented severe injury and 
chronic inflammation of the liver induced by Hyper IL-6, it was apparent these mice 
suffered from acute inflammation with elevated levels of Haptoglobin and 
hepatocyte degeneration evident. Surprisingly, sgp130Fc co-treatment was unable 
to ameliorate insulin resistance associated with prolonged Hyper IL-6 treatment. It 
is plausible that the insulin resistance associated with Hyper IL-6 treatment, 
regardless of the presence of sgp130, is due to the enhanced bioactivity and 
delayed clearance of the designer cytokine.  
 
Although Hyper IL-6 was a useful tool in the examination of IL-6/sIL-6R signalling 
within various tissues it remains a poor candidate as a therapeutic tool in the war 
against obesity. This is primarily due to its enhanced bioactivity as a consequence 
of high binding affinity for the gp130 receptor and slow internalisation resulting in 
hyper activation of many pro-inflammatory pathways. As a consequence of the 
enhanced bioactivity, co-treating with sgp130Fc may have not been adequate to 
prevent inflammation induced by this designer cytokine. This, however, does not 
discount the potential of a gp130 receptor/ligand like drug design as an anti-obesity 
agent. Studies aimed at examining the effects of IL-6 treatment within transgenic 
mice over expressing sgp130Fc, with the ideal of determining if it is possible to 
prevent “pro-inflammatory” signalling associated with gp130 receptor/ligand activity 
whilst maintaining beneficial metabolic signalling are planned for the near future. 
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Similar studies to those performed in this dissertation utilising recombinant IL-6, 
rather than the potent and highly bioactive Hyper IL-6, in the presence of sgp130Fc 
may provide insight into the mechanism behind the beneficial effects associated 
with membrane bound IL-6R signalling. Not withstanding, many IL-6 family 
cytokines utilise gp130 to mediate cellular functions and hence potentially 
modulate metabolism and inflammation. Through understanding how gp130 
ligands elicit cellular effects, it may be possible to design a cytokine/ therapeutic 
agent that utilises specific components of individual IL-6 family members thereby 
selectively targetting components of gp130 mediated signalling. This would 
ultimately ensure beneficial effects on metabolism are maintained whilst avoiding 
those that may contribute to the pathogenesis of inflammation.     
  
Collectively, these data demonstrate in skeletal muscle Hyper IL-6 induced trans-
signalling, regardless of the presence of sgp130Fc remains intact, contrary to that 
of hepatocytes in vitro. In C57BL6, acute administration of this designer cytokine 
by IP injection is able to regulate signalling pathways associated with metabolism 
and inflammation, an effect that sgp130Fc co-administration inhibited in a tissue 
type dependent manner. Although prolonged Hyper IL-6 treatment in mice on a 
HFD led to a propensity towards fat mass loss, it also caused severe liver injury 
and insulin resistance, an affect that was unable to be prevented by co-treatment 
with sgp130Fc.  As a consequence Hyper IL-6 remains a poor candidate as an 
anti-obesity drug.  
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